Tocilizumab Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated: May 20, 2026

The clinical evidence base for Tocilizumab comprises 693 peer-reviewed publications across 15 journals, 151 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Arthritis, Rheumatoid, COVID-19, Inflammation, and Appetitive Behavior. Most recent publication: First-in-human phase 1 study of RO7119929, an oral TLR7 agonist prodrug, in patients with advanced primary or metastatic liver cancers., J Immunother Cancer, 2026.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group · Lancet · 2022
PubMed: PMID 33933206 · NCT04381936 (RECOVERY) · COVID-19
Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group · Lancet Infect Dis · 2025
PubMed: PMID 40886716 · NCT04381936 (RECOVERY) · COVID-19
Molnupiravir or nirmatrelvir-ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group · Lancet Infect Dis · 2025
PubMed: PMID 40383127 · NCT04381936 (RECOVERY) · COVID-19
Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group · Lancet Diabetes Endocrinol · 2023
PubMed: PMID 37865101 · NCT04381936 (RECOVERY) · COVID-19
Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group. Electronic address: [email protected], RECOVERY Collaborative Group · Lancet · 2023
PubMed: PMID 37060915 · NCT04381936 (RECOVERY) · COVID-19
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial.
RECOVERY Collaborative Group · Lancet · 2022
PubMed: PMID 34000257 · NCT04381936 (RECOVERY) · COVID-19
Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group · Lancet Respir Med · 2022
PubMed: PMID 34672950 · NCT04381936 (RECOVERY) · COVID-19
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group · Lancet · 2022
PubMed: PMID 35151397 · NCT04381936 (RECOVERY) · COVID-19

Primary-outcome results across pivotal trials

Per-arm reported values from Phase 2/3 and Phase 3 trials with results posted to ClinicalTrials.gov.

Trial	Indication	Primary endpoint	Arm	Value
NCT00106535	Arthritis, Rheumatoid	Change From Baseline in Modified Total Sharp-Genant Score at Week 52 Baseline, Week 52	Placebo + Methotrexate	1.13 Score on a scale (±2.962 Standard Deviation)
			Tocilizumab 4 mg/kg + Methotrexate	0.34 Score on a scale (±1.451 Standard Deviation)
			Tocilizumab 8 mg/kg + Methotrexate	0.29 Score on a scale (±1.282 Standard Deviation)
NCT00106535	Arthritis, Rheumatoid	Change From Baseline in the Modified Total Sharp-Genant Score at Week 104 Baseline, Week 104	Placebo + Methotrexate	1.96 Score on a scale (±5.956 Standard Deviation)
			Tocilizumab 4 mg/kg + Methotrexate	0.58 Score on a scale (±2.357 Standard Deviation)
			Tocilizumab 8 mg/kg + Methotrexate	0.37 Score on a scale (±1.547 Standard Deviation)
NCT00106535	Arthritis, Rheumatoid	Change in Physical Function as Measured by the Area Under the Curve (AUC) for the Change From Baseline in the Health Assessment Questionnaire (HAQ) Disability Index at Week 52 Baseline to Week 52	Placebo + Methotrexate	-58.11 Score on a scale*week (±150.839 Full Range)
			Tocilizumab 4 mg/kg + Methotrexate	-128.37 Score on a scale*week (±165.084 Full Range)
			Tocilizumab 8 mg/kg + Methotrexate	-144.06 Score on a scale*week (±173.372 Full Range)
NCT00106535	Arthritis, Rheumatoid	Change in Physical Function as Measured by the Area Under the Curve for the Change From Baseline in the Health Assessment Questionnaire- Disability Index (HAQ-DI) at Week 104 Baseline to Week 104	Placebo + Methotrexate	-139.40 Score on a scale*week (±365.682 Full Range)
			Tocilizumab 4 mg/kg + Methotrexate	-287.50 Score on a scale*week (±383.201 Full Range)
			Tocilizumab 8 mg/kg + Methotrexate	-320.80 Score on a scale*week (±385.741 Full Range)
NCT00106535	Arthritis, Rheumatoid	Percentage of Participants With American College of Rheumatology-ACR20 Response Baseline, Week 24	Placebo + Methotrexate	27.0 Percentage of participants
			Tocilizumab 4 mg/kg + Methotrexate	50.6 Percentage of participants
			Tocilizumab 8 mg/kg + Methotrexate	56.3 Percentage of participants
NCT00531817 ROSE	Arthritis, Rheumatoid	Percentage of Patients With an Improvement of at Least 50% in American College of Rheumatology (ACR) Score (ACR50) From Baseline at Week 24 Baseline to Week 24	Placebo + DMARDs	11.2 Percentage of participants
NCT00531817 ROSE	Arthritis, Rheumatoid		Tocilizumab 8 mg/kg + DMARDs	30.1 Percentage of participants
NCT00535782	Arthritis, Rheumatoid	Change From Baseline in Small Low Density Lipoprotein (sLDL) Particle Numbers Baseline and Week 12	Placebo + MTX	777.71 nmol/L (±394.527 Standard Deviation)
			Placebo + MTX	22.41 nmol/L (±237.476 Standard Deviation)
			Placebo + MTX	792.78 nmol/L (±392.051 Standard Deviation)
			TCZ + MTX	23.73 nmol/L (±368.273 Standard Deviation)
			TCZ + MTX	768.04 nmol/L (±628.281 Standard Deviation)
			TCZ + MTX	737.79 nmol/L (±467.097 Standard Deviation)
NCT00535782	Arthritis, Rheumatoid	Change From Baseline to Week 12 in Aortic Pulse Wave Velocity (PWV) Baseline and Week 12	Placebo + MTX	8.39 meters/second (±1.836 Standard Deviation)
			Placebo + MTX	9.01 meters/second (±2.519 Standard Deviation)
			Placebo + MTX	-0.68 meters/second (±1.741 Standard Deviation)
			TCZ + MTX	8.97 meters/second (±1.970 Standard Deviation)
			TCZ + MTX	-0.03 meters/second (±1.970 Standard Deviation)
			TCZ + MTX	8.94 meters/second (±2.510 Standard Deviation)
NCT00642460	Arthritis, Juvenile	Part I: Percentage of Participants With ≥30% Improvement in Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) Core Set and Absence of Fever Baseline, Week 12	Placebo	24.3 Percentage of participants
NCT00642460	Arthritis, Juvenile		Tocilizumab	85.3 Percentage of participants
NCT00642460	Arthritis, Juvenile	Part II: Percentage of Participants With Decreases in Oral Corticosteroid Dose at Week 104 Baseline, Week 104	Tocilizumab	47 Percentage of participants
			Tocilizumab	76 Percentage of participants
			Tocilizumab	73 Percentage of participants
			Tocilizumab	62 Percentage of participants
NCT00720798	Arthritis, Rheumatoid	Percentage of Participants With ≥ 1 Adverse Event Baseline to the end of the study (up to 7 years, 7 months)	Tocilizumab	96.3 Percentage of participants
NCT00721123	Arthritis, Rheumatoid	Adverse Event (AE) Summary Over Time through 264 Weeks	Months 0 - 12	24 Participants
			Months 0 - 12	433 Participants
			Months 0 - 12	55 Participants
			Months 13 - 24	17 Participants
			Months 13 - 24	55 Participants
			Months 13 - 24	390 Participants
			Months 25 - 36	55 Participants
			Months 25 - 36	333 Participants
			Months 25 - 36	22 Participants
			Months 37 - 48	294 Participants
			Months 37 - 48	35 Participants
			Months 37 - 48	8 Participants
			Months Greater Than 48	32 Participants
			Months Greater Than 48	329 Participants
			Months Greater Than 48	74 Participants
NCT00721123	Arthritis, Rheumatoid	Overall Death Rate Over Time through 264 Weeks	Tocilizumab 8 mg/kg	0.41 Deaths per 100 PY
NCT00721123	Arthritis, Rheumatoid	Summary Adverse Event Rates Over Time through 264 Weeks	Months 0 - 12	0 Adverse Events per 100 Patient Years
			Months 0 - 12	393.76 Adverse Events per 100 Patient Years
			Months 0 - 12	27.35 Adverse Events per 100 Patient Years
			Months 0 - 12	0 Adverse Events per 100 Patient Years
			Months 0 - 12	0.62 Adverse Events per 100 Patient Years
			Months 0 - 12	92.94 Adverse Events per 100 Patient Years
			Months 0 - 12	3.29 Adverse Events per 100 Patient Years
			Months 0 - 12	0.41 Adverse Events per 100 Patient Years
			Months 0 - 12	12.54 Adverse Events per 100 Patient Years
			Months 0 - 12	0.62 Adverse Events per 100 Patient Years
			Months 0 - 12	5.14 Adverse Events per 100 Patient Years
			Months 0 - 12	0.21 Adverse Events per 100 Patient Years
			Months 0 - 12	1.23 Adverse Events per 100 Patient Years
			Months 0 - 12	0.21 Adverse Events per 100 Patient Years
			Months 13 - 24	87.52 Adverse Events per 100 Patient Years
			Months 13 - 24	0.22 Adverse Events per 100 Patient Years
			Months 13 - 24	9.90 Adverse Events per 100 Patient Years
			Months 13 - 24	0.90 Adverse Events per 100 Patient Years
			Months 13 - 24	0 Adverse Events per 100 Patient Years
			Months 13 - 24	0.22 Adverse Events per 100 Patient Years
			Months 13 - 24	0 Adverse Events per 100 Patient Years
			Months 13 - 24	1.80 Adverse Events per 100 Patient Years
			Months 13 - 24	0 Adverse Events per 100 Patient Years
			Months 13 - 24	0.45 Adverse Events per 100 Patient Years
			Months 13 - 24	2.47 Adverse Events per 100 Patient Years
			Months 13 - 24	3.82 Adverse Events per 100 Patient Years
			Months 13 - 24	13.05 Adverse Events per 100 Patient Years
			Months 13 - 24	286.17 Adverse Events per 100 Patient Years
			Months 25 - 36	5.35 Adverse Events per 100 Patient Years
			Months 25 - 36	0.49 Adverse Events per 100 Patient Years
			Months 25 - 36	260.14 Adverse Events per 100 Patient Years
			Months 25 - 36	5.60 Adverse Events per 100 Patient Years
			Months 25 - 36	5.35 Adverse Events per 100 Patient Years
			Months 25 - 36	87.36 Adverse Events per 100 Patient Years
			Months 25 - 36	0 Adverse Events per 100 Patient Years
			Months 25 - 36	0.49 Adverse Events per 100 Patient Years
			Months 25 - 36	0.73 Adverse Events per 100 Patient Years
			Months 25 - 36	0.24 Adverse Events per 100 Patient Years
			Months 25 - 36	0 Adverse Events per 100 Patient Years
			Months 25 - 36	0.49 Adverse Events per 100 Patient Years
			Months 25 - 36	0.97 Adverse Events per 100 Patient Years
			Months 25 - 36	18.74 Adverse Events per 100 Patient Years
			Months 37 - 48	12.62 Adverse Events per 100 Patient Years
			Months 37 - 48	0.77 Adverse Events per 100 Patient Years
			Months 37 - 48	0.77 Adverse Events per 100 Patient Years
			Months 37 - 48	0 Adverse Events per 100 Patient Years
			Months 37 - 48	0.26 Adverse Events per 100 Patient Years
			Months 37 - 48	1.03 Adverse Events per 100 Patient Years
			Months 37 - 48	87.32 Adverse Events per 100 Patient Years
			Months 37 - 48	3.35 Adverse Events per 100 Patient Years
			Months 37 - 48	3.86 Adverse Events per 100 Patient Years
			Months 37 - 48	2.06 Adverse Events per 100 Patient Years
			Months 37 - 48	0.52 Adverse Events per 100 Patient Years
			Months 37 - 48	249.84 Adverse Events per 100 Patient Years
			Months 37 - 48	0.26 Adverse Events per 100 Patient Years
			Months 37 - 48	0.26 Adverse Events per 100 Patient Years
			Months Greater Than 48	1.50 Adverse Events per 100 Patient Years
			Months Greater Than 48	0.68 Adverse Events per 100 Patient Years
			Months Greater Than 48	13.12 Adverse Events per 100 Patient Years
			Months Greater Than 48	0.27 Adverse Events per 100 Patient Years
			Months Greater Than 48	0.68 Adverse Events per 100 Patient Years
			Months Greater Than 48	3.55 Adverse Events per 100 Patient Years
			Months Greater Than 48	72.82 Adverse Events per 100 Patient Years
			Months Greater Than 48	0 Adverse Events per 100 Patient Years
Months Greater Than 48	4.10 Adverse Events per 100 Patient Years
Months Greater Than 48	0.41 Adverse Events per 100 Patient Years
Months Greater Than 48	0 Adverse Events per 100 Patient Years
Months Greater Than 48	4.37 Adverse Events per 100 Patient Years
Months Greater Than 48	212.04 Adverse Events per 100 Patient Years
Months Greater Than 48	0.27 Adverse Events per 100 Patient Years
NCT00750880	Arthritis, Rheumatoid	Percentage of Participants With Adverse Events (AEs): Overall Summary Weeks 4, 8, 12, 16, 20, and 24	Tocilizumab 8 mg/kg	77.4 percentage of participants
			Tocilizumab 8 mg/kg	0.4 percentage of participants
			Tocilizumab 8 mg/kg	0.2 percentage of participants
			Tocilizumab 8 mg/kg	58.4 percentage of participants
			Tocilizumab 8 mg/kg	7.8 percentage of participants
			Tocilizumab 8 mg/kg	7.8 percentage of participants
			Tocilizumab 8 mg/kg	3.5 percentage of participants
			Tocilizumab 8 mg/kg	5.1 percentage of participants
			Tocilizumab 8 mg/kg	10.8 percentage of participants
			Tocilizumab 8 mg/kg	35.3 percentage of participants
			Tocilizumab 8 mg/kg	2.1 percentage of participants
			Tocilizumab 8 mg/kg	17.3 percentage of participants
			Tocilizumab 8 mg/kg	6.7 percentage of participants
			Tocilizumab 8 mg/kg	12.6 percentage of participants
NCT00754559	Arthritis, Rheumatoid	Percentage of Participants With Low Disease Activity Score at Week 24 Week 24	Tocilizumab	57 Percentage of Participants
NCT00754572	Arthritis, Rheumatoid	Percentage of Participants With American College of Rheumatology (ACR) 50 Response at Week 24 Week 24	Tocilizumab	73.23 percentage of participants
NCT00773461	Arthritis, Rheumatoid	Percentage of Participants With an American College of Rheumatology (ACR)20 Response at Week 24 Week 24	Placebo + DMARDs	24.6 Percentage of Participants
			Placebo + DMARDs	24.6 Percentage of Participants
			Tocilizumab + DMARDs	73.4 Percentage of Participants
			Tocilizumab + DMARDs	69.8 Percentage of Participants
NCT00810199	Arthritis, Rheumatoid	Percentage of Participants With Disease Activity Score 28 Joints (DAS28) Remission at Week 24 Week 24	Tocilizumab + Methotrexate	40.4 Percentage of participants
NCT00810199	Arthritis, Rheumatoid		Tocilizumab + Placebo	34.8 Percentage of participants
NCT00810277	Arthritis, Rheumatoid	Percentage of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs) Baseline up to Week 24	Tocilizumab	7.1 percentage of participants
NCT00810277	Arthritis, Rheumatoid		Tocilizumab	92.9 percentage of participants
NCT00848120	Arthritis, Rheumatoid	Percentage of Participants Achieving American College of Rheumatology (ACR) 20 Percent (%) Improvement (ACR20 Response) at Week 24 Week 24	Tocilizumab 8 mg/kg	86 percentage of participants
NCT00883753	Arthritis, Rheumatoid	Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) 108 Weeks	Tocilizumab + > 1 DMARD	7.3 percentage of participants
			Tocilizumab + > 1 DMARD	73.2 percentage of participants
			Tocilizumab + 1 DMARD	5.7 percentage of participants
			Tocilizumab + 1 DMARD	68.6 percentage of participants
			Tocilizumab Monotherapy	65.0 percentage of participants
			Tocilizumab Monotherapy	8.5 percentage of participants
NCT00891020	Arthritis, Rheumatoid	Percentage of Participants Experiencing at Least One Serious Adverse Event (SAE) During the 24 Week Treatment Period 24 Weeks	Tocilizumab 4 mg/kg + DMARD	8.0 Percentage of Participants
			Tocilizumab 8 mg/kg + DMARD	8.4 Percentage of Participants
			Tocilizumab 8 mg/kg Monotherapy	5.8 Percentage of Participants
NCT00951275	Arthritis, Rheumatoid	Improvement in Fatigue at Week 4 Assessed as Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Scores Week 4	Tocilizumab 8 mg/kg	8.76 units on a scale (±8.83 Standard Deviation)
NCT00951275	Arthritis, Rheumatoid	Improvement of Anemia at Week 4 Assessed as Change From Baseline in Hemoglobin Week 4	Tocilizumab 8 mg/kg	0.40 g/dL (±0.78 Standard Deviation)
NCT00977106	Arthritis, Rheumatoid	Percentage of Participants With Clinically Significant Improvement in Health Assessment Questionnaire - Disability Index (HAQ-DI) at Week 4 Week 4	Placebo, Tocilizumab	42.0 percentage of participants
NCT00977106	Arthritis, Rheumatoid		Tocilizumab	49.1 percentage of participants
NCT00988221	Arthritis, Juvenile	Percent of Patients With a Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology 30 (ACR30) Flare in Part II of the Study (Weeks 16-40) Week 16 through Week 40	Placebo	48.1 Percent of patients
NCT00988221	Arthritis, Juvenile		Tocilizumab 8 or 10 mg/kg	25.6 Percent of patients
NCT00996606	Arthritis, Rheumatoid	Change From Baseline to Week 4 in Synovitis of the Wrist According to Rate of Early Enhancement (REE) Per Second Before and After Contrast Injection Baseline and Week 4	Tocilizumab in Active RA	-0.10 percent rate of early enhancement (±0.86 Standard Deviation)
NCT00996606	Arthritis, Rheumatoid		Tocilizumab in Active RA	1.19 percent rate of early enhancement (±1.04 Standard Deviation)
NCT00996606	Arthritis, Rheumatoid	Change From Baseline to Week 4 in Synovitis of the Wrist According to Relative Enhancement (RE) Before and After Contrast Injection Baseline and Week 4	Tocilizumab in Active RA	99.25 percent relative enhancement (±57.85 Standard Deviation)
NCT00996606	Arthritis, Rheumatoid		Tocilizumab in Active RA	-0.48 percent relative enhancement (±47.85 Standard Deviation)
NCT00996606	Arthritis, Rheumatoid	Change From Baseline to Week 4 in Synovitis of the Wrist According to Rheumatoid Arthritis Magnetic Resonance Imaging (RAMRIS) Score Baseline and Week 4	Tocilizumab in Active RA	-0.88 units on a scale (±1.56 Standard Deviation)
NCT00996606	Arthritis, Rheumatoid		Tocilizumab in Active RA	5.78 units on a scale (±2.72 Standard Deviation)
NCT01007435	Arthritis, Rheumatoid	Percentage of Participants With a Disease Activity Score 28 (DAS28) Remission Response at Week 24 Week 24	Placebo to Tocilizumab + Methotrexate	15.0 Percentage of participants
			Tocilizumab 4 mg/kg + Methotrexate	31.9 Percentage of participants
			Tocilizumab 8 mg/kg + Methotrexate	44.8 Percentage of participants
			Tocilizumab 8 mg/kg + Placebo to Methotrexate	38.7 Percentage of participants
NCT01034137	Arthritis, Rheumatoid	Percentage of Participants Achieving Sustained Remission Rate At Week 104 Week 104	Methotrexate + Placebo Tocilizumab	44.4 Percentage of participants
			Tocilizumab + Methotrexate	85.8 Percentage of participants
			Tocilizumab + Placebo Methotrexate	83.5 Percentage of participants
NCT01044498	Arthritis, Rheumatoid	Serum Progesterone Level Day 21 of Cycles 1-3 for Group 1 and Day 21 of Cycle 1 for Group 2	Ortho-Novum® 1/35 (Group 2)	NA ng/mL (±NA Standard Deviation)
			Ortho-Novum® 1/35 (Group 2)	NA ng/mL (±NA Standard Deviation)
			Ortho-Novum® 1/35 (Group 2)	0.57 ng/mL (±0.39 Standard Deviation)
			Tocilizumab 8 mg/kg + Ortho-Novum® 1/35 (Group 1)	0.22 ng/mL (±0.10 Standard Deviation)
			Tocilizumab 8 mg/kg + Ortho-Novum® 1/35 (Group 1)	0.19 ng/mL (±0.00 Standard Deviation)
			Tocilizumab 8 mg/kg + Ortho-Novum® 1/35 (Group 1)	0.21 ng/mL (±0.07 Standard Deviation)
NCT01063062	Arthritis, Rheumatoid	Percentage of Participants Achieving Disease Activity Score 28 (DAS28) Low Disease Activity Baseline to Week 24 (Weeks 4, 8, 12, 16, 20, 24)	Tocilizumab	34.48 percentage of participants
			Tocilizumab	34.48 percentage of participants
			Tocilizumab	27.59 percentage of participants
			Tocilizumab	58.62 percentage of participants
			Tocilizumab	44.83 percentage of participants
			Tocilizumab	62.07 percentage of participants
			Tocilizumab + MTX	47.37 percentage of participants
			Tocilizumab + MTX	18.42 percentage of participants
			Tocilizumab + MTX	40.79 percentage of participants
			Tocilizumab + MTX	38.16 percentage of participants
			Tocilizumab + MTX	57.89 percentage of participants
			Tocilizumab + MTX	59.21 percentage of participants
NCT01063062	Arthritis, Rheumatoid	Time to DAS28 Low Disease Activity 24 Weeks	Tocilizumab	107.2 days
NCT01063062	Arthritis, Rheumatoid	Time to DAS28 Low Disease Activity 24 Weeks	Tocilizumab + MTX	100.2 days
NCT01194414	Arthritis, Rheumatoid	Percentage of Participants Achieving an American College of Rheumatology Criteria (ACR20) Response at Week 24 Baseline, 24 weeks	Tocilizumab IV	73.4 Percentage of participants
NCT01194414	Arthritis, Rheumatoid		Tocilizumab SC	69.4 Percentage of participants
NCT01194414	Arthritis, Rheumatoid	Percentage of Participants With Adverse Events, Serious Adverse Events and Clinically Significant Laboratory Assessments Baseline to up to 3 months after last dose of study drug (approximately up to 2 years)	Tocilizumab IV	87.8 percentage of participants
			Tocilizumab IV	28.2 percentage of participants
			Tocilizumab IV	12.7 percentage of participants
			Tocilizumab IV Then Tocilizumab SC	86.6 percentage of participants
			Tocilizumab IV Then Tocilizumab SC	11.3 percentage of participants
			Tocilizumab IV Then Tocilizumab SC	19.4 percentage of participants
			Tocilizumab SC	37.7 percentage of participants
			Tocilizumab SC	91.6 percentage of participants
			Tocilizumab SC	13.9 percentage of participants
			Tocilizumab SC Then Tocilizumab IV	81.3 percentage of participants
			Tocilizumab SC Then Tocilizumab IV	25.0 percentage of participants
			Tocilizumab SC Then Tocilizumab IV	12.5 percentage of participants
NCT01209689	Spondylitis, Ankylosing	Percentage of ASsessment in Ankylosing Spondylitis 20 (ASAS20) Responders at Week 12 Baseline to Week 12	Placebo	14.3 Percentage of patients
NCT01209689	Spondylitis, Ankylosing		Tocilizumab 4 or 8 mg/kg	12.7 Percentage of patients
NCT01209702	Spondylitis, Ankylosing	Part 1: Percentage of Participants Achieving a 20% Improvement in Assessment in Ankylosing Spondylitis (ASAS20) at Week 12 Baseline and Week 12	Part 1: Placebo	27.5 percentage of participants
NCT01209702	Spondylitis, Ankylosing		Part 1: Tocilizumab	37.3 percentage of participants
NCT01209702	Spondylitis, Ankylosing	Part 2: Percentage of Participants Achieving a 20% Improvement in Assessment in Ankylosing Spondylitis (ASAS20) at Week 12 Baseline and Week 12	Part 2: Placebo	7.8 percentage of participants
NCT01209702	Spondylitis, Ankylosing		Part 2: Tocilizumab	9.2 percentage of participants
NCT01232569	Arthritis, Rheumatoid	Percentage of Patients With an American College of Rheumatology 20 (ACR20) Response at Week 24 Baseline to Week 24	Placebo sc	31.5 Percentage of patients
NCT01232569	Arthritis, Rheumatoid		Tocilizumab 162 mg sc	60.9 Percentage of patients
NCT01235507	Arthritis, Rheumatoid	Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and AEs of Special Interest (AESIs) Screening Visit, Baseline, Weeks 4, 8, 12, 16, 20 and 24	Tocilizumab Plus MTX	4.2 percentage of participants
			Tocilizumab Plus MTX	14.1 percentage of participants
			Tocilizumab Plus MTX	2.8 percentage of participants
NCT01245439	Arthritis, Rheumatoid	Safety: Percentage of Participants With Treatment Emergent Adverse /Serious Adverse Events 24 weeks	Tocilizumab 8 mg/kg	9.2 percentage of participants
			Tocilizumab 8 mg/kg	90.8 percentage of participants
			Tocilizumab 8 mg/kg	52.3 percentage of participants
NCT01254331	Arthritis, Rheumatoid	Percentage of Participants With Adverse Events (AEs), Serious AEs (SAEs), Related AEs, Discontinuation Due to AEs, or Death Baseline, every 4 weeks through Week 52	Tocilizumab	0 percentage of participants
			Tocilizumab	78.4 percentage of participants
			Tocilizumab	5.9 percentage of participants
			Tocilizumab	15.2 percentage of participants
			Tocilizumab	7.8 percentage of participants
NCT01326962	Arthritis, Rheumatoid	Change in Fatigue as Measured Using the Fatigue Visual Analog Scale Up to 1 year	Tocilizumab	14.4 units on a scale
			Tocilizumab	20.1 units on a scale
			Tocilizumab	29.0 units on a scale
			Tocilizumab	32.3 units on a scale
			Tocilizumab	38.1 units on a scale
			Tocilizumab	32.0 units on a scale
			Tocilizumab	26.3 units on a scale
			Tocilizumab	23.9 units on a scale
			Tocilizumab	19.1 units on a scale
			Tocilizumab	20.7 units on a scale
			Tocilizumab	13.1 units on a scale
			Tocilizumab	18.0 units on a scale
NCT01326962	Arthritis, Rheumatoid	Changes in Participant's Fatigue Assessed Using the Mean FACIT-Fatigue Score Up to 1 year	Tocilizumab	19.1 Units on a scale
			Tocilizumab	23.5 Units on a scale
			Tocilizumab	24.1 Units on a scale
			Tocilizumab	23.6 Units on a scale
			Tocilizumab	24.0 Units on a scale
			Tocilizumab	21.6 Units on a scale
			Tocilizumab	22.0 Units on a scale
			Tocilizumab	22.3 Units on a scale
			Tocilizumab	27.8 Units on a scale
			Tocilizumab	27.3 Units on a scale
			Tocilizumab	26.6 Units on a scale
			Tocilizumab	25.6 Units on a scale
NCT01326962	Arthritis, Rheumatoid	Disease Activity as Measured by Disease Activity Score 28 (DAS28) Up to 1 year	Tocilizumab	2.0 units on a scale
			Tocilizumab	2.3 units on a scale
			Tocilizumab	5.4 units on a scale
			Tocilizumab	3.5 units on a scale
			Tocilizumab	2.1 units on a scale
			Tocilizumab	2.8 units on a scale
			Tocilizumab	2.2 units on a scale
			Tocilizumab	1.9 units on a scale
			Tocilizumab	1.7 units on a scale
			Tocilizumab	1.7 units on a scale
			Tocilizumab	1.5 units on a scale
			Tocilizumab	1.9 units on a scale
			Tocilizumab	1.7 units on a scale
NCT01326962	Arthritis, Rheumatoid	Number of Participants Who Achieved a Clinically Meaningful Improvement in DAS28 (Reduction of At Least 1.2 Units) Up to 1 year	Tocilizumab	11 participants
			Tocilizumab	21 participants
			Tocilizumab	20 participants
			Tocilizumab	20 participants
			Tocilizumab	22 participants
			Tocilizumab	21 participants
			Tocilizumab	20 participants
			Tocilizumab	19 participants
			Tocilizumab	20 participants
			Tocilizumab	17 participants
			Tocilizumab	12 participants
			Tocilizumab	4 participants
NCT01326962	Arthritis, Rheumatoid	Number of Participants Who Achieved Clinically Meaningful Health Assessment Questionnaire Response Up to 1 year	Tocilizumab	4 participants
			Tocilizumab	5 participants
			Tocilizumab	4 participants
			Tocilizumab	3 participants
			Tocilizumab	4 participants
			Tocilizumab	2 participants
			Tocilizumab	7 participants
			Tocilizumab	7 participants
			Tocilizumab	6 participants
			Tocilizumab	6 participants
			Tocilizumab	6 participants
NCT01326962	Arthritis, Rheumatoid	Number of Participants Who Achieved Low Disease Activity (DAS28 < 3.2) Up to 1 year	Tocilizumab	7 participants
			Tocilizumab	7 participants
			Tocilizumab	7 participants
			Tocilizumab	4 participants
			Tocilizumab	3 participants
			Tocilizumab	3 participants
			Tocilizumab	2 participants
			Tocilizumab	2 participants
			Tocilizumab	9 participants
			Tocilizumab	4 participants
			Tocilizumab	1 participants
			Tocilizumab	0 participants
NCT01326962	Arthritis, Rheumatoid	Number of Participants Who Achieved Remission (DAS28 < 2.6) Up to 1 year	Tocilizumab	7 participants
			Tocilizumab	15 participants
			Tocilizumab	4 participants
			Tocilizumab	8 participants
			Tocilizumab	18 participants
			Tocilizumab	13 participants
			Tocilizumab	3 participants
			Tocilizumab	7 participants
			Tocilizumab	12 participants
			Tocilizumab	14 participants
			Tocilizumab	17 participants
			Tocilizumab	16 participants
NCT01326962	Arthritis, Rheumatoid	Time to Das28 Remission Up to 1 year	Tocilizumab	189.01 Day (±7.053 Standard Error)
NCT01332994	Arthritis, Rheumatoid	Percentage of Participants Achieving Remission at Week 16 According to DAS28 Week 16	TCZ/TCZ or TCZ/RTX	42.8 percentage of participants
NCT01353859	Arthritis, Rheumatoid	Percentage of Participants Achieving Low Disease Activity Score Week 24	Tocilizumab + MTX	100 percentage of participants
NCT01532869	Scleroderma, Systemic	Change From Baseline in Modified Rodnan Skin Score (mRSS) at Week 24 Baseline, Week 24	Placebo	-1.22 unit on a scale
NCT01532869	Scleroderma, Systemic		Tocilizumab	-3.92 unit on a scale
NCT01532869	Scleroderma, Systemic	Percentage of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) Week 48	Placebo	90.9 percentage of participants
			Placebo	34.1 percentage of participants
			Tocilizumab	97.7 percentage of participants
			Tocilizumab	32.6 percentage of participants
NCT01575769	Arthritis, Juvenile	Percentage of Participants With Adverse Events (AEs) Baseline to 12 weeks after last actual study medication (up to 101 weeks)	Tocilizumab	0.0 percentage of participants
			Tocilizumab	22.0 percentage of participants
			Tocilizumab	0.0 percentage of participants
			Tocilizumab	2.4 percentage of participants
			Tocilizumab	0.0 percentage of participants
			Tocilizumab	2.4 percentage of participants
			Tocilizumab	56.1 percentage of participants
			Tocilizumab	29.3 percentage of participants
			Tocilizumab	7.3 percentage of participants
			Tocilizumab	2.4 percentage of participants
NCT01587989	Arthritis, Rheumatoid	Change From Week 12 (Randomization) to Week 24 in DAS28 Weeks 12 and 24	Group A: TCZ + MTX	0.17 score on a scale (±0.83 Standard Deviation)
NCT01587989	Arthritis, Rheumatoid		Group B: TCZ + Placebo	-0.16 score on a scale (±1.13 Standard Deviation)
NCT01610791	Arthritis, Rheumatoid	Percentage of Participants With Adverse Events Baseline, Weeks 4, 8, 12, 16, 20, and 24	Tocilizumab 8 mg/kg	0.8 percentage of participants
			Tocilizumab 8 mg/kg	8.3 percentage of participants
			Tocilizumab 8 mg/kg	48.8 percentage of participants
			Tocilizumab 8 mg/kg	10.7 percentage of participants
			Tocilizumab 8 mg/kg	5.8 percentage of participants
			Tocilizumab 8 mg/kg	10.7 percentage of participants
			Tocilizumab 8 mg/kg	4.1 percentage of participants
			Tocilizumab 8 mg/kg	5.0 percentage of participants
NCT01649804	Arthritis, Rheumatoid	Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and AEs of Special Interest (AESIs) End of Study (Week 104 or early withdrawal)	Tocilizumab	75 percentage of participants
			Tocilizumab	0 percentage of participants
			Tocilizumab	0 percentage of participants
NCT01655381	Arthritis, Rheumatoid	Percentage of Participants With Any Adverse Event (AE) Up to 160 weeks	Tocilizumab	6.7 percentage of participants
			Tocilizumab	0 percentage of participants
			Tocilizumab	20.0 percentage of participants
			Tocilizumab	20.0 percentage of participants
			Tocilizumab	80.0 percentage of participants
			Tocilizumab	80.0 percentage of participants
			Tocilizumab	93.3 percentage of participants
			Tocilizumab	6.7 percentage of participants
			Tocilizumab	0 percentage of participants
			Tocilizumab	33.3 percentage of participants
			Tocilizumab	93.3 percentage of participants
NCT01662063	Arthritis, Rheumatoid	Number of Participants With at Least One Serious Adverse Event (SAE) From Baseline to 8 weeks after last dose; assessed continuously during treatment (up to 96 weeks) and up to 8 weeks after last dose (up to 2 years overall)	SC TCZ Q2W	4 participants
NCT01662063	Arthritis, Rheumatoid		SC TCZ QW	19 participants
NCT01662063	Arthritis, Rheumatoid	Percentage of Participants With a Positive Anti-TCZ Antibody Assay at Any Timepoint From Baseline to 8 weeks after last dose; assessed at Baseline; Weeks 12, 24, 36, 48, 60, 72, 84, 96; and up to 8 weeks after last dose (up to 2 years overall)	SC TCZ Q2W	4.5 percentage of participants
NCT01662063	Arthritis, Rheumatoid		SC TCZ QW	7.8 percentage of participants
NCT01662063	Arthritis, Rheumatoid	Percentage of Participants With a Positive Anti-TCZ Antibody Assay at Baseline Baseline	SC TCZ Q2W	2.3 percentage of participants
NCT01662063	Arthritis, Rheumatoid		SC TCZ QW	4.8 percentage of participants
NCT01662063	Arthritis, Rheumatoid	Percentage of Participants With a Positive Anti-TCZ Antibody Assay Post-Baseline From Week 12 up to 8 weeks after last dose; assessed at Weeks 12, 24, 36, 48, 60, 72, 84, 96; and up to 8 weeks after last dose (up to 2 years overall)	SC TCZ Q2W	0 percentage of participants
			SC TCZ Q2W	0 percentage of participants
			SC TCZ Q2W	2.3 percentage of participants
			SC TCZ QW	0.6 percentage of participants
			SC TCZ QW	3.0 percentage of participants
			SC TCZ QW	0.6 percentage of participants
NCT01662063	Arthritis, Rheumatoid	Percentage of Participants With at Least One SAE From Baseline to 8 weeks after last dose; assessed continuously during treatment (up to 96 weeks) and up to 8 weeks after last dose (up to 2 years overall)	SC TCZ Q2W	9.1 percentage of participants
NCT01662063	Arthritis, Rheumatoid		SC TCZ QW	11.0 percentage of participants
NCT01664598	Arthritis, Rheumatoid	Percentage of Adverse Events (AEs) Leading to Dose Modification and AEs Leading to Study Withdrawal Up to 112 weeks	Tocilizumab	1.1 percentage of adverse events
NCT01664598	Arthritis, Rheumatoid		Tocilizumab	34.5 percentage of adverse events
NCT01664598	Arthritis, Rheumatoid	Percentage of Adverse Events With Severity as Mild, Moderate, and Severe Up to 112 weeks	Tocilizumab	62.1 percentage of adverse events
			Tocilizumab	1.1 percentage of adverse events
			Tocilizumab	36.8 percentage of adverse events
NCT01664598	Arthritis, Rheumatoid	Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and AEs of Special Interest (AESIs) Up to 112 weeks	Tocilizumab	17.2 percentage of participants
			Tocilizumab	10.2 percentage of participants
			Tocilizumab	69.4 percentage of participants
NCT01665430	Arthritis, Rheumatoid	Percentage of Participants With Adverse Events (AEs), AEs of Special Interest and Serious Adverse Events (SAEs) Baseline up to 112 weeks	Tocilizumab	34.2 percentage of participants
			Tocilizumab	7.9 percentage of participants
			Tocilizumab	65.8 percentage of participants
NCT01667471	Arthritis, Juvenile	Number of AEs of Special Interest and Study Drug Related AEs Baseline and every 4 weeks up to Week 76 and Final Follow-Up Visit (up to 82 weeks)	Tocilizumab 8 mg/kg	2 adverse events
			Tocilizumab 8 mg/kg	2 adverse events
			Tocilizumab 8 mg/kg	0 adverse events
			Tocilizumab 8 mg/kg	22 adverse events
NCT01667471	Arthritis, Juvenile	Number of Participants With Adverse Events of Special Interest and Study-Drug Related Adverse Events Baseline and every 4 weeks up to Week 76 and Final Follow-Up Visit (up to 82 weeks)	Tocilizumab	6 participants
			Tocilizumab	1 participants
			Tocilizumab	0 participants
			Tocilizumab	1 participants
NCT01668966	Arthritis, Rheumatoid	Percentage of Participants With TEAEs Leading to Change in Dose or Study Drug Discontinuation Baseline up to approximately 104 weeks	Tocilizumab	28.6 percentage of participants
NCT01668966	Arthritis, Rheumatoid		Tocilizumab	4.8 percentage of participants
NCT01668966	Arthritis, Rheumatoid	Percentage of Participants With TEAEs of Special Interest Baseline up to approximately 104 weeks	Tocilizumab	95.2 percentage of participants
NCT01668966	Arthritis, Rheumatoid	Percentage of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) Baseline up to approximately 104 weeks	Tocilizumab	9.5 percentage of participants
NCT01668966	Arthritis, Rheumatoid		Tocilizumab	95.2 percentage of participants
NCT01673919	Arthritis, Juvenile	Number of Participants With Adverse Events of Special Interest Approximately 2 years	Tocilizumab (8 mg/kg)	1 participants
			Tocilizumab (8 mg/kg)	1 participants
			Tocilizumab (8 mg/kg)	1 participants
			Tocilizumab (8 mg/kg)	1 participants
			Tocilizumab (8 mg/kg)	1 participants
			Tocilizumab (8 mg/kg)	1 participants
			Tocilizumab (8 mg/kg)	1 participants
			Tocilizumab (8 mg/kg)	1 participants
			Tocilizumab (8 mg/kg)	1 participants
			Tocilizumab (8 mg/kg)	1 participants
			Tocilizumab (8 mg/kg)	1 participants
			Tocilizumab (8 mg/kg)	1 participants
			Tocilizumab (8 mg/kg)	2 participants
			Tocilizumab (8 mg/kg)	1 participants
			Tocilizumab (8 mg/kg)	1 participants
			Tocilizumab (8 mg/kg)	2 participants
			Tocilizumab (8 mg/kg)	1 participants
			Tocilizumab (8 mg/kg)	1 participants
			Tocilizumab (8 mg/kg)	1 participants
			Tocilizumab (8 mg/kg)	1 participants
			Tocilizumab (8 mg/kg)	1 participants
NCT01673919	Arthritis, Juvenile	Number of Participants With Adverse Events Related to Tocilizumab Approximately 2 years	Tocilizumab (8 mg/kg)	1 participants
			Tocilizumab (8 mg/kg)	5 participants
			Tocilizumab (8 mg/kg)	2 participants
NCT01673919	Arthritis, Juvenile	Number of Participants With Any Adverse Events and Any Serious Adverse Events Approximately 2 years	Tocilizumab (8 mg/kg)	0 participants
NCT01673919	Arthritis, Juvenile		Tocilizumab (8 mg/kg)	7 participants
NCT01734993	Arthritis, Rheumatoid	Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) Baseline up to approximately 142 weeks	Tocilizumab	100 Percentage of participants
NCT01734993	Arthritis, Rheumatoid		Tocilizumab	18.2 Percentage of participants
NCT01734993	Arthritis, Rheumatoid	Percentage of Participants With Adverse Events of Special Interest (AESIs) Baseline up to approximately 142 weeks	Tocilizumab	18.2 Percentage of participants
NCT01734993	Arthritis, Rheumatoid	Percentage of Participants With AEs and SAEs Related to TCZ Baseline up to approximately 142 weeks	Tocilizumab	9.1 Percentage of participants
NCT01734993	Arthritis, Rheumatoid		Tocilizumab	72.7 Percentage of participants
NCT01734993	Arthritis, Rheumatoid	Percentage of Participants With AEs Leading to TCZ Discontinuation, Interruption, or Dose Modification Baseline up to approximately 142 weeks	Tocilizumab	63.6 Percentage of participants
			Tocilizumab	0.0 Percentage of participants
			Tocilizumab	9.1 Percentage of participants
NCT01734993	Arthritis, Rheumatoid	Percentage of Participants With AESIs Related to TCZ Baseline up to approximately 142 weeks	Tocilizumab	18.2 Percentage of participants
NCT01734993	Arthritis, Rheumatoid	Percentage of Participants With Anti-TCZ Antibodies Baseline up to approximately 142 weeks	Tocilizumab	0.0 Percentage of participants
NCT01734993	Arthritis, Rheumatoid	Percentage of Participants With Clinically Significant Laboratory Abnormalities Baseline up to approximately 142 weeks	Tocilizumab	9.1 Percentage of participants
NCT01734993	Arthritis, Rheumatoid	Percentage of Participants With Clinically Significant Physical Examinations and Vital Signs Abnormalities Baseline up to approximately 142 weeks	Tocilizumab	0.0 Percentage of participants
NCT01768572	Arthritis, Rheumatoid	Number of Participants With Treatment Emergent Adverse Events (TEAEs) Up to 211 days	Sarilumab 150 mg q2w	1 participants
			Sarilumab 150 mg q2w	33 participants
			Sarilumab 150 mg q2w	6 participants
			Sarilumab 150 mg q2w	0 participants
			Sarilumab 200 mg q2w	36 participants
			Sarilumab 200 mg q2w	8 participants
			Sarilumab 200 mg q2w	0 participants
			Sarilumab 200 mg q2w	3 participants
			Tocilizumab q4w	68 participants
			Tocilizumab q4w	1 participants
			Tocilizumab q4w	4 participants
			Tocilizumab q4w	7 participants
NCT01772316	Arthritis, Rheumatoid	Change From Baseline in DAS28-ESR at Week 96 Baseline, Week 96	Tocilizumab Subcutaneous (SC)	-0.804 units on a scale (±0.230 Standard Deviation)
NCT01772316	Arthritis, Rheumatoid	Change From Baseline in Disease Activity Score 28 - Erythrocyte Sedimentation Rate (DAS28-ESR) at Week 48 Baseline, Week 48	Tocilizumab Subcutaneous (SC)	-0.832 units on a scale (±0.292 Standard Deviation)
NCT01772316	Arthritis, Rheumatoid		Tocilizumab Subcutaneous (SC)	2.9 units on a scale (±1.4 Standard Deviation)
NCT01772316	Arthritis, Rheumatoid	Change From Baseline in SDAI at Week 96 Baseline, Week 96	Tocilizumab Subcutaneous (SC)	-6.599 units on a scale (±2.210 Standard Deviation)
NCT01772316	Arthritis, Rheumatoid	Change From Baseline in Simplified Disease Activity Index (SDAI) at Week 48 Baseline, Week 48	Tocilizumab Subcutaneous (SC)	-7.572 units on a scale (±2.115 Standard Deviation)
NCT01772316	Arthritis, Rheumatoid		Tocilizumab Subcutaneous (SC)	12.2 units on a scale (±10.7 Standard Deviation)
NCT01772316	Arthritis, Rheumatoid	Change From Baseline in SJC at Week 96 Baseline, Week 96	Tocilizumab Subcutaneous (SC)	-1.188 units on a scale (±0.543 Standard Deviation)
NCT01772316	Arthritis, Rheumatoid	Change From Baseline in Swollen Joint Count (SJC) at Week 48 Baseline, Week 48	Tocilizumab Subcutaneous (SC)	-1.531 units on a scale (±0.587 Standard Deviation)
NCT01772316	Arthritis, Rheumatoid		Tocilizumab Subcutaneous (SC)	1.8 units on a scale (±3.4 Standard Deviation)
NCT01772316	Arthritis, Rheumatoid	Change From Baseline in Total Tender Joint Count (TJC) at Week 48 Baseline, Week 48	Tocilizumab Subcutaneous (SC)	2.5 units on a scale (±4.1 Standard Deviation)
NCT01772316	Arthritis, Rheumatoid		Tocilizumab Subcutaneous (SC)	1.3 units on a scale (±2.0 Standard Deviation)
NCT01772316	Arthritis, Rheumatoid	Change From Baseline in Total TJC at Week 96 Baseline, Week 96	Tocilizumab Subcutaneous (SC)	1.5 units on a scale (±3.6 Standard Deviation)
NCT01772316	Arthritis, Rheumatoid	Percentage of Participants With an Adverse Event (AE) Baseline up to follow-up (Week 104)	Tocilizumab Subcutaneous (SC)	83 percentage of participants
NCT01772316	Arthritis, Rheumatoid	Percentage of Participants Withdrawn From the Study Due to Lack of Therapeutic Response Baseline up to follow-up (Week 104)	Tocilizumab Subcutaneous (SC)	0 percentage of participants
NCT01791153	Giant Cell Arteritis	Percentage of Participants in Sustained Remission at Week 52 (Tocilizumab + 26 Weeks Prednisone Taper Versus Placebo + 26 Weeks Prednisone Taper) Week 52	Part 1: Placebo + 26 Weeks Prednisone Taper	14.0 percentage of participants
			Part 1: Tocilizumab q2w + 26 Weeks Prednisone Taper	53.1 percentage of participants
			Part 1: Tocilizumab qw + 26 Weeks Prednisone Taper	56.0 percentage of participants
NCT01855789	Arthritis, Rheumatoid	Change From Week 24 in Disease Activity Score Based on 28 Joints (DAS28) Score at Week 40 Week 24, Week 40	Period 2: Randomized Participants (TCZ + MTX)	2.13 units on a scale (±0.816 Standard Deviation)
			Period 2: Randomized Participants (TCZ + MTX)	0.15 units on a scale (±1.127 Standard Deviation)
			Period 2: Randomized Participants (TCZ + PBO)	2.11 units on a scale (±0.822 Standard Deviation)
			Period 2: Randomized Participants (TCZ + PBO)	0.48 units on a scale (±1.275 Standard Deviation)
NCT01941095	Arthritis, Rheumatoid	Percentage of Participants Who Achieved Disease Activity Score Based on 28 Joint Count and Erythrocyte Sedimentation Rate (DAS28-ESR) Remission at Week 24 Week 24	Tocilizumab	40 percentage of participants
NCT01941940	Arthritis, Rheumatoid	Change From Baseline in CDAI at Week 12 Baseline, Week 12	Tocilizumab	-19.1 units on a scale (±12.46 Standard Deviation)
NCT01941940	Arthritis, Rheumatoid	Change From Baseline in CDAI at Week 16 Baseline, Week 16	Tocilizumab	-20.2 units on a scale (±12.53 Standard Deviation)
NCT01941940	Arthritis, Rheumatoid	Change From Baseline in CDAI at Week 2 Baseline, Week 2	Tocilizumab	-9.1 units on a scale (±9.71 Standard Deviation)
NCT01941940	Arthritis, Rheumatoid	Change From Baseline in CDAI at Week 20 Baseline, Week 20	Tocilizumab	-21.3 units on a scale (±12.87 Standard Deviation)
NCT01941940	Arthritis, Rheumatoid	Change From Baseline in CDAI at Week 4 Baseline, Week 4	Tocilizumab	-14.0 units on a scale (±11.57 Standard Deviation)
NCT01941940	Arthritis, Rheumatoid	Change From Baseline in CDAI at Week 8 Baseline, Week 8	Tocilizumab	-17.7 units on a scale (±12.07 Standard Deviation)
NCT01941940	Arthritis, Rheumatoid	Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 24 Baseline, Week 24	Tocilizumab	-21.6 units on a scale (±13.25 Standard Deviation)
NCT01951170	Arthritis, Rheumatoid	Change From Baseline in Genant-modified Total Sharp Score (mTSS) From baseline to Week 24	Tocilizumab	0 units on a scale
NCT01951170	Arthritis, Rheumatoid		Tocilizumab	7.00 units on a scale
NCT01987479 OSCAR	Arthritis, Rheumatoid	Percentage of Participants With Adverse Events Baseline up to Week 32	Tocilizumab Alone or in Combination With Methotrexate or DMARD	91.3 percentage of participants
NCT01988012	Arthritis, Rheumatoid	Change From Baseline in CDAI Baseline, Week 24	Tocilizumab	31.89 units on a scale (±14.35 Standard Deviation)
NCT01988012	Arthritis, Rheumatoid	Change From Baseline in CDAI Baseline, Week 24	Tocilizumab	-18.29 units on a scale (±14.52 Standard Deviation)
NCT01988012	Arthritis, Rheumatoid	Change From Baseline in Disease Activity Score 28-Erythrocyte-Sedimentation Rate (DAS28-ESR) Baseline, Week 24	Tocilizumab	-2.47 units on a scale (±1.29 Standard Deviation)
NCT01988012	Arthritis, Rheumatoid		Tocilizumab	4.98 units on a scale (±0.98 Standard Deviation)
NCT01988012	Arthritis, Rheumatoid	Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Baseline, Week 24	Tocilizumab	-0.34 units on a scale (±0.62 Standard Deviation)
NCT01988012	Arthritis, Rheumatoid		Tocilizumab	1.55 units on a scale (±0.80 Standard Deviation)
NCT01988012	Arthritis, Rheumatoid	Change From Baseline in Patient Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Baseline, Week 24	Tocilizumab	23.46 units on a scale (±11.32 Standard Deviation)
NCT01988012	Arthritis, Rheumatoid		Tocilizumab	6.95 units on a scale (±9.70 Standard Deviation)
NCT01988012	Arthritis, Rheumatoid	Change From Baseline in Patient Global Assessment of Disease Activity Visual Analog Scale (PGA VAS) Baseline, Week 24	Tocilizumab	69.73 units on a scale (±24.55 Standard Deviation)
NCT01988012	Arthritis, Rheumatoid		Tocilizumab	-31.22 units on a scale (±28.43 Standard Deviation)
NCT01988012	Arthritis, Rheumatoid	Change From Baseline in Patient Pain VAS Baseline, Week 24	Tocilizumab	64.82 units on a scale (±26.39 Standard Deviation)
NCT01988012	Arthritis, Rheumatoid	Change From Baseline in Patient Pain VAS Baseline, Week 24	Tocilizumab	-29.11 units on a scale (±29.16 Standard Deviation)
NCT01988012	Arthritis, Rheumatoid	Change From Baseline in Percentage of Participants on Tocilizumab Monotherapy Baseline, Week 24	Tocilizumab	12 percentage of participants
NCT01988012	Arthritis, Rheumatoid		Tocilizumab	26 percentage of participants
NCT01988012	Arthritis, Rheumatoid	Change From Baseline in SDAI Baseline, Week 24	Tocilizumab	33.73 units on a scale (±14.83 Standard Deviation)
NCT01988012	Arthritis, Rheumatoid	Change From Baseline in SDAI Baseline, Week 24	Tocilizumab	-21.41 units on a scale (±14.99 Standard Deviation)
NCT01988012	Arthritis, Rheumatoid	Change From Baseline in TJC and SJC Baseline, Week 24	Tocilizumab	-7.54 joint count (±9.60 Standard Deviation)
			Tocilizumab	21.42 joint count (±15.20 Standard Deviation)
			Tocilizumab	-11.91 joint count (±13.59 Standard Deviation)
			Tocilizumab	10.30 joint count (±10.27 Standard Deviation)
NCT01988012	Arthritis, Rheumatoid	Percentage of Participants Achieving 20%, 50% and 70% Improvement in American College of Rheumatology (ACR) Response Scores (ACR20, ACR50 and ACR70) Week 24	Tocilizumab	20.0 percentage of participants
			Tocilizumab	62.4 percentage of participants
			Tocilizumab	37.6 percentage of participants
NCT01988012	Arthritis, Rheumatoid	Percentage of Participants With Clinical Disease Activity Index (CDAI) Remission and CDAI Low Disease Activity Week 24	Tocilizumab	16.5 percentage of participants
NCT01988012	Arthritis, Rheumatoid		Tocilizumab	34.1 percentage of participants
NCT01988012	Arthritis, Rheumatoid	Percentage of Participants With Good to Moderate European League Against Rheumatism (EULAR) Response Week 24	Tocilizumab	96.4 percentage of participants
NCT01988012	Arthritis, Rheumatoid	Percentage of Participants With Simplified Disease Activity Index (SDAI) Remission and SDAI Low Disease Activity Week 24	Tocilizumab	19.2 percentage of participants
NCT01988012	Arthritis, Rheumatoid		Tocilizumab	38.5 percentage of participants
NCT01988012	Arthritis, Rheumatoid	Total Scores on Hamilton Depression Rating Scale (HDRS) and Hamilton Anxiety Scale (HAS) Baseline, Week 24	Tocilizumab	4.94 units on a scale (±5.85 Standard Deviation)
			Tocilizumab	5.93 units on a scale (±7.17 Standard Deviation)
			Tocilizumab	7.87 units on a scale (±7.19 Standard Deviation)
			Tocilizumab	8.56 units on a scale (±8.43 Standard Deviation)
NCT01995201	Arthritis, Rheumatoid	Percentage of Participants Achieving Sustained Clinical Remission, Disease Activity Scale 28 - Erythrocyte Sedimentation Rate <26 (DAS28-ESR <2.6) at Week 20 and Week 24 Week 20 and Week 24	Phase 1: Combination Therapy	52.9 Percentage of participants
NCT01995201	Arthritis, Rheumatoid		Phase 1: Tocilizumab Monotherapy	48.4 Percentage of participants
NCT02001987 TOSCA	Arthritis, Rheumatoid	Change From Baseline in Disease Activity Score Based on 28-joints Count and Erythrocyte Sedimentation Rate (DAS28-ESR) at Week 24 Baseline, Week 24	TCZ - All Participants - Core Study Period	-3.07 units on a scale (±1.52 Standard Deviation)
NCT02001987 TOSCA	Arthritis, Rheumatoid		TCZ - All Participants - Core Study Period	5.80 units on a scale (±1.14 Standard Deviation)
NCT02031471	Arthritis, Rheumatoid	Change From Baseline in Disease Activity Score 28 - Erythrocyte Sedimentation Rate (DAS28-ESR) Score in the Full Analysis Set (FAS) From baseline to Week 24	Tocilizumab	-3.24 Units on a scale (±1.47 Standard Deviation)
NCT02031471	Arthritis, Rheumatoid		Tocilizumab	5.55 Units on a scale (±1.17 Standard Deviation)
NCT02031471	Arthritis, Rheumatoid	Change From Baseline in Disease Activity Score 28 - Erythrocyte Sedimentation Rate (DAS28-ESR) Score in the Per Protocol Set (PPS) From baseline to Week 24	Tocilizumab	5.73 Units on a scale (±1.33 Standard Deviation)
NCT02031471	Arthritis, Rheumatoid		Tocilizumab	-3.21 Units on a scale (±1.42 Standard Deviation)
NCT02046603 ACT-MOVE	Arthritis, Rheumatoid	Change From Baseline in DAS28-ESR at Early Withdrawal Baseline, early withdrawal (up to Week 52)	Tocilizumab in Combination With Methotrexate or Other DMARDs	-1.63 units on a scale (±1.480 Standard Deviation)
NCT02046603 ACT-MOVE	Arthritis, Rheumatoid		Tocilizumab Monotherapy	-2.88 units on a scale (±1.236 Standard Deviation)
NCT02046603 ACT-MOVE	Arthritis, Rheumatoid	Change From Baseline in DAS28-ESR at Week 12 Baseline, Week 12	Tocilizumab in Combination With Methotrexate or Other DMARDs	-2.99 units on a scale (±1.510 Standard Deviation)
NCT02046603 ACT-MOVE	Arthritis, Rheumatoid		Tocilizumab Monotherapy	-2.33 units on a scale (±1.522 Standard Deviation)
NCT02046603 ACT-MOVE	Arthritis, Rheumatoid	Change From Baseline in DAS28-ESR at Week 16 Baseline, Week 16	Tocilizumab in Combination With Methotrexate or Other DMARDs	-3.07 units on a scale (±1.532 Standard Deviation)
NCT02046603 ACT-MOVE	Arthritis, Rheumatoid		Tocilizumab Monotherapy	-2.93 units on a scale (±1.218 Standard Deviation)
NCT02046603 ACT-MOVE	Arthritis, Rheumatoid	Change From Baseline in DAS28-ESR at Week 20 Baseline, Week 20	Tocilizumab in Combination With Methotrexate or Other DMARDs	-3.13 units on a scale (±1.525 Standard Deviation)
NCT02046603 ACT-MOVE	Arthritis, Rheumatoid		Tocilizumab Monotherapy	-3.17 units on a scale (±1.346 Standard Deviation)
NCT02046603 ACT-MOVE	Arthritis, Rheumatoid	Change From Baseline in DAS28-ESR at Week 24 Baseline, Week 24	Tocilizumab in Combination With Methotrexate or Other DMARDs	-3.33 units on a scale (±1.470 Standard Deviation)
NCT02046603 ACT-MOVE	Arthritis, Rheumatoid		Tocilizumab Monotherapy	-3.28 units on a scale (±1.379 Standard Deviation)
NCT02046603 ACT-MOVE	Arthritis, Rheumatoid	Change From Baseline in DAS28-ESR at Week 28 Baseline, Week 28	Tocilizumab in Combination With Methotrexate or Other DMARDs	-3.32 units on a scale (±1.552 Standard Deviation)
NCT02046603 ACT-MOVE	Arthritis, Rheumatoid		Tocilizumab Monotherapy	-3.54 units on a scale (±1.260 Standard Deviation)
NCT02046603 ACT-MOVE	Arthritis, Rheumatoid	Change From Baseline in DAS28-ESR at Week 32 Baseline, Week 32	Tocilizumab in Combination With Methotrexate or Other DMARDs	-3.54 units on a scale (±1.448 Standard Deviation)
NCT02046603 ACT-MOVE	Arthritis, Rheumatoid		Tocilizumab Monotherapy	-3.19 units on a scale (±1.418 Standard Deviation)
NCT02046603 ACT-MOVE	Arthritis, Rheumatoid	Change From Baseline in DAS28-ESR at Week 36 Baseline, Week 36	Tocilizumab in Combination With Methotrexate or Other DMARDs	-3.55 units on a scale (±1.589 Standard Deviation)
NCT02046603 ACT-MOVE	Arthritis, Rheumatoid		Tocilizumab Monotherapy	-3.57 units on a scale (±1.358 Standard Deviation)
NCT02046603 ACT-MOVE	Arthritis, Rheumatoid	Change From Baseline in DAS28-ESR at Week 4 Baseline, Week 4	Tocilizumab in Combination With Methotrexate or Other DMARDs	-2.11 units on a scale (±1.215 Standard Deviation)
NCT02046603 ACT-MOVE	Arthritis, Rheumatoid		Tocilizumab Monotherapy	-1.86 units on a scale (±1.016 Standard Deviation)
NCT02046603 ACT-MOVE	Arthritis, Rheumatoid	Change From Baseline in DAS28-ESR at Week 40 Baseline, Week 40	Tocilizumab in Combination With Methotrexate or Other DMARDs	-3.64 units on a scale (±1.524 Standard Deviation)
NCT02046603 ACT-MOVE	Arthritis, Rheumatoid		Tocilizumab Monotherapy	-3.82 units on a scale (±1.143 Standard Deviation)
NCT02046603 ACT-MOVE	Arthritis, Rheumatoid	Change From Baseline in DAS28-ESR at Week 44 Baseline, Week 44	Tocilizumab in Combination With Methotrexate or Other DMARDs	-3.65 units on a scale (±1.574 Standard Deviation)
NCT02046603 ACT-MOVE	Arthritis, Rheumatoid		Tocilizumab Monotherapy	-3.61 units on a scale (±1.325 Standard Deviation)
NCT02046603 ACT-MOVE	Arthritis, Rheumatoid	Change From Baseline in DAS28-ESR at Week 48 Baseline, Week 48	Tocilizumab in Combination With Methotrexate or Other DMARDs	-3.65 units on a scale (±1.552 Standard Deviation)
NCT02046603 ACT-MOVE	Arthritis, Rheumatoid		Tocilizumab Monotherapy	-3.54 units on a scale (±1.146 Standard Deviation)
NCT02046603 ACT-MOVE	Arthritis, Rheumatoid	Change From Baseline in DAS28-ESR at Week 52 Baseline, Week 52	Tocilizumab in Combination With Methotrexate or Other DMARDs	-3.67 units on a scale (±1.592 Standard Deviation)
NCT02046603 ACT-MOVE	Arthritis, Rheumatoid		Tocilizumab Monotherapy	-3.75 units on a scale (±1.361 Standard Deviation)
NCT02046603 ACT-MOVE	Arthritis, Rheumatoid	Change From Baseline in DAS28-ESR at Week 8 Baseline, Week 8	Tocilizumab in Combination With Methotrexate or Other DMARDs	-2.62 units on a scale (±1.482 Standard Deviation)
NCT02046603 ACT-MOVE	Arthritis, Rheumatoid		Tocilizumab Monotherapy	-2.42 units on a scale (±1.352 Standard Deviation)
NCT02046603 ACT-MOVE	Arthritis, Rheumatoid	Change From Baseline in Disease Activity Score 28-Erythrocyte Sedimentation Rate (DAS28-ESR) at Week 2 Baseline, Week 2	Tocilizumab in Combination With Methotrexate or Other DMARDs	5.53 units on a scale (±1.257 Standard Deviation)
			Tocilizumab in Combination With Methotrexate or Other DMARDs	-1.22 units on a scale (±1.131 Standard Deviation)
			Tocilizumab Monotherapy	5.52 units on a scale (±1.014 Standard Deviation)
			Tocilizumab Monotherapy	-1.41 units on a scale (±0.994 Standard Deviation)
NCT02046616	Arthritis, Rheumatoid	Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 12 Baseline, Week 12	Tocilizumab Alone or Combined With Methotrexate or Other DMARD	24.9 units on a scale (±10.5 Standard Deviation)
NCT02046616	Arthritis, Rheumatoid		Tocilizumab Alone or Combined With Methotrexate or Other DMARD	-16.6 units on a scale (±12.1 Standard Deviation)
NCT02453256 focuSSced	Scleroderma, Systemic	Change in Modified Rodnan Skin Score (mRSS) During Double-blind Period From baseline to week 48	Double-Blind Placebo	-4.41 Units on a scale
NCT02453256 focuSSced	Scleroderma, Systemic		Double-Blind Tocilizumab	-6.14 Units on a scale
NCT04320615 COVACTA	—	Clinical Status Assessed Using a 7-Category Ordinal Scale at Day 28 (Week 4) Day 28	Placebo Modified Intent-to-Treat (mITT) Arm	2.8 Percentage of Participants
			Placebo Modified Intent-to-Treat (mITT) Arm	5.6 Percentage of Participants
			Placebo Modified Intent-to-Treat (mITT) Arm	49.3 Percentage of Participants
			Placebo Modified Intent-to-Treat (mITT) Arm	6.9 Percentage of Participants
			Placebo Modified Intent-to-Treat (mITT) Arm	9.7 Percentage of Participants
			Placebo Modified Intent-to-Treat (mITT) Arm	6.3 Percentage of Participants
			Placebo Modified Intent-to-Treat (mITT) Arm	19.4 Percentage of Participants
			Tocilizumab (TCZ) mITT Arm	19.7 Percentage of Participants
			Tocilizumab (TCZ) mITT Arm	6.1 Percentage of Participants
			Tocilizumab (TCZ) mITT Arm	8.8 Percentage of Participants
			Tocilizumab (TCZ) mITT Arm	2.0 Percentage of Participants
			Tocilizumab (TCZ) mITT Arm	56.5 Percentage of Participants
			Tocilizumab (TCZ) mITT Arm	2.0 Percentage of Participants
			Tocilizumab (TCZ) mITT Arm	4.8 Percentage of Participants
NCT04330638 COV-AID	COVID-19	Time to Clinical Improvement at day 15	IL-6 Blockade	11 days
			IL 1 Blockade	12 days
			No IL-1 Blockade	12 days
			No IL-6 Blockade	12 days
NCT04356937	—	Mechanical Ventilation or Death 28 days	Placebo	12.5 percentage of patients with event
			Placebo	10.0 percentage of patients with event
			Tocilizumab	10.6 percentage of patients with event
			Tocilizumab	9.9 percentage of patients with event
NCT04372186 EMPACTA	—	Cumulative Proportion of Participants Who Died or Required Mechanical Ventilation by Day 28 Up to Day 28	Placebo	19.26 Percentage of Participants
NCT04372186 EMPACTA	—		Tocilizumab	12.04 Percentage of Participants
NCT04409262 REMDACTA	—	Time to Hospital Discharge or "Ready for Discharge" up to Day 28 Up to Day 28	Remdesivir + Placebo (RDV+Placebo) - mITT Population	14.0 days
NCT04409262 REMDACTA	—		Remdesivir + Tocilizumab (RDV+TCZ) - mITT Population	14.0 days
NCT05171647 SUNMO	Lymphoma, Non-Hodgkin	Objective Response Rate (ORR) as Determined by the Independent Review Facility (IRF), According to Lugano Response Criteria 2014 (LRC) Using Positron Emission Tomography-computed Tomography (PET-CT) or CT Scans in Interim Analysis Population (IAP) Up to approximately 23.8 months	Arm A: Mosun-Pola	69.7 percentage of participants
NCT05171647 SUNMO	Lymphoma, Non-Hodgkin		Arm B: R-GemOx	44.1 percentage of participants
NCT05171647 SUNMO	Lymphoma, Non-Hodgkin	Progression-free Survival (PFS) as Determined by the IRF, According to LRC Using PET-CT or CT Scans Up to 32 months	Arm A: Mosun-Pola	11.5 months
NCT05171647 SUNMO	Lymphoma, Non-Hodgkin		Arm B: R-GemOx	3.8 months

Publications by year

1976–2026: 693 publications.

1976

1985

1986

1987

1989

1990

1992

1993

1994

1995

1996

1997

1998

1999

2000

2001

2002

2003

2004

2005

2006

2007

2008

2009

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

2022

2023

2024

2025

2026

Publications by indication

Arthritis, Rheumatoid (140)

Efficacy and safety of filgotinib versus tocilizumab in active rheumatoid arthritis: A randomized, open-label, multicenter study with clinical and musculoskeletal ultrasound evaluation (TRANSFORM study).
Drug Discov Ther · 2026 · PMID 42036316 · NCT05090410
Validation of Boolean 2.0 criteria for remission and quality of life prediction in Korean patients with rheumatoid arthritis receiving targeted therapy.
Rheumatology (Oxford) · 2026 · PMID 41025512 · NCT04449224
Abatacept versus tocilizumab for the treatment of rheumatoid arthritis in TNF inhibitor inadequate responders: study protocol of the SUNSTAR randomised controlled open-label superiority trial.
BMJ Open · 2025 · PMID 40527572 · NCT03227419
Tocilizumab Monotherapy or Combined With Methotrexate for Rheumatoid Arthritis: A Randomized Clinical Trial.
JAMA Netw Open · 2025 · PMID 40388166 · NCT03155347
Usability, efficacy, and safety of candidate tocilizumab biosimilar CT-P47 self-administration via auto-injector and pre-filled syringe in patients with rheumatoid arthritis: a single-arm, open-label, phase 3 study.
Expert Rev Clin Immunol · 2025 · PMID 39803727 · NCT05725434

COVID-19 (103)

Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Lancet Infect Dis · 2025 · PMID 40886716 · NCT04381936
Molnupiravir or nirmatrelvir-ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Lancet Infect Dis · 2025 · PMID 40383127 · NCT04381936
Effect of hydrocortisone on mortality in patients with severe community-acquired pneumonia : The REMAP-CAP Corticosteroid Domain Randomized Clinical Trial.
Intensive Care Med · 2025 · PMID 40261382 · NCT02735707
Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial.
EClinicalMedicine · 2025 · PMID 40036152 · NCT04381936
Tocilizumab, sarilumab and anakinra in critically ill patients with COVID-19: a randomised, controlled, open-label, adaptive platform trial.
Thorax · 2025 · PMID 40360262 · NCT02735707

Inflammation (72)

Interleukin 6 blockage alters the plasma metabolome in out-of-hospital cardiac arrest.
Resuscitation · 2024 · PMID 39510308 · NCT03863015
Neutrophil Extracellular Traps in ST-Segment Elevation Myocardial Infarction: Reduced by Tocilizumab and Associated With Infarct Size.
JACC Adv · 2024 · PMID 39247678 · NCT03004703
Interleukin-6 receptor antibodies (tocilizumab) in acute myocardial infarction with intermediate to high risk of cardiogenic shock development (DOBERMANN-T): study protocol for a double-blinded, placebo-controlled, single-center, randomized clinical trial.
Trials · 2024 · PMID 39501388 · NCT05350592
Low-dose dobutamine in acute myocardial infarction with intermediate to high risk of cardiogenic shock development (the DOBERMANN-D trial): study protocol for a double-blinded, placebo-controlled, single-center, randomized clinical trial.
Trials · 2024 · PMID 39478521 · NCT05350592
Cytokine pattern in patients with ST-elevation myocardial infarction treated with the interleukin-6 receptor antagonist tocilizumab.
Open Heart · 2023 · PMID 37591633 · NCT03004703

Appetitive Behavior (39)

World Cancer Report: Cancer research for cancer prevention
2020 · PMID 39432694 · NCT04616235
Effects of Exercise on Gene Expression of Inflammatory Markers in Human Peripheral Blood Cells: A Systematic Review.
Curr Cardiovasc Risk Rep · 2020 · PMID 26005511 · NCT04616235
Tissue Determinants of Human NK Cell Development, Function, and Residence.
Cell · 2020 · PMID 32059780 · NCT04616235
Lymphocytes and monocytes egress peripheral blood within minutes after cessation of steady state exercise: A detailed temporal analysis of leukocyte extravasation.
Physiol Behav · 2019 · PMID 29885920 · NCT04616235
Interleukin-6 Delays Gastric Emptying in Humans with Direct Effects on Glycemic Control.
Cell Metab · 2019 · PMID 29731416 · NCT04616235

Graves Ophthalmopathy (26)

Tocilizumab in Active, Moderate-to-Severe, Glucocorticoid-Resistant Thyroid Eye Disease: An Open-Label Prospective Study in Two Independent Cohorts.
Thyroid · 2026 · PMID 42117357 · NCT06367517
Long-term remission of corticosteroid-resistant Graves' orbitopathy after therapy with tocilizumab.
Endokrynol Pol · 2024 · PMID 38497401 · NCT06367517
Management of Thyroid Eye Disease: A Consensus Statement by the American Thyroid Association and the European Thyroid Association.
Thyroid · 2022 · PMID 36480280 · NCT06367517
The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy.
Eur J Endocrinol · 2021 · PMID 34297684 · NCT06367517
Efficacy of Tocilizumab in Patients With Moderate-to-Severe Corticosteroid-Resistant Graves Orbitopathy: A Randomized Clinical Trial.
Am J Ophthalmol · 2019 · PMID 30081019 · NCT06367517

Cytokine Release Syndrome (23)

Low-Dose radiation therapy for benign pathologies.
Rep Pract Oncol Radiother · 2023 · PMID 32140081 · NCT04394182
Low dose lung radiotherapy for COVID-19 pneumonia. The rationale for a cost-effective anti-inflammatory treatment.
Clin Transl Radiat Oncol · 2023 · PMID 32373721 · NCT04394182
Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial.
BMJ · 2021 · PMID 33472855 · NCT04403685
COVID-19 pneumonia treated with ultra-low doses of radiotherapy (ULTRA-COVID study): a single institution report of two cases.
Strahlenther Onkol · 2021 · PMID 33502567 · NCT04394182
Is low dose radiation therapy a potential treatment for COVID-19 pneumonia?
Radiother Oncol · 2020 · PMID 32342871 · NCT04394182

Publications by journal

Ann Rheum Dis55 papers
N Engl J Med28 papers
Lancet25 papers
Rheumatology (Oxford)24 papers
Arthritis Rheum22 papers
JAMA14 papers
Arthritis Res Ther14 papers
Blood13 papers
Circulation13 papers
Arthritis Rheumatol12 papers

Trial-results highlights

In the NCT00106535 study for rheumatoid arthritis, the mean change from baseline in the Modified Total Sharp-Genant Score at Week 52 was 1.13 for participants receiving placebo plus methotrexate. For those receiving Tocilizumab 4 mg/kg plus methotrexate, the mean change was 0.34, and for Tocilizumab 8 mg/kg plus methotrexate, it was 0.29. At Week 104, these scores were 1.96 for placebo plus methotrexate, 0.58 for Tocilizumab 4 mg/kg plus methotrexate, and 0.37 for Tocilizumab 8 mg/kg plus methotrexate. Physical function, measured by the Area Under the Curve for the change from baseline in the Health Assessment Questionnaire Disability Index at Week 52, showed a least squares mean of -58.11 for placebo plus methotrexate, -128.37 for Tocilizumab 4 mg/kg plus methotrexate, and -144.06 for Tocilizumab 8 mg/kg plus methotrexate. At Week 104, these values were -139.40 for placebo plus methotrexate, -287.50 for Tocilizumab 4 mg/kg plus methotrexate, and -320.80 for Tocilizumab 8 mg/kg plus methotrexate.

Regarding American College of Rheumatology (ACR) responses, in NCT00106535, the percentage of participants achieving an ACR20 response at Week 24 was 27.0% for placebo plus methotrexate. For participants receiving Tocilizumab 4 mg/kg plus methotrexate, this was 50.6%, and for Tocilizumab 8 mg/kg plus methotrexate, it was 56.3%. Another study, NCT00531817 (ROSE), evaluated the percentage of patients with an ACR50 improvement at Week 24. In this study, 11.2% of participants in the placebo plus DMARDs arm achieved an ACR50 response, while 30.1% of participants in the Tocilizumab 8 mg/kg plus DMARDs arm achieved this response.

In the NCT00535782 study, changes from baseline in small low-density lipoprotein (sLDL) particle numbers were evaluated at Week 12. For the placebo plus MTX arm, the mean values reported were 777.71 nmol/L, 22.41 nmol/L, and 792.78 nmol/L. For the Tocilizumab plus MTX arm, the mean values reported were 23.73 nmol/L, 768.04 nmol/L, and 737.79 nmol/L. Also in NCT00535782, the change from baseline to Week 12 in Aortic Pulse Wave Velocity (PWV) was measured. The mean baseline PWV for placebo plus MTX was 8.39 meters/second, with a Week 12 mean of 9.01 meters/second, and a mean change of -0.68 meters/second. For Tocilizumab plus MTX, the mean baseline PWV was 8.97 meters/second, with a Week 12 mean of 8.94 meters/second, and a mean change of -0.03 meters/second.

All values presented are sourced from primary registry reporting; individual publications should be consulted for clinical decisions.

All Tocilizumab publications (693)

2026 (11 papers)

First-in-human phase 1 study of RO7119929, an oral TLR7 agonist prodrug, in patients with advanced primary or metastatic liver cancers.
Yoo C, Fabregat-Franco C, Lin CC, et al. · J Immunother Cancer · 2026 · Derived
PubMed: PMID 41802810 · NCT04338685 · Carcinoma, Hepatocellular
Efficacy and safety of filgotinib versus tocilizumab in active rheumatoid arthritis: A randomized, open-label, multicenter study with clinical and musculoskeletal ultrasound evaluation (TRANSFORM study).
Shimizu T, Kawashiri SY, Koga T, et al. · Drug Discov Ther · 2026 · Derived
PubMed: PMID 42036316 · NCT05090410 (TRANSFORM) · Arthritis, Rheumatoid
Adalimumab, Anakinra, and Tocilizumab in Patients With Noninfectious Uveitis: A Multicenter Randomized Controlled Trial.
Saadoun D, Ghembaza A, Touhami S, et al. · Am J Ophthalmol · 2026 · Derived
PubMed: PMID 41643758 · NCT02929251 (RUBI) · Uveitis
Tocilizumab in Active, Moderate-to-Severe, Glucocorticoid-Resistant Thyroid Eye Disease: An Open-Label Prospective Study in Two Independent Cohorts.
Rymuza J, Kuś A, Nedeljković Beleslin B, et al. · Thyroid · 2026 · Derived
PubMed: PMID 42117357 · NCT06367517 · Graves Ophthalmopathy
Levels of circulating kidney injury markers and IL-10 identify non-critically ill patients with COVID-19 at risk of death.
Lenoir O, Morin F, Walter-Petrich A, et al. · JCI Insight · 2026 · Derived
PubMed: PMID 41574613 · NCT04331808 (CORIMUNO-TOC) · Coronavirus Infections
Two Distinct Phenotypes of Takayasu Arteritis Associated With TNF-α and IL-6: Implications for Endotype-driven Precise Therapy.
Kong X, Li M, Chang S, et al. · Can J Cardiol · 2026 · Derived
PubMed: PMID 42025686 · NCT03893136 · Takayasu Arteritis
Myokine IL-6 activity enhances post-exercise fatty acid accumulation in skeletal muscle but does not affect glycogen resynthesis.
Kistner TM, Trinh B, Mfeketo K, et al. · Mol Metab · 2026 · Derived
PubMed: PMID 41242537 · NCT05349149 (REX-6)
Effect of IL-6 receptor inhibition on infarct volume after endovascular treatment for ischaemic stroke: a phase 2, randomised, placebo-controlled trial.
Chu X, Lan J, Ma Z, et al. · EBioMedicine · 2026 · Derived
PubMed: PMID 41687453 · NCT06238024 (IRIS) · Ischemic Stroke
Validation of Boolean 2.0 criteria for remission and quality of life prediction in Korean patients with rheumatoid arthritis receiving targeted therapy.
Cho SK, Choi SR, Nam E, et al. · Rheumatology (Oxford) · 2026 · Derived
PubMed: PMID 41025512 · NCT04449224 · Arthritis, Rheumatoid
Interim assessment by circulating tumor DNA in primary mediastinal large B-cell lymphoma: a multicenter LYSA study.
Camus V, Krzisch D, Bruscaggin A, et al. · Blood Adv · 2026 · Derived
PubMed: PMID 41979332 · NCT04980222 · Lymphoma
Mosunetuzumab plus polatuzumab vedotin in relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 study.
Budde LE, Kamdar M, Assouline SE, et al. · Blood · 2026 · Derived
PubMed: PMID 42013019 · NCT03671018 · Lymphoma, B-Cell

2025 (22 papers)

Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group · Lancet Infect Dis · 2025 · Trial result
PubMed: PMID 40886716 · NCT04381936 (RECOVERY) · COVID-19
Molnupiravir or nirmatrelvir-ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group · Lancet Infect Dis · 2025 · Trial result
PubMed: PMID 40383127 · NCT04381936 (RECOVERY) · COVID-19
Mosunetuzumab plus Pola-CHP compared with Pola-R-CHP in previously untreated DLBCL: final results from a phase 2 study.
Westin J, Phillips TJ, Mehta A, et al. · Blood Adv · 2025 · Derived
PubMed: PMID 39908481 · NCT03677141 · Lymphoma, B-Cell
Inhibition of basal IL-6 activity promotes subcutaneous fat retention in humans during fasting and postprandial states.
Trinh B, Rasmussen SJ, Brøgger-Jensen ME, et al. · Cell Rep Med · 2025 · Derived
PubMed: PMID 40147447 · NCT04687540 · Obesity
Immediate versus gradual TocilizuMab discontinuAtion in GIant Cell Arteritis: protocol of the multicentre randomised open-label MAGICA trial.
Samson M, Fournel I, Bourredjem A, et al. · BMJ Open · 2025 · Derived
PubMed: PMID 41067765 · NCT06037460 (MAGICA) · Giant Cell Arteritis
Preclinical advances in glofitamab combinations: a new frontier for non-Hodgkin lymphoma.
Sam J, Leclercq-Cohen G, Gebhardt S, et al. · Blood · 2025 · Derived
PubMed: PMID 40749164 · NCT04408638 · Lymphoma, Large B-Cell, Diffuse
Effect of hydrocortisone on mortality in patients with severe community-acquired pneumonia : The REMAP-CAP Corticosteroid Domain Randomized Clinical Trial.
REMAP-CAP Investigators, Angus DC · Intensive Care Med · 2025 · Derived
PubMed: PMID 40261382 · NCT02735707 (REMAP-CAP) · COVID-19
Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group · EClinicalMedicine · 2025 · Derived
PubMed: PMID 40036152 · NCT04381936 (RECOVERY) · COVID-19
Phase 2 trial of cyclosporine-A, mycophenolate mofetil, and tocilizumab GVHD prophylaxis in cord blood transplantation.
Politikos I, Brown S, Fein JA, et al. · Blood Adv · 2025 · Derived
PubMed: PMID 40423982 · NCT03434730 · Lymphoma, Non-Hodgkin
Glofitamab in Relapsed/Refractory Mantle Cell Lymphoma: Results From a Phase I/II Study.
Phillips TJ, Carlo-Stella C, Morschhauser F, et al. · J Clin Oncol · 2025 · Derived
PubMed: PMID 39365960 · NCT03075696 · Lymphoma, Non-Hodgkin
Abatacept versus tocilizumab for the treatment of rheumatoid arthritis in TNF inhibitor inadequate responders: study protocol of the SUNSTAR randomised controlled open-label superiority trial.
Pascart T, Fautrel B, Gottenberg JE, et al. · BMJ Open · 2025 · Derived
PubMed: PMID 40527572 · NCT03227419 (SUNSTAR) · Arthritis, Rheumatoid
Treatment of giant cell arteritis with ultra-short glucocorticoids and tocilizumab: results from the extension of the TOPAZIO study.
Muratore F, Marvisi C, Cassone G, et al. · Rheumatology (Oxford) · 2025 · Derived
PubMed: PMID 39150490 · NCT05394909 (TOPAZIO)
Tocilizumab Monotherapy or Combined With Methotrexate for Rheumatoid Arthritis: A Randomized Clinical Trial.
Liu T, Wang L, Zhang X, et al. · JAMA Netw Open · 2025 · Derived
PubMed: PMID 40388166 · NCT03155347 · Arthritis, Rheumatoid
Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a Phase Ib/II Trial.
Hutchings M, Sureda A, Bosch F, et al. · J Clin Oncol · 2025 · Derived
PubMed: PMID 41115257 · NCT03533283 · Lymphoma, Non-Hodgkin
Dose escalation study of the HLA-A2-WT1 CD3 bispecific antibody RO7283420 in relapsed/refractory acute myeloid leukemia.
Hutchings M, Korfi K, Montesinos P, et al. · Blood Neoplasia · 2025 · Derived
PubMed: PMID 40746940 · NCT04580121 · Leukemia, Myeloid, Acute
Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b-2, study.
Finn RS, Ryoo BY, Hsu CH, et al. · Lancet Oncol · 2025 · Derived
PubMed: PMID 39855251 · NCT04524871 (MORPHEUS-LIVER)
Exploring total inflammatory vascular volume as a diagnostic and prognostic biomarker in giant cell arteritis.
Durmo R, Muratore F, Marvisi C, et al. · Rheumatology (Oxford) · 2025 · Derived
PubMed: PMID 40650989 · NCT05394909 (TOPAZIO)
Tocilizumab, sarilumab and anakinra in critically ill patients with COVID-19: a randomised, controlled, open-label, adaptive platform trial.
Derde L, Gordon AC, Mouncey PR, et al. · Thorax · 2025 · Derived
PubMed: PMID 40360262 · NCT02735707 (REMAP-CAP) · COVID-19
Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatment in Advanced Pancreatic Cancer: Survival and Cachexia.
Chen IM, Johansen JS, Theile S, et al. · J Clin Oncol · 2025 · Derived
PubMed: PMID 40354592 · NCT02767557 (PACTO)
Usability, efficacy, and safety of candidate tocilizumab biosimilar CT-P47 self-administration via auto-injector and pre-filled syringe in patients with rheumatoid arthritis: a single-arm, open-label, phase 3 study.
Burmester G, Klimiuk PA, Trefler J, et al. · Expert Rev Clin Immunol · 2025 · Derived
PubMed: PMID 39803727 · NCT05725434 · Arthritis, Rheumatoid
Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial.
Budde LE, Zhang H, Kim WS, et al. · J Clin Oncol · 2025 · Derived
PubMed: PMID 41037766 · NCT05171647 (SUNMO) · Lymphoma, Non-Hodgkin
Management of systemic sclerosis: British Society for Rheumatology guideline scope.
Denton CP, De Lorenzis E, Roblin E, et al. · Rheumatol Adv Pract · 2025 · Background
PubMed: PMID 36923262 · NCT06297096 (NINTOC-TU) · Scleroderma, Systemic

2024 (29 papers)

Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group, Horby PW, Peto L, et al. · Nat Commun · 2024 · Trial result
PubMed: PMID 38296965 · NCT04381936 (RECOVERY) · COVID-19
Treatment efficacy and safety of adalimumab versus tocilizumab in patients with active and severe Takayasu arteritis: an open-label study.
Wang J, Kong X, Ma L, et al. · Rheumatology (Oxford) · 2024 · Derived
PubMed: PMID 37540159 · NCT04300686 · Takayasu Arteritis
Treatment for giant cell arteritis with 8 weeks of prednisone in combination with tocilizumab: a single-arm, open-label, proof-of-concept study.
Unizony S, Matza MA, Jarvie A, et al. · Lancet Rheumatol · 2024 · Derived
PubMed: PMID 38251564 · NCT03726749 · Giant Cell Arteritis
Anakinra or tocilizumab in patients admitted to hospital with severe covid-19 at high risk of deterioration (IMMCoVA): A randomized, controlled, open-label trial.
Sundén-Cullberg J, Chen P, Häbel H, et al. · PLoS One · 2024 · Derived
PubMed: PMID 38157348 · NCT04412291 · COVID-19
Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial.
Stone JH, Han J, Aringer M, et al. · Lancet Rheumatol · 2024 · Derived
PubMed: PMID 38279390 · NCT01791153 · Giant Cell Arteritis
Phase 1, first-in-human study of TYRP1-TCB (RO7293583), a novel TYRP1-targeting CD3 T-cell engager, in metastatic melanoma: active drug monitoring to assess the impact of immune response on drug exposure.
Spreafico A, Couselo EM, Irmisch A, et al. · Front Oncol · 2024 · Derived
PubMed: PMID 38577337 · NCT04551352 · Melanoma
CD19-CD28: an affinity-optimized CD28 agonist for combination with glofitamab (CD20-TCB) as off-the-shelf immunotherapy.
Sam J, Hofer T, Kuettel C, et al. · Blood · 2024 · Derived
PubMed: PMID 38437725 · NCT05219513 · Lymphoma, Non-Hodgkin
Simvastatin in Critically Ill Patients with Covid-19.
REMAP-CAP Investigators, Hills TE, Lorenzi E, et al. · N Engl J Med · 2024 · Derived
PubMed: PMID 37888913 · NCT02735707 (REMAP-CAP) · COVID-19
Identification of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis Using Machine Learning and Clinical Trial Data.
Rehberg M, Giegerich C, Praestgaard A, et al. · Rheumatol Ther · 2024 · Derived
PubMed: PMID 34519964 · NCT01768572 · Arthritis, Rheumatoid
Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group · Lancet Child Adolesc Health · 2024 · Derived
PubMed: PMID 38272046 · NCT04381936 (RECOVERY) · COVID-19
Clinical trial results in context: comparison of baseline characteristics and outcomes of 38,510 RECOVERY trial participants versus a reference population of 346,271 people hospitalised with COVID-19 in England.
Pessoa-Amorim G, Goldacre R, Crichton C, et al. · Trials · 2024 · Derived
PubMed: PMID 38951929 · NCT04381936 (RECOVERY) · COVID-19
Interleukin 6 blockage alters the plasma metabolome in out-of-hospital cardiac arrest.
Paulin Beske R, Meyer MAS, Emil Roelsgaard Obling L, et al. · Resuscitation · 2024 · Derived
PubMed: PMID 39510308 · NCT03863015 (IMICA) · Inflammation
Treatment of giant cell arteritis with ultra-short glucocorticoids and tocilizumab: the role of imaging in a prospective observational study.
Muratore F, Marvisi C, Cassone G, et al. · Rheumatology (Oxford) · 2024 · Derived
PubMed: PMID 37195423 · NCT05394909 (TOPAZIO)
Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity.
Locke FL, Siddiqi T, Jacobson CA, et al. · Blood · 2024 · Derived
PubMed: PMID 38635762 · NCT02348216 (ZUMA-1) · Lymphoma, Large B-Cell, Diffuse
Neutrophil Extracellular Traps in ST-Segment Elevation Myocardial Infarction: Reduced by Tocilizumab and Associated With Infarct Size.
Kindberg KM, Broch K, Andersen GØ, et al. · JACC Adv · 2024 · Derived
PubMed: PMID 39247678 · NCT03004703 (ASSAIL-MI) · Inflammation
Validation of a Prognostic Multivariable Prediction Model for Insufficient Clinical Response to Methotrexate in Early Rheumatoid Arthritis and Its Clinical Application in Evidencio.
Gosselt HR, Verhoeven MMA, de Rotte MCFJ, et al. · Rheumatol Ther · 2024 · Derived
PubMed: PMID 32926395 · NCT01034137 · Arthritis, Rheumatoid
Prognostic and predictive markers of systemic sclerosis-associated interstitial lung disease in a clinical trial and long-term observational cohort.
Ghuman A, Khanna D, Lin CJF, et al. · Rheumatology (Oxford) · 2024 · Derived
PubMed: PMID 37228011 · NCT02453256 (focuSSced) · Scleroderma, Systemic
Tocilizumab monotherapy after ultra-short glucocorticoid administration in giant cell arteritis: a single-arm, open-label, proof-of-concept study.
Christ L, Seitz L, Scholz G, et al. · Lancet Rheumatol · 2024 · Derived
PubMed: PMID 38287611 · NCT03745586 (GUSTO) · Giant Cell Arteritis
A phase 2, open label, multicenter, single arm study of tocilizumab on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia (TOCIVID-19 trial): Statistical analysis plan.
Chiodini P, Arenare L, Piccirillo MC, et al. · Contemp Clin Trials Commun · 2024 · Derived
PubMed: PMID 33043164 · NCT04317092 (TOCIVID-19) · COVID-19
Investigating the Influence of Covariates on Axicabtagene Ciloleucel (axi-cel) Kinetics in Patients with Non-Hodgkin's Lymphoma.
Chartier M, Filosto S, Peyret T, et al. · Clin Pharmacokinet · 2024 · Derived
PubMed: PMID 39240498 · NCT02348216 (ZUMA-1) · Lymphoma, Large B-Cell, Diffuse
Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial.
Budde LE, Olszewski AJ, Assouline S, et al. · Nat Med · 2024 · Derived
PubMed: PMID 38072960 · NCT03671018 · Lymphoma, B-Cell
Long-term efficacy and safety of subcutaneous tocilizumab in clinical trials of polyarticular or systemic juvenile idiopathic arthritis.
Brunner HI, Ruperto N, Ramanan AV, et al. · Rheumatology (Oxford) · 2024 · Derived
PubMed: PMID 38552315 · NCT02165345 · Arthritis, Juvenile
GWAS breakthroughs: mapping the journey from one locus to 393 significant coronary artery disease associations.
Aherrahrou R, Reinberger T, Hashmi S, et al. · Cardiovasc Res · 2024 · Derived
PubMed: PMID 39073758 · NCT01491074 · Non-ST Elevated Myocardial Infarction
Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial.
Abramson JS, Ku M, Hertzberg M, et al. · Lancet · 2024 · Derived
PubMed: PMID 39550172 · NCT04408638 · Lymphoma, Large B-Cell, Diffuse
Tocilizumab in chronic active antibody-mediated rejection: rationale and protocol of an in-progress randomized controlled open-label multi-center trial (INTERCEPT study).
Streichart L, Felldin M, Ekberg J, et al. · Trials · 2024 · Background
PubMed: PMID 38519988 · NCT04561986 (INTERCEPT)
Long-term remission of corticosteroid-resistant Graves' orbitopathy after therapy with tocilizumab.
Rymuza J, Kuś A, Białas-Niedziela D, et al. · Endokrynol Pol · 2024 · Background
PubMed: PMID 38497401 · NCT06367517 · Graves Ophthalmopathy
Interleukin-6 receptor antibodies (tocilizumab) in acute myocardial infarction with intermediate to high risk of cardiogenic shock development (DOBERMANN-T): study protocol for a double-blinded, placebo-controlled, single-center, randomized clinical trial.
Kunkel JB, Holle SLD, Hassager C, et al. · Trials · 2024 · Background
PubMed: PMID 39501388 · NCT05350592 (DOBERMANN) · Inflammation
Low-dose dobutamine in acute myocardial infarction with intermediate to high risk of cardiogenic shock development (the DOBERMANN-D trial): study protocol for a double-blinded, placebo-controlled, single-center, randomized clinical trial.
Holle SLD, Kunkel JB, Hassager C, et al. · Trials · 2024 · Background
PubMed: PMID 39478521 · NCT05350592 (DOBERMANN) · Inflammation
Insights into the Recent 2019 Novel Coronavirus (SARS-CoV-2) in Light of Past Human Coronavirus Outbreaks.
Ashour HM, Elkhatib WF, Rahman MM, et al. · Pathogens · 2024 · Background
PubMed: PMID 32143502 · NCT04315480

2023 (36 papers)

Low-Dose radiation therapy for benign pathologies.
Torres Royo L, Antelo Redondo G, Árquez Pianetta M, et al. · Rep Pract Oncol Radiother · 2023 · Trial result
PubMed: PMID 32140081 · NCT04394182 (ULTRA-COVID) · Cytokine Release Syndrome
Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group · Lancet Diabetes Endocrinol · 2023 · Trial result
PubMed: PMID 37865101 · NCT04381936 (RECOVERY) · COVID-19
Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group. Electronic address: [email protected], RECOVERY Collaborative Group · Lancet · 2023 · Trial result
PubMed: PMID 37060915 · NCT04381936 (RECOVERY) · COVID-19
Low dose lung radiotherapy for COVID-19 pneumonia. The rationale for a cost-effective anti-inflammatory treatment.
Lara PC, Burgos J, Macias D, et al. · Clin Transl Radiat Oncol · 2023 · Trial result
PubMed: PMID 32373721 · NCT04394182 (ULTRA-COVID) · Cytokine Release Syndrome
Mitigation of gastrointestinal graft-versus-host disease with tocilizumab prophylaxis is accompanied by preservation of microbial diversity and attenuation of enterococcal domination.
Chhabra S, Szabo A, Clurman A, et al. · Haematologica · 2023 · Trial result
PubMed: PMID 36106394 · NCT03699631 · Hematologic Neoplasms
Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support-Free Days in Patients Hospitalized With COVID-19: A Randomized Clinical Trial.
Writing Committee for the REMAP-CAP Investigators, Lawler PR, Derde LPG, et al. · JAMA · 2023 · Derived
PubMed: PMID 37039790 · NCT02735707 (REMAP-CAP) · COVID-19
Cytokine pattern in patients with ST-elevation myocardial infarction treated with the interleukin-6 receptor antagonist tocilizumab.
Woxholt S, Ueland T, Aukrust P, et al. · Open Heart · 2023 · Derived
PubMed: PMID 37591633 · NCT03004703 (ASSAIL-MI) · Inflammation
Efficacy and safety of selective JAK 1 inhibitor filgotinib in active rheumatoid arthritis patients with inadequate response to methotrexate: comparative study with filgotinib and tocilizumab examined by clinical index as well as musculoskeletal ultrasound assessment (TRANSFORM study): study protocol for a randomized, open-label, parallel-group, multicenter, and non-inferiority clinical trial.
Shimizu T, Kawashiri SY, Morimoto S, et al. · Trials · 2023 · Derived
PubMed: PMID 36869356 · NCT05090410 (TRANSFORM) · Arthritis, Rheumatoid
Evaluation of infliximab/tocilizumab versus tocilizumab among COVID-19 patients with cytokine storm syndrome.
Sarhan NM, Warda AEA, Ibrahim HSG, et al. · Sci Rep · 2023 · Derived
PubMed: PMID 37081046 · NCT04734678 · COVID-19
Dynamic CD8+ T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes.
Rahim MK, Okholm TLH, Jones KB, et al. · Cell · 2023 · Derived
PubMed: PMID 36931243 · NCT03708224 · Neoplasms
Tocilizumab in combination with a standard induction chemotherapy in acute myeloid leukaemia patients (TOCILAM study): a single-centre, single-arm, phase 1 trial.
Peterlin P, Garnier A, Le Bourgeois A, et al. · EClinicalMedicine · 2023 · Derived
PubMed: PMID 37786451 · NCT04547062 (Tocilam) · Leukemia, Myeloid, Acute
Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study.
Olszewski AJ, Phillips TJ, Hoffmann MS, et al. · Blood Adv · 2023 · Derived
PubMed: PMID 37581593 · NCT03677141 · Lymphoma, B-Cell
The Relationship Between SARS-CoV-2 Neutralizing Antibody Titers and Avidity in Plasma Collected From Convalescent Nonvaccinated and Vaccinated Blood Donors.
Nurmi V, Knight C, Estcourt L, et al. · J Infect Dis · 2023 · Derived
PubMed: PMID 36967714 · NCT02735707 (REMAP-CAP) · COVID-19
Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma.
Neelapu SS, Jacobson CA, Ghobadi A, et al. · Blood · 2023 · Derived
PubMed: PMID 36821768 · NCT02348216 (ZUMA-1) · Lymphoma, Large B-Cell, Diffuse
Modulation of inflammation by treatment with tocilizumab after out-of-hospital cardiac arrest and associations with clinical status, myocardial- and brain injury.
Meyer MAS, Bjerre M, Wiberg S, et al. · Resuscitation · 2023 · Derived
PubMed: PMID 36572373 · NCT03863015 (IMICA) · Inflammation
Intravenous Vitamin C for Patients Hospitalized With COVID-19: Two Harmonized Randomized Clinical Trials.
LOVIT-COVID Investigators, on behalf of the Canadian Critical Care Trials Group, and the REMAP-CAP Investigators, Adhikari NKJ, Hashmi M, et al. · JAMA · 2023 · Derived
PubMed: PMID 37877585 · NCT02735707 (REMAP-CAP) · COVID-19
Probability of Response in the First Sixteen Weeks After Starting Biologics: An Analysis of Juvenile Idiopathic Arthritis Biologics Trials.
Lim LSH, Lokku A, Pullenayegum E, et al. · Arthritis Care Res (Hoboken) · 2023 · Derived
PubMed: PMID 36651601 · NCT00988221 · Arthritis, Juvenile
Efficacy and tolerance of methotrexate in a real-life monocentric cohort of patients with giant cell arteritis.
Lavergne A, Dumont A, Deshayes S, et al. · Semin Arthritis Rheum · 2023 · Derived
PubMed: PMID 36963127 · NCT03892785 (METOGiA) · Giant Cell Arteritis
Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study Platform.
Ko AH, Kim KP, Siveke JT, et al. · Oncologist · 2023 · Derived
PubMed: PMID 36940261 · NCT03193190
More rapid blood interferon α2 decline in fatal versus surviving COVID-19 patients.
Joly C, Desjardins D, Porcher R, et al. · Front Immunol · 2023 · Derived
PubMed: PMID 38077399 · NCT04331808 (CORIMUNO-TOC) · Coronavirus Infections
Convalescent plasma for people with COVID-19: a living systematic review.
Iannizzi C, Chai KL, Piechotta V, et al. · Cochrane Database Syst Rev · 2023 · Derived
PubMed: PMID 37162745 · NCT04381936 (RECOVERY) · COVID-19
Convalescent plasma for people with COVID-19: a living systematic review.
Iannizzi C, Chai KL, Piechotta V, et al. · Cochrane Database Syst Rev · 2023 · Derived
PubMed: PMID 36734509 · NCT04381936 (RECOVERY) · COVID-19
Heterogeneous Treatment Effects of Therapeutic-Dose Heparin in Patients Hospitalized for COVID-19.
Goligher EC, Lawler PR, Jensen TP, et al. · JAMA · 2023 · Derived
PubMed: PMID 36942550 · NCT02735707 (REMAP-CAP) · COVID-19
Interleukin 6 Blockade With Tocilizumab Diminishes Indices of Inflammation That Are Linked to Mortality in Treated Human Immunodeficiency Virus Infection.
Funderburg NT, Shive CL, Chen Z, et al. · Clin Infect Dis · 2023 · Derived
PubMed: PMID 37011013 · NCT02049437 (IL-6) · HIV Infections
Factors influencing the use of tocilizumab as monotherapy in patients with rheumatoid arthritis in a real-life setting: results at 1 year of the ACT-SOLO study.
Flipo RM, Maillefert JF, Chazerain P, et al. · RMD Open · 2023 · Derived
PubMed: PMID 28123778 · NCT01474291 (ACT SOLO) · Arthritis, Rheumatoid
Antiplatelet agents for the treatment of adults with COVID-19.
Fischer AL, Messer S, Riera R, et al. · Cochrane Database Syst Rev · 2023 · Derived
PubMed: PMID 37489818 · NCT02735707 (REMAP-CAP) · COVID-19
Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events.
Fa'ak F, Buni M, Falohun A, et al. · J Immunother Cancer · 2023 · Derived
PubMed: PMID 37328287 · NCT03999749 · Melanoma
Cytochrome P450 activity in rheumatoid arthritis patients during continuous IL-6 receptor antagonist therapy.
Dunvald AD, Søltoft K, Sheetal E, et al. · Eur J Clin Pharmacol · 2023 · Derived
PubMed: PMID 37831074 · NCT04842981 · Arthritis, Rheumatoid
Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma).
Drakaki A, Powles T, Bamias A, et al. · Clin Cancer Res · 2023 · Derived
PubMed: PMID 37651261 · NCT03869190 · Urinary Bladder Neoplasms
Serum proteomics in giant cell arteritis in response to a three-day pulse of glucocorticoid followed by tocilizumab monotherapy (the GUSTO trial).
Christ L, Gloor AD, Kollert F, et al. · Front Immunol · 2023 · Derived
PubMed: PMID 37287970 · NCT03745586 (GUSTO) · Giant Cell Arteritis
Challenges of using external data in clinical trials- an illustration in patients with COVID-19.
Chevret S, Timsit JF, Biard L, et al. · BMC Med Res Methodol · 2023 · Derived
PubMed: PMID 36522698 · NCT04381936 (RECOVERY) · COVID-19
Phase 2 study of ipilimumab, nivolumab, and tocilizumab combined with stereotactic body radiotherapy in patients with refractory pancreatic cancer (TRIPLE-R).
Chen IM, Donia M, Chamberlain CA, et al. · Eur J Cancer · 2023 · Derived
PubMed: PMID 36592507 · NCT04258150 (TRIPPLE-R) · Pancreatic Neoplasms
Power doppler ultrasound signal predicts abnormal HDL function in patients with rheumatoid arthritis.
Charles-Schoeman C, Wang J, Shahbazian A, et al. · Rheumatol Int · 2023 · Derived
PubMed: PMID 36828925 · NCT01717859 (RASTS) · Arthritis, Rheumatoid
"Tocilizumab-an option for patients with COVID-19 associated cytokine release syndrome: A single center experience", a retrospective study-original article.
Chachar AZK, Khan KA, Iqbal J, et al. · Ann Med Surg (Lond) · 2023 · Derived
PubMed: PMID 33585031 · NCT04730323 · COVID-19
A Review of Recent Advances Using Tocilizumab in the Treatment of Rheumatic Diseases.
Rubbert-Roth A, Furst DE, Nebesky JM, et al. · Rheumatol Ther · 2023 · Background
PubMed: PMID 29502236 · NCT04924829 · COVID-19
The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - The latest 2019 novel coronavirus outbreak in Wuhan, China.
Hui DS, I Azhar E, Madani TA, et al. · Int J Infect Dis · 2023 · Background
PubMed: PMID 31953166 · NCT04363853

2022 (54 papers)

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group · Lancet · 2022 · Trial result
PubMed: PMID 33933206 · NCT04381936 (RECOVERY) · COVID-19
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial.
RECOVERY Collaborative Group · Lancet · 2022 · Trial result
PubMed: PMID 34000257 · NCT04381936 (RECOVERY) · COVID-19
Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group · Lancet Respir Med · 2022 · Trial result
PubMed: PMID 34672950 · NCT04381936 (RECOVERY) · COVID-19
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group · Lancet · 2022 · Trial result
PubMed: PMID 35151397 · NCT04381936 (RECOVERY) · COVID-19
Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis.
RECOVERY Collaborative Group · Lancet · 2022 · Trial result
PubMed: PMID 35908569 · NCT04381936 (RECOVERY) · COVID-19
Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group · Lancet · 2022 · Trial result
PubMed: PMID 34800427 · NCT04381936 (RECOVERY) · COVID-19
Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group.
Hermine O, Mariette X, Porcher R, et al. · Eur Respir J · 2022 · Trial result
PubMed: PMID 35115337 · NCT04331808 (CORIMUNO-TOC) · Coronavirus Infections
Tocilizumab plus dexamethasone versus dexamethasone in patients with moderate-to-severe COVID-19 pneumonia: A randomised clinical trial from the CORIMUNO-19 study group.
Hermine O, Mariette X, Porcher R, et al. · EClinicalMedicine · 2022 · Trial result
PubMed: PMID 35350097 · NCT04476979 (TOCIDEX) · Coronavirus Infections
Non-TNF-Targeted Biologic vs a Second Anti-TNF Drug to Treat Rheumatoid Arthritis in Patients With Insufficient Response to a First Anti-TNF Drug: A Randomized Clinical Trial.
Gottenberg JE, Brocq O, Perdriger A, et al. · JAMA · 2022 · Trial result
PubMed: PMID 27654603 · NCT01000441 (ROC) · Arthritis, Rheumatoid
Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial.
Felten R, Devauchelle-Pensec V, Seror R, et al. · Ann Rheum Dis · 2022 · Trial result
PubMed: PMID 33208345 · NCT01782235 (ETAP)
Inhibition of IL-6 in the treatment of fibrous dysplasia of bone: The randomized double-blind placebo-controlled TOCIDYS trial.
Chapurlat R, Gensburger D, Trolliet C, et al. · Bone · 2022 · Trial result
PubMed: PMID 35104665 · NCT01791842 (TOCIDYS) · Fibrous Dysplasia of Bone
A Critical Role for Fas-Mediated Off-Target Tumor Killing in T-cell Immunotherapy.
Upadhyay R, Boiarsky JA, Pantsulaia G, et al. · Cancer Discov · 2022 · Derived
PubMed: PMID 33334730 · NCT02348216 (ZUMA-1) · Lymphoma, Large B-Cell, Diffuse
Amino Acid Metabolism and Protein Turnover in Lean and Obese Humans During Exercise-Effect of IL-6 Receptor Blockade.
Trinh B, Peletier M, Simonsen C, et al. · J Clin Endocrinol Metab · 2022 · Derived
PubMed: PMID 35442403 · NCT03967691 · Obesity
Blocking endogenous IL-6 impairs mobilization of free fatty acids during rest and exercise in lean and obese men.
Trinh B, Peletier M, Simonsen C, et al. · Cell Rep Med · 2022 · Derived
PubMed: PMID 34622233 · NCT03967691 · Obesity
Mendelian randomisation and experimental medicine approaches to interleukin-6 as a drug target in pulmonary arterial hypertension.
Toshner M, Church C, Harbaum L, et al. · Eur Respir J · 2022 · Derived
PubMed: PMID 34588193 · NCT02676947 (TRANSFORM-UK) · Pulmonary Arterial Hypertension
Prognostic and Predictive Biomarkers in Patients With Coronavirus Disease 2019 Treated With Tocilizumab in a Randomized Controlled Trial.
Tom J, Bao M, Tsai L, et al. · Crit Care Med · 2022 · Derived
PubMed: PMID 34612846 · NCT04320615 (COVACTA)
Impact of tocilizumab monotherapy on patient-reported outcomes in patients with rheumatoid arthritis from two randomised controlled trials.
Strand V, Michalska M, Birchwood C, et al. · RMD Open · 2022 · Derived
PubMed: PMID 28955499 · NCT00109408 · Arthritis, Rheumatoid
New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extension.
Stone JH, Spotswood H, Unizony SH, et al. · Rheumatology (Oxford) · 2022 · Derived
PubMed: PMID 34718434 · NCT01791153 · Giant Cell Arteritis
Intravenous tocilizumab for the treatment of giant cell arteritis: a phase Ib dose-ranging pharmacokinetic bridging study.
Schmitt C, Brockwell L, Giraudon M, et al. · Arthritis Res Ther · 2022 · Derived
PubMed: PMID 35659282 · NCT03923738 · Giant Cell Arteritis
Posterior segment inflammatory outcomes assessed using fluorescein angiography in the STOP-UVEITIS study.
Sadiq MA, Hassan M, Afridi R, et al. · Int J Retina Vitreous · 2022 · Derived
PubMed: PMID 33042579 · NCT01717170 (STOP-Uveitis) · Uveitis, Intermediate
Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA).
Rosas IO, Bräu N, Waters M, et al. · EClinicalMedicine · 2022 · Derived
PubMed: PMID 35475258 · NCT04320615 (COVACTA)
Effect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial.
REMAP-CAP Writing Committee for the REMAP-CAP Investigators, Bradbury CA, Lawler PR, et al. · JAMA · 2022 · Derived
PubMed: PMID 35315874 · NCT02735707 (REMAP-CAP) · COVID-19
Real-world evidence on methotrexate-free subcutaneous tocilizumab therapy in patients with rheumatoid arthritis: 24-week data from the SIMPACT study.
Nagy G, Géher P, Tamási L, et al. · Rheumatol Adv Pract · 2022 · Derived
PubMed: PMID 35663154 · NCT02402686 (SIMPACT) · Arthritis, Rheumatoid
Efficacy and Outcome of Remdesivir and Tocilizumab Combination Against Dexamethasone for the Treatment of Severe COVID-19: A Randomized Controlled Trial.
Mohiuddin Chowdhury ATM, Kamal A, Abbas KU, et al. · Front Pharmacol · 2022 · Derived
PubMed: PMID 35450050 · NCT04678739 · COVID-19
Multiple site place-of-care manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patients.
Maschan M, Caimi PF, Reese-Koc J, et al. · Nat Commun · 2022 · Derived
PubMed: PMID 34893603 · NCT03467256 · Burkitt Lymphoma
The target antigen determines the mechanism of acquired resistance to T cell-based therapies.
Martínez-Sabadell A, Morancho B, Rius Ruiz I, et al. · Cell Rep · 2022 · Derived
PubMed: PMID 36261015 · NCT02324257
Janus kinase inhibitors for the treatment of COVID-19.
Kramer A, Prinz C, Fichtner F, et al. · Cochrane Database Syst Rev · 2022 · Derived
PubMed: PMID 35695334 · NCT04381936 (RECOVERY) · COVID-19
Long-Term Safety and Efficacy of Subcutaneously Administered Tocilizumab for Adult Rheumatoid Arthritis: A Multicenter Phase 3b Long-term Extension Study.
Kivitz A, Wallace T, Olech E, et al. · Rheumatol Ther · 2022 · Derived
PubMed: PMID 27747585 · NCT01662063 · Arthritis, Rheumatoid
Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis-Interstitial Lung Disease: Open-Label Extension of a Phase 3 Randomized Controlled Trial.
Khanna D, Lin CJF, Furst DE, et al. · Am J Respir Crit Care Med · 2022 · Derived
PubMed: PMID 34851799 · NCT02453256 (focuSSced) · Scleroderma, Systemic
Development of a Generic Physiologically-Based Pharmacokinetic Model for Lactation and Prediction of Maternal and Infant Exposure to Ondansetron via Breast Milk.
Job KM, Dallmann A, Parry S, et al. · Clin Pharmacol Ther · 2022 · Derived
PubMed: PMID 35076931 · NCT03511118
Efficacy and safety of subcutaneous tocilizumab in rheumatoid arthritis over 1 year: a UK real-world, open-label study.
Isaacs JD, Salih A, Sheeran T, et al. · Rheumatol Adv Pract · 2022 · Derived
PubMed: PMID 31431998 · NCT02046603 (ACT-MOVE) · Arthritis, Rheumatoid
COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis.
Holmstroem RB, Nielsen OH, Jacobsen S, et al. · J Immunother Cancer · 2022 · Derived
PubMed: PMID 36096534 · NCT03601611 (COLAR) · Arthritis
SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19.
Hirsch C, Park YS, Piechotta V, et al. · Cochrane Database Syst Rev · 2022 · Derived
PubMed: PMID 35713300 · NCT04381936 (RECOVERY) · COVID-19
Rheumatoid arthritis patients with predominantly tender joints rarely achieve clinical remission despite being in ultrasound remission.
Hammer HB, Jensen Hansen IM, Järvinen P, et al. · Rheumatol Adv Pract · 2022 · Derived
PubMed: PMID 34131623 · NCT02046616 · Arthritis, Rheumatoid
Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity.
Hailemichael Y, Johnson DH, Abdel-Wahab N, et al. · Cancer Cell · 2022 · Derived
PubMed: PMID 35537412 · NCT04940299 · Carcinoma, Non-Small-Cell Lung
IL-6 receptor blockade does not slow β cell loss in new-onset type 1 diabetes.
Greenbaum CJ, Serti E, Lambert K, et al. · JCI Insight · 2022 · Derived
PubMed: PMID 34747368 · NCT02293837 (EXTEND) · Diabetes Mellitus, Type 1
Osteopontin Links Myeloid Activation and Disease Progression in Systemic Sclerosis.
Gao X, Jia G, Guttman A, et al. · Cell Rep Med · 2022 · Derived
PubMed: PMID 33294861 · NCT02453256 (focuSSced) · Scleroderma, Systemic
Novel in Vivo and in Vitro Pharmacokinetic/Pharmacodynamic-Based Human Starting Dose Selection for Glofitamab.
Frances N, Bacac M, Bray-French K, et al. · J Pharm Sci · 2022 · Derived
PubMed: PMID 34953862 · NCT03075696 · Lymphoma, Non-Hodgkin
Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Dickinson MJ, Carlo-Stella C, Morschhauser F, et al. · N Engl J Med · 2022 · Derived
PubMed: PMID 36507690 · NCT03075696 · Lymphoma, Non-Hodgkin
Effect of Tocilizumab on Disease Activity in Patients With Active Polymyalgia Rheumatica Receiving Glucocorticoid Therapy: A Randomized Clinical Trial.
Devauchelle-Pensec V, Carvajal-Alegria G, Dernis E, et al. · JAMA · 2022 · Derived
PubMed: PMID 36125471 · NCT02908217 · Polymyalgia Rheumatica
Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial.
Declercq J, Van Damme KFA, De Leeuw E, et al. · Lancet Respir Med · 2022 · Derived
PubMed: PMID 34756178 · NCT04330638 (COV-AID) · COVID-19
Interleukin-1 blocking agents for treating COVID-19.
Davidson M, Menon S, Chaimani A, et al. · Cochrane Database Syst Rev · 2022 · Derived
PubMed: PMID 35080773 · NCT04330638 (COV-AID) · COVID-19
Ultrasound detects synovitis in replaced and other surgically operated joints in rheumatoid arthritis patients.
Choate EA, Kaeley GS, Brook J, et al. · BMC Rheumatol · 2022 · Derived
PubMed: PMID 32025629 · NCT01717859 (RASTS) · Arthritis, Rheumatoid
Pharmacodynamics and molecular correlates of response to glofitamab in relapsed/refractory non-Hodgkin lymphoma.
Bröske AE, Korfi K, Belousov A, et al. · Blood Adv · 2022 · Derived
PubMed: PMID 34941996 · NCT03075696 · Lymphoma, Non-Hodgkin
Tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): a phase 2/3 randomised controlled trial.
Bonelli M, Radner H, Kerschbaumer A, et al. · Ann Rheum Dis · 2022 · Derived
PubMed: PMID 35210264 · NCT03263715 · Polymyalgia Rheumatica
AC-CUTE: An Open-Label Study to Evaluate Progression of Structural Joint Damage and Inflammation in Subjects with Moderate to Severe Rheumatoid Arthritis.
Bird P, Peterfy C, Countryman P, et al. · Int J Rheumatol · 2022 · Derived
PubMed: PMID 29849651 · NCT01951170 · Arthritis, Rheumatoid
Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody.
Augsberger C, Hänel G, Xu W, et al. · Blood · 2022 · Derived
PubMed: PMID 34280257 · NCT04580121 · Leukemia, Myeloid, Acute
Low dose anti-inflammatory radiotherapy for the treatment of pneumonia by covid-19: A proposal for a multi-centric prospective trial.
Algara M, Arenas M, Marin J, et al. · Clin Transl Radiat Oncol · 2022 · Derived
PubMed: PMID 32613089 · NCT04380818 · COVID-19
Early estimation of the case fatality rate of COVID-19 in mainland China: a data-driven analysis.
Yang S, Cao P, Du P, et al. · Ann Transl Med · 2022 · Background
PubMed: PMID 32175421 · NCT04335071 (CORON-ACT) · COVID-19
Tocilizumab in the treatment of systemic-onset juvenile idiopathic arthritis - single-centre experience.
Roszkiewicz J, Orczyk K, Smolewska E, et al. · Reumatologia · 2022 · Background
PubMed: PMID 30505008 · NCT05233397 · Craniopharyngioma
Systemic Sclerosis-Associated Interstitial Lung Disease: How to Incorporate Two Food and Drug Administration-Approved Therapies in Clinical Practice.
Khanna D, Lescoat A, Roofeh D, et al. · Arthritis Rheumatol · 2022 · Background
PubMed: PMID 34313399 · NCT06297096 (NINTOC-TU) · Scleroderma, Systemic
Efficacy and safety of nintedanib in Japanese patients with progressive fibrosing interstitial lung diseases: Subgroup analysis of the randomised, double-blind, placebo-controlled, phase 3 INBUILD trial.
Inoue Y, Suda T, Kitamura H, et al. · Respir Med · 2022 · Background
PubMed: PMID 34564020 · NCT06297096 (NINTOC-TU) · Scleroderma, Systemic
Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease.
Flaherty KR, Brown KK, Wells AU, et al. · BMJ Open Respir Res · 2022 · Background
PubMed: PMID 29018526 · NCT06297096 (NINTOC-TU) · Scleroderma, Systemic
Management of Thyroid Eye Disease: A Consensus Statement by the American Thyroid Association and the European Thyroid Association.
Burch HB, Perros P, Bednarczuk T, et al. · Thyroid · 2022 · Background
PubMed: PMID 36480280 · NCT06367517 · Graves Ophthalmopathy

2021 (67 papers)

COVIDOSE: A Phase II Clinical Trial of Low-Dose Tocilizumab in the Treatment of Noncritical COVID-19 Pneumonia.
Strohbehn GW, Heiss BL, Rouhani SJ, et al. · Clin Pharmacol Ther · 2021 · Trial result
PubMed: PMID 33210302 · NCT04331795 (COVIDOSE) · COVID-19
Dexamethasone in Hospitalized Patients with Covid-19.
RECOVERY Collaborative Group, Horby P, Lim WS, et al. · N Engl J Med · 2021 · Trial result
PubMed: PMID 32678530 · NCT04381936 (RECOVERY) · COVID-19
Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group · Lancet · 2021 · Trial result
PubMed: PMID 33031764 · NCT04381936 (RECOVERY) · COVID-19
Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group · Lancet · 2021 · Trial result
PubMed: PMID 33545096 · NCT04381936 (RECOVERY) · COVID-19
Tocilizumab in patients with symptomatic Kaposi sarcoma herpesvirus-associated multicentric Castleman disease.
Ramaswami R, Lurain K, Peer CJ, et al. · Blood · 2021 · Trial result
PubMed: PMID 32276276 · NCT01441063 · Castleman Disease
Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma.
Oluwole OO, Bouabdallah K, Muñoz J, et al. · Br J Haematol · 2021 · Trial result
PubMed: PMID 34296427 · NCT02348216 (ZUMA-1) · Lymphoma, Large B-Cell, Diffuse
Effectiveness of Tocilizumab in Patients Hospitalized With COVID-19: A Follow-up of the CORIMUNO-TOCI-1 Randomized Clinical Trial.
Mariette X, Hermine O, Tharaux PL, et al. · JAMA Intern Med · 2021 · Trial result
PubMed: PMID 34028504 · NCT04331808 (CORIMUNO-TOC) · Coronavirus Infections
Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial.
Hermine O, Mariette X, Tharaux PL, et al. · JAMA Intern Med · 2021 · Trial result
PubMed: PMID 33080017 · NCT04331808 (CORIMUNO-TOC) · Coronavirus Infections
Interleukin-6 blockade with tocilizumab increases Tregs and reduces T effector cytokines in renal graft inflammation: A randomized controlled trial.
Chandran S, Leung J, Hu C, et al. · Am J Transplant · 2021 · Trial result
PubMed: PMID 33331082 · NCT02108600 · Inflammation
Effect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial.
Writing Committee for the REMAP-CAP Investigators, Estcourt LJ, Turgeon AF, et al. · JAMA · 2021 · Derived
PubMed: PMID 34606578 · NCT02735707 (REMAP-CAP) · COVID-19
Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: Observations from the JULIET, ZUMA-1, and TRANSCEND trials.
Westin JR, Kersten MJ, Salles G, et al. · Am J Hematol · 2021 · Derived
PubMed: PMID 34310745 · NCT02348216 (ZUMA-1) · Lymphoma, Large B-Cell, Diffuse
Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial.
Veiga VC, Prats JAGG, Farias DLC, et al. · BMJ · 2021 · Derived
PubMed: PMID 33472855 · NCT04403685 (TOCIBRAS) · Cytokine Release Syndrome
Implementation of the Randomized Embedded Multifactorial Adaptive Platform for COVID-19 (REMAP-COVID) trial in a US health system-lessons learned and recommendations.
UPMC REMAP-COVID Group, on behalf of the REMAP-CAP Investigators · Trials · 2021 · Derived
PubMed: PMID 33509275 · NCT02735707 (REMAP-CAP) · COVID-19
Treatment failure in giant cell arteritis.
Unizony SH, Bao M, Han J, et al. · Ann Rheum Dis · 2021 · Derived
PubMed: PMID 34049857 · NCT01791153 · Giant Cell Arteritis
Serum PCSK9 is modified by interleukin-6 receptor antagonism in patients with hypercholesterolaemia following non-ST-elevation myocardial infarction.
Ueland T, Kleveland O, Michelsen AE, et al. · Open Heart · 2021 · Derived
PubMed: PMID 30258647 · NCT01491074 · Non-ST Elevated Myocardial Infarction
Research Priorities for U.K. Pediatric Critical Care in 2019: Healthcare Professionals' and Parents' Perspectives.
Tume LN, Menzies JC, Ray S, et al. · Pediatr Crit Care Med · 2021 · Derived
PubMed: PMID 33394942 · NCT02735707 (REMAP-CAP) · COVID-19
Increased high molecular weight adiponectin and lean mass during tocilizumab treatment in patients with rheumatoid arthritis: a 12-month multicentre study.
Toussirot E, Marotte H, Mulleman D, et al. · Arthritis Res Ther · 2021 · Derived
PubMed: PMID 32993784 · NCT02843789 (ADIPRAT) · Arthritis, Rheumatoid
The Misleading "Pooled Effect Estimate" of Crude Data from Observational Studies at Critical Risk of Bias: The Case of Tocilizumab in Coronavirus Disease 2019 (COVID-19).
Tleyjeh IM · Clin Infect Dis · 2021 · Derived
PubMed: PMID 33201228 · NCT04372186 (EMPACTA)
Quantitative ultrasound to monitor the vascular response to tocilizumab in giant cell arteritis.
Seitz L, Christ L, Lötscher F, et al. · Rheumatology (Oxford) · 2021 · Derived
PubMed: PMID 34117737 · NCT03745586 (GUSTO) · Giant Cell Arteritis
Efficacy of the early treatment with tocilizumab-hydroxychloroquine and tocilizumab-remdesivir in severe COVID-19 Patients.
Sarhan RM, Harb HS, Abou Warda AE, et al. · J Infect Public Health · 2021 · Derived
PubMed: PMID 34764044 · NCT04779047 · COVID-19
Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial.
Salvarani C, Dolci G, Massari M, et al. · JAMA Intern Med · 2021 · Derived
PubMed: PMID 33080005 · NCT04346355
Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia.
Salama C, Han J, Yau L, et al. · N Engl J Med · 2021 · Derived
PubMed: PMID 33332779 · NCT04372186 (EMPACTA)
Decreased serum levels of the inflammaging marker miR-146a are associated with clinical non-response to tocilizumab in COVID-19 patients.
Sabbatinelli J, Giuliani A, Matacchione G, et al. · Mech Ageing Dev · 2021 · Derived
PubMed: PMID 33307107 · NCT04315480
Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis.
Ruperto N, Brunner HI, Ramanan AV, et al. · Rheumatology (Oxford) · 2021 · Derived
PubMed: PMID 33506875 · NCT01904292 · Arthritis, Juvenile
Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia.
Rosas IO, Bräu N, Waters M, et al. · N Engl J Med · 2021 · Derived
PubMed: PMID 33631066 · NCT04320615 (COVACTA)
Tocilizumab Prevents Progression of Early Systemic Sclerosis-Associated Interstitial Lung Disease.
Roofeh D, Lin CJF, Goldin J, et al. · Arthritis Rheumatol · 2021 · Derived
PubMed: PMID 33538094 · NCT02453256 (focuSSced) · Scleroderma, Systemic
Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19.
REMAP-CAP Investigators, Gordon AC, Mouncey PR, et al. · N Engl J Med · 2021 · Derived
PubMed: PMID 33631065 · NCT02735707 (REMAP-CAP) · COVID-19
Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19.
REMAP-CAP Investigators, ACTIV-4a Investigators, ATTACC Investigators, et al. · N Engl J Med · 2021 · Derived
PubMed: PMID 34351722 · NCT02735707 (REMAP-CAP) · COVID-19
Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.
Piechotta V, Iannizzi C, Chai KL, et al. · Cochrane Database Syst Rev · 2021 · Derived
PubMed: PMID 34013969 · NCT04381936 (RECOVERY) · COVID-19
A Prospective Controlled Trial to Evaluate Safety and Efficacy of in vitro Expanded Recipient Regulatory T Cell Therapy and Tocilizumab Together With Donor Bone Marrow Infusion in HLA-Mismatched Living Donor Kidney Transplant Recipients (Trex001).
Oberbauer R, Edinger M, Berlakovich G, et al. · Front Med (Lausanne) · 2021 · Derived
PubMed: PMID 33585521 · NCT03867617
Fetuin-A and thyroxin binding globulin predict rituximab response in rheumatoid arthritis patients with insufficient response to anti-TNFα.
Nguyen MVC, Courtier A, Adrait A, et al. · Clin Rheumatol · 2021 · Derived
PubMed: PMID 32212002 · NCT01000441 (ROC) · Arthritis, Rheumatoid
Subcutaneous Tocilizumab in Monotherapy or in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Latin American Patients With Moderate to Severe Active Rheumatoid Arthritis: A Multicenter, Phase IIIb Study.
Mysler E, Cardiel MH, Xavier RM, et al. · J Clin Rheumatol · 2021 · Derived
PubMed: PMID 32251060 · NCT02011334 · Arthritis, Rheumatoid
Doppler ultrasound impacts response to intravenous tocilizumab in rheumatoid arthritis patients.
Morris NT, Brook J, Ben-Artzi A, et al. · Clin Rheumatol · 2021 · Derived
PubMed: PMID 34269927 · NCT01717859 (RASTS) · Arthritis, Rheumatoid
COVID-19 pneumonia treated with ultra-low doses of radiotherapy (ULTRA-COVID study): a single institution report of two cases.
Moreno-Olmedo E, Suárez-Gironzini V, Pérez M, et al. · Strahlenther Onkol · 2021 · Derived
PubMed: PMID 33502567 · NCT04394182 (ULTRA-COVID) · Cytokine Release Syndrome
Tocilizumab is safe and tolerable and reduces C-reactive protein concentrations in the plasma and cerebrospinal fluid of ALS patients.
Milligan C, Atassi N, Babu S, et al. · Muscle Nerve · 2021 · Derived
PubMed: PMID 34075589 · NCT02469896 (TCZALS-001) · Amyotrophic Lateral Sclerosis
Colchicine for the treatment of COVID-19.
Mikolajewska A, Fischer AL, Piechotta V, et al. · Cochrane Database Syst Rev · 2021 · Derived
PubMed: PMID 34658014 · NCT04381936 (RECOVERY) · COVID-19
Treatment Effects of Interleukin-6 Receptor Antibodies for Modulating the Systemic Inflammatory Response After Out-of-Hospital Cardiac Arrest (The IMICA Trial): A Double-Blinded, Placebo-Controlled, Single-Center, Randomized, Clinical Trial.
Meyer MAS, Wiberg S, Grand J, et al. · Circulation · 2021 · Derived
PubMed: PMID 33745292 · NCT03863015 (IMICA) · Inflammation
Interleukin-6 Receptor Antibodies for Modulating the Systemic Inflammatory Response after Out-of-Hospital Cardiac Arrest (IMICA): study protocol for a double-blinded, placebo-controlled, single-center, randomized clinical trial.
Meyer MAS, Wiberg S, Grand J, et al. · Trials · 2021 · Derived
PubMed: PMID 33081828 · NCT03863015 (IMICA) · Inflammation
Tocilizumab in treatment-naïve patients with Takayasu arteritis: TOCITAKA French prospective multicenter open-labeled trial.
Mekinian A, Saadoun D, Vicaut E, et al. · Arthritis Res Ther · 2021 · Derived
PubMed: PMID 32943098 · NCT02101333 (TOCITAKA) · Takayasu Arteritis
Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma.
Maloney DG, Kuruvilla J, Liu FF, et al. · J Hematol Oncol · 2021 · Derived
PubMed: PMID 34493319 · NCT02348216 (ZUMA-1) · Lymphoma, Large B-Cell, Diffuse
Tocilizumab may slow radiographic progression in patients with systemic or polyarticular-course juvenile idiopathic arthritis: post hoc radiographic analysis from two randomized controlled trials.
Malattia C, Ruperto N, Pederzoli S, et al. · Arthritis Res Ther · 2021 · Derived
PubMed: PMID 32912276 · NCT00642460 · Arthritis, Juvenile
Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma.
Locke FL, Rossi JM, Neelapu SS, et al. · Blood Adv · 2021 · Derived
PubMed: PMID 33035333 · NCT02348216 (ZUMA-1) · Lymphoma, Large B-Cell, Diffuse
Sentinel joint scoring in rheumatoid arthritis: an individualized power Doppler assessment strategy.
Kuo D, Morris NT, Kaeley GS, et al. · Clin Rheumatol · 2021 · Derived
PubMed: PMID 32803573 · NCT01717859 (RASTS) · Arthritis, Rheumatoid
SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19.
Kreuzberger N, Hirsch C, Chai KL, et al. · Cochrane Database Syst Rev · 2021 · Derived
PubMed: PMID 34473343 · NCT02735707 (REMAP-CAP) · COVID-19
Population Pharmacodynamic Model of Neutrophil Margination and Tolerance to Describe Effect of Sarilumab on Absolute Neutrophil Count in Patients with Rheumatoid Arthritis.
Kovalenko P, Paccaly A, Boyapati A, et al. · CPT Pharmacometrics Syst Pharmacol · 2021 · Derived
PubMed: PMID 32453485 · NCT01768572 · Arthritis, Rheumatoid
Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical Trial.
Kadauke S, Myers RM, Li Y, et al. · J Clin Oncol · 2021 · Derived
PubMed: PMID 33417474 · NCT02906371 · Precursor Cell Lymphoblastic Leukemia-Lymphoma
Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial.
Hutchings M, Morschhauser F, Iacoboni G, et al. · J Clin Oncol · 2021 · Derived
PubMed: PMID 33739857 · NCT03075696 · Lymphoma, Non-Hodgkin
Real-World 1-Year Retention Rate of Subcutaneous Tocilizumab Treatment in Patients with Moderate to Severe Active Rheumatoid Arthritis: TANDEM Study.
Hilliquin P, Barnetche T, Baillet A, et al. · Rheumatol Ther · 2021 · Derived
PubMed: PMID 33216287 · NCT02608112 · Arthritis, Rheumatoid
Major reduction of ultrasound-detected synovitis during subcutaneous tocilizumab treatment: results from a multicentre 24 week study of patients with rheumatoid arthritis.
Hammer HB, Hansen I, Järvinen P, et al. · Scand J Rheumatol · 2021 · Derived
PubMed: PMID 33464147 · NCT02046616 · Arthritis, Rheumatoid
Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.
Ernst M, Oeser A, Besiroglu B, et al. · Cochrane Database Syst Rev · 2021 · Derived
PubMed: PMID 34515338 · NCT02348216 (ZUMA-1) · Lymphoma, Large B-Cell, Diffuse
GLP-1 secretion is regulated by IL-6 signalling: a randomised, placebo-controlled study.
Ellingsgaard H, Seelig E, Timper K, et al. · Diabetologia · 2021 · Derived
PubMed: PMID 31796986 · NCT01073826 (Exil-6) · Obesity
Connective tissue remodelling is differently modulated by tocilizumab versus methotrexate monotherapy in patients with early rheumatoid arthritis: the AMBITION study.
Drobinski PJ, Bay-Jensen AC, Karsdal MA, et al. · Arthritis Res Ther · 2021 · Derived
PubMed: PMID 33413588 · NCT00109408 · Arthritis, Rheumatoid
Tocilizumab Increases Body Weight and Serum Adipokine Levels in Patients with Rheumatoid Arthritis Independently of Their Treatment Response: a Retrospective Cohort Study.
Choi IA, Sagawa A, Lee EY, et al. · J Korean Med Sci · 2021 · Derived
PubMed: PMID 32508063 · NCT01211834 · Arthritis, Rheumatoid
Randomized Trial of Interleukin-6 Receptor Inhibition in Patients With Acute ST-Segment Elevation Myocardial Infarction.
Broch K, Anstensrud AK, Woxholt S, et al. · J Am Coll Cardiol · 2021 · Derived
PubMed: PMID 33858620 · NCT03004703 (ASSAIL-MI) · Inflammation
Plasma Ferritin as Marker of Macrophage Activation-Like Syndrome in Critically Ill Patients With Community-Acquired Pneumonia.
Brands X, de Vries FMC, Uhel F, et al. · Crit Care Med · 2021 · Derived
PubMed: PMID 33935163 · NCT04330638 (COV-AID) · COVID-19
Tocilizumab treatment in patients with Schnitzler syndrome: An open-label study.
Bonnekoh H, Frischbutter S, Roll S, et al. · J Allergy Clin Immunol Pract · 2021 · Derived
PubMed: PMID 33545397 · NCT03046381 (TOCISCH) · Schnitzler Syndrome
Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19.
ATTACC Investigators, ACTIV-4a Investigators, REMAP-CAP Investigators, et al. · N Engl J Med · 2021 · Derived
PubMed: PMID 34351721 · NCT02735707 (REMAP-CAP) · COVID-19
Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial.
Arabi YM, Gordon AC, Derde LPG, et al. · Intensive Care Med · 2021 · Derived
PubMed: PMID 34251506 · NCT02735707 (REMAP-CAP) · COVID-19
Rationale for the ASSAIL-MI-trial: a randomised controlled trial designed to assess the effect of tocilizumab on myocardial salvage in patients with acute ST-elevation myocardial infarction (STEMI).
Anstensrud AK, Woxholt S, Sharma K, et al. · Open Heart · 2021 · Derived
PubMed: PMID 31673391 · NCT03004703 (ASSAIL-MI) · Inflammation
Elevated interleukin-6 is associated with severity of COVID-19: A meta-analysis.
Zhu J, Pang J, Ji P, et al. · J Med Virol · 2021 · Background
PubMed: PMID 32470146 · NCT04924829 · COVID-19
Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial.
Soin AS, Kumar K, Choudhary NS, et al. · Lancet Respir Med · 2021 · Background
PubMed: PMID 33676589 · NCT04924829 · COVID-19
Acute respiratory distress syndrome in the forward environment. Retrospective analysis of acute respiratory distress syndrome cases among French Army war casualties.
Schmitt J, Boutonnet M, Goutorbe P, et al. · J Trauma Acute Care Surg · 2021 · Background
PubMed: PMID 32102034 · NCT04363853
Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle.
Lu H, Stratton CW, Tang YW, et al. · J Med Virol · 2021 · Background
PubMed: PMID 31950516 · NCT04363853
Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia.
Leng Z, Zhu R, Hou W, et al. · Aging Dis · 2021 · Background
PubMed: PMID 32257537 · NCT04492501 · COVID-19
Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases.
Cottin V, Richeldi L, Rosas I, et al. · Respir Res · 2021 · Background
PubMed: PMID 33726766 · NCT06297096 (NINTOC-TU) · Scleroderma, Systemic
The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy.
Bartalena L, Kahaly GJ, Baldeschi L, et al. · Eur J Endocrinol · 2021 · Background
PubMed: PMID 34297684 · NCT06367517 · Graves Ophthalmopathy
Interleukin-6 receptor blockade in patients with COVID-19: placing clinical trials into context.
Angriman F, Ferreyro BL, Burry L, et al. · Lancet Respir Med · 2021 · Background
PubMed: PMID 33930329 · NCT04924829 · COVID-19

2020 (71 papers)

Exercise-Induced Changes in Visceral Adipose Tissue Mass Are Regulated by IL-6 Signaling: A Randomized Controlled Trial.
Wedell-Neergaard AS, Lang Lehrskov L, Christensen RH, et al. · Cell Metab · 2020 · Trial result
PubMed: PMID 30595477 · NCT02901496 · Obesity
Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19.
RECOVERY Collaborative Group, Horby P, Mafham M, et al. · N Engl J Med · 2020 · Trial result
PubMed: PMID 33031652 · NCT04381936 (RECOVERY) · COVID-19
Is low dose radiation therapy a potential treatment for COVID-19 pneumonia?
Kirkby C, Mackenzie M · Radiother Oncol · 2020 · Trial result
PubMed: PMID 32342871 · NCT04394182 (ULTRA-COVID) · Cytokine Release Syndrome
Application of Low Doses of Ionizing Radiation in Medical Therapies.
Cuttler JM · Dose Response · 2020 · Trial result
PubMed: PMID 31933547 · NCT04394182 (ULTRA-COVID) · Cytokine Release Syndrome
Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial.
Zhang C, Zhang M, Qiu W, et al. · Lancet Neurol · 2020 · Derived
PubMed: PMID 32333897 · NCT03350633 (TANGO) · Neuromyelitis Optica
Comparative effect of tumour necrosis factor inhibitors versus other biological agents on cardiovascular risk-associated biomarkers in patients with rheumatoid arthritis.
Virone A, Bastard JP, Fellahi S, et al. · RMD Open · 2020 · Derived
PubMed: PMID 31413865 · NCT01000441 (ROC) · Arthritis, Rheumatoid
Health-related quality of life in patients with giant cell arteritis treated with tocilizumab in a phase 3 randomised controlled trial.
Strand V, Dimonaco S, Tuckwell K, et al. · Arthritis Res Ther · 2020 · Derived
PubMed: PMID 30786937 · NCT01791153 · Giant Cell Arteritis
Glucocorticoid Dosages and Acute-Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of Tocilizumab.
Stone JH, Tuckwell K, Dimonaco S, et al. · Arthritis Rheumatol · 2020 · Derived
PubMed: PMID 30835950 · NCT01791153 · Giant Cell Arteritis
Efficacy of Tocilizumab in Patients Hospitalized with Covid-19.
Stone JH, Frigault MJ, Serling-Boyd NJ, et al. · N Engl J Med · 2020 · Derived
PubMed: PMID 33085857 · NCT04356937
Reducing or Maintaining the Dose of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis in Clinical Remission: A Randomized, Open-Label Trial.
Sanmarti R, Veale DJ, Martin-Mola E, et al. · Arthritis Rheumatol · 2020 · Derived
PubMed: PMID 31087542 · NCT01995201 · Arthritis, Rheumatoid
TOCIVID-19 - A multicenter study on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia. Study protocol.
Piccirillo MC, Ascierto P, Atripaldi L, et al. · Contemp Clin Trials · 2020 · Derived
PubMed: PMID 33031955 · NCT04317092 (TOCIVID-19) · COVID-19
Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial.
Perrone F, Piccirillo MC, Ascierto PA, et al. · J Transl Med · 2020 · Derived
PubMed: PMID 33087150 · NCT04317092 (TOCIVID-19) · COVID-19
Neutropenia During Tocilizumab Treatment Is Not Associated with Infection Risk in Systemic or Polyarticular-course Juvenile Idiopathic Arthritis.
Pardeo M, Wang J, Ruperto N, et al. · J Rheumatol · 2020 · Derived
PubMed: PMID 30824645 · NCT00642460 · Arthritis, Juvenile
Intravenous dosing of tocilizumab in patients younger than two years of age with systemic juvenile idiopathic arthritis: results from an open-label phase 1 clinical trial.
Mallalieu NL, Wimalasundera S, Hsu JC, et al. · Pediatr Rheumatol Online J · 2020 · Derived
PubMed: PMID 31438986 · NCT01455701 · Arthritis, Juvenile
Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.
Maes B, Bosteels C, De Leeuw E, et al. · Trials · 2020 · Derived
PubMed: PMID 32493441 · NCT04330638 (COV-AID) · COVID-19
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.
Locke FL, Ghobadi A, Jacobson CA, et al. · Lancet Oncol · 2020 · Derived
PubMed: PMID 30518502 · NCT02348216 (ZUMA-1) · Lymphoma, Large B-Cell, Diffuse
Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial.
Khanna D, Lin CJF, Furst DE, et al. · Lancet Respir Med · 2020 · Derived
PubMed: PMID 32866440 · NCT02453256 (focuSSced) · Scleroderma, Systemic
Predictive value of serum amyloid a levels for requirement of concomitant methotrexate in tocilizumab initiation: A post hoc analysis of the SURPRISE study.
Kato M, Kaneko Y, Tanaka Y, et al. · Mod Rheumatol · 2020 · Derived
PubMed: PMID 31106666 · NCT01120366 (SURPRISE) · Arthritis, Rheumatoid
Tocilizumab improves oxidative stress and endothelial glycocalyx: A mechanism that may explain the effects of biological treatment on COVID-19.
Ikonomidis I, Pavlidis G, Katsimbri P, et al. · Food Chem Toxicol · 2020 · Derived
PubMed: PMID 32822775 · NCT03288584 · Arthritis, Rheumatoid
Differential effects of inhibition of interleukin 1 and 6 on myocardial, coronary and vascular function.
Ikonomidis I, Pavlidis G, Katsimbri P, et al. · Clin Res Cardiol · 2020 · Derived
PubMed: PMID 30859382 · NCT03288584 · Arthritis, Rheumatoid
Cardiovascular Safety of Tocilizumab Versus Etanercept in Rheumatoid Arthritis: A Randomized Controlled Trial.
Giles JT, Sattar N, Gabriel S, et al. · Arthritis Rheumatol · 2020 · Derived
PubMed: PMID 31469238 · NCT01331837 · Arthritis, Rheumatoid
Evidence of bioequivalence and positive patient user handling of a tocilizumab autoinjector.
Fettner S, Mela C, Wildenhahn F, et al. · Expert Opin Drug Deliv · 2020 · Derived
PubMed: PMID 31043095 · NCT02682823 · Arthritis, Rheumatoid
Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoid arthritis.
Emery P, Rondon J, Parrino J, et al. · Rheumatology (Oxford) · 2020 · Derived
PubMed: PMID 30590833 · NCT01768572 · Arthritis, Rheumatoid
Effect of Aerobic and Resistance Exercise on Cardiac Adipose Tissues: Secondary Analyses From a Randomized Clinical Trial.
Christensen RH, Wedell-Neergaard AS, Lehrskov LL, et al. · JAMA Cardiol · 2020 · Derived
PubMed: PMID 31268469 · NCT02901496 · Obesity
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Choy E, Caporali R, Xavier R, et al. · Rheumatology (Oxford) · 2020 · Derived
PubMed: PMID 30649524 · NCT01988012 · Arthritis, Rheumatoid
Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial.
Burmester GR, Buttgereit F, Bernasconi C, et al. · Lancet · 2020 · Derived
PubMed: PMID 32711802 · NCT02573012 · Arthritis, Rheumatoid
Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial.
Angus DC, Derde L, Al-Beidh F, et al. · JAMA · 2020 · Derived
PubMed: PMID 32876697 · NCT02735707 (REMAP-CAP) · COVID-19
The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia) Study. Rationale and Design.
Angus DC, Berry S, Lewis RJ, et al. · Ann Am Thorac Soc · 2020 · Derived
PubMed: PMID 32267771 · NCT02735707 (REMAP-CAP) · COVID-19
Host-directed therapies and holistic care for tuberculosis.
Zumla A, Ippolito G, Ntoumi F, et al. · Lancet Respir Med · 2020 · Background
PubMed: PMID 32113574 · NCT04315480
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.
Zhou F, Yu T, Du R, et al. · Lancet · 2020 · Background
PubMed: PMID 32171076 · NCT04335071 (CORON-ACT) · COVID-19
Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality.
Zhang C, Wu Z, Li JW, et al. · Int J Antimicrob Agents · 2020 · Background
PubMed: PMID 32234467 · NCT04377503 · COVID-19
The pathogenesis and treatment of the `Cytokine Storm' in COVID-19.
Ye Q, Wang B, Mao J, et al. · J Infect · 2020 · Background
PubMed: PMID 32283152 · NCT04377503 · COVID-19
Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study.
Yang X, Yu Y, Xu J, et al. · Lancet Respir Med · 2020 · Background
PubMed: PMID 32105632 · NCT04363853
Effective treatment of severe COVID-19 patients with tocilizumab.
Xu X, Han M, Li T, et al. · Proc Natl Acad Sci U S A · 2020 · Background
PubMed: PMID 32350134 · NCT04492501 · COVID-19
Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention.
Wu Z, McGoogan JM · JAMA · 2020 · Background
PubMed: PMID 32091533 · NCT04363853
Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China.
Wu C, Chen X, Cai Y, et al. · JAMA Intern Med · 2020 · Background
PubMed: PMID 32167524 · NCT04377503 · COVID-19
World Cancer Report: Cancer research for cancer prevention
· 2020 · Background
PubMed: PMID 39432694 · NCT04616235 · Appetitive Behavior
Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study.
Wichmann D, Sperhake JP, Lütgehetmann M, et al. · Ann Intern Med · 2020 · Background
PubMed: PMID 32374815 · NCT04560205 (TC19LGH) · COVID-19
Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China.
Wang W, Tang J, Wei F, et al. · J Med Virol · 2020 · Background
PubMed: PMID 31994742 · NCT04363853
Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.
Wang D, Hu B, Hu C, et al. · JAMA · 2020 · Background
PubMed: PMID 32031570 · NCT04363853
Pulmonary Pathology of Early-Phase 2019 Novel Coronavirus (COVID-19) Pneumonia in Two Patients With Lung Cancer.
Tian S, Hu W, Niu L, et al. · J Thorac Oncol · 2020 · Background
PubMed: PMID 32114094 · NCT04315480
Applied Clinical Pharmacology in a Crisis: Interleukin-6 Axis Blockade and COVID-19.
Strohbehn GW, Reid PD, Ratain MJ, et al. · Clin Pharmacol Ther · 2020 · Background
PubMed: PMID 32488861 · NCT04479358 (COVIDOSE-2) · COVID-19
Successful treatment with plasma exchange followed by intravenous immunoglobulin in a critically ill patient with COVID-19.
Shi H, Zhou C, He P, et al. · Int J Antimicrob Agents · 2020 · Background
PubMed: PMID 32298745 · NCT04492501 · COVID-19
Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China.
Ruan Q, Yang K, Wang W, et al. · Intensive Care Med · 2020 · Background
PubMed: PMID 32125452 · NCT04335071 (CORON-ACT) · COVID-19
Use of Tocilizumab for COVID-19-Induced Cytokine Release Syndrome: A Cautionary Case Report.
Radbel J, Narayanan N, Bhatt PJ, et al. · Chest · 2020 · Background
PubMed: PMID 32343968 · NCT04560205 (TC19LGH) · COVID-19
The vascular endothelium: the cornerstone of organ dysfunction in severe SARS-CoV-2 infection.
Pons S, Fodil S, Azoulay E, et al. · Crit Care · 2020 · Background
PubMed: PMID 32546188 · NCT04924829 · COVID-19
Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study.
Pawar A, Desai RJ, Solomon DH, et al. · Ann Rheum Dis · 2020 · Background
PubMed: PMID 30679153 · NCT04115423 · Arthritis, Rheumatoid
Coronavirus Infections-More Than Just the Common Cold.
Paules CI, Marston HD, Fauci AS, et al. · JAMA · 2020 · Background
PubMed: PMID 31971553 · NCT04363853
COVID-19: consider cytokine storm syndromes and immunosuppression.
Mehta P, McAuley DF, Brown M, et al. · Lancet · 2020 · Background
PubMed: PMID 32192578 · NCT04377503 · COVID-19
Efficacy of Remdesivir in COVID-19.
McCreary EK, Angus DC · JAMA · 2020 · Background
PubMed: PMID 32821934 · NCT04924829 · COVID-19
Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?
Liu B, Li M, Zhou Z, et al. · J Autoimmun · 2020 · Background
PubMed: PMID 32291137 · NCT04560205 (TC19LGH) · COVID-19
A novel treatment approach to the novel coronavirus: an argument for the use of therapeutic plasma exchange for fulminant COVID-19.
Keith P, Day M, Perkins L, et al. · Crit Care · 2020 · Background
PubMed: PMID 32241301 · NCT04492501 · COVID-19
New insights and long-term safety of tocilizumab in rheumatoid arthritis.
Jones G, Panova E · Ther Adv Musculoskelet Dis · 2020 · Background
PubMed: PMID 30327685 · NCT04115423 · Arthritis, Rheumatoid
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.
Huang C, Wang Y, Li X, et al. · Lancet · 2020 · Background
PubMed: PMID 31986264 · NCT04335071 (CORON-ACT) · COVID-19
On the Alert for Cytokine Storm: Immunopathology in COVID-19.
Henderson LA, Canna SW, Schulert GS, et al. · Arthritis Rheumatol · 2020 · Background
PubMed: PMID 32293098 · NCT04560205 (TC19LGH) · COVID-19
Clinical Characteristics of Coronavirus Disease 2019 in China.
Guan WJ, Ni ZY, Hu Y, et al. · N Engl J Med · 2020 · Background
PubMed: PMID 32109013 · NCT04377503 · COVID-19
Targeting IL-6 Is a Potential Treatment for Primary Cystic Craniopharyngioma.
Grob S, Mirsky DM, Donson AM, et al. · Front Oncol · 2020 · Background
PubMed: PMID 31497533 · NCT05233397 · Craniopharyngioma
Compassionate Use of Remdesivir for Patients with Severe Covid-19.
Grein J, Ohmagari N, Shin D, et al. · N Engl J Med · 2020 · Background
PubMed: PMID 32275812 · NCT04377503 · COVID-19
Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy.
Grasselli G, Zangrillo A, Zanella A, et al. · JAMA · 2020 · Background
PubMed: PMID 32250385 · NCT04377503 · COVID-19
Effects of Exercise on Gene Expression of Inflammatory Markers in Human Peripheral Blood Cells: A Systematic Review.
Gjevestad GO, Holven KB, Ulven SM, et al. · Curr Cardiovasc Risk Rep · 2020 · Background
PubMed: PMID 26005511 · NCT04616235 · Appetitive Behavior
Tissue Determinants of Human NK Cell Development, Function, and Residence.
Dogra P, Rancan C, Ma W, et al. · Cell · 2020 · Background
PubMed: PMID 32059780 · NCT04616235 · Appetitive Behavior
Low dose radiation therapy as a potential life saving treatment for COVID-19-induced acute respiratory distress syndrome (ARDS).
Dhawan G, Kapoor R, Dhawan R, et al. · Radiother Oncol · 2020 · Background
PubMed: PMID 32437820 · NCT04380818 · COVID-19
Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies.
Conti P, Ronconi G, Caraffa A, et al. · J Biol Regul Homeost Agents · 2020 · Background
PubMed: PMID 32171193 · NCT04380818 · COVID-19
Aerobic Exercise Induces Cardiac Fat Loss and Alters Cardiac Muscle Mass Through an Interleukin-6 Receptor-Dependent Mechanism: Cardiac Analysis of a Double-Blind Randomized Controlled Clinical Trial in Abdominally Obese Humans.
Christensen RH, Lehrskov LL, Wedell-Neergaard AS, et al. · Circulation · 2020 · Background
PubMed: PMID 31710522 · NCT04687540 · Obesity
Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.
Chen N, Zhou M, Dong X, et al. · Lancet · 2020 · Background
PubMed: PMID 32007143 · NCT04335071 (CORON-ACT) · COVID-19
Convalescent plasma as a potential therapy for COVID-19.
Chen L, Xiong J, Bao L, et al. · Lancet Infect Dis · 2020 · Background
PubMed: PMID 32113510 · NCT04492501 · COVID-19
A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.
Cao B, Wang Y, Wen D, et al. · N Engl J Med · 2020 · Background
PubMed: PMID 32187464 · NCT04377503 · COVID-19
Covid-19 in Critically Ill Patients in the Seattle Region - Case Series.
Bhatraju PK, Ghassemieh BJ, Nichols M, et al. · N Engl J Med · 2020 · Background
PubMed: PMID 32227758 · NCT04363853
The association of serum interleukin-6 levels with clinical outcomes in antineutrophil cytoplasmic antibody-associated vasculitis.
Berti A, Warner R, Johnson K, et al. · J Autoimmun · 2020 · Background
PubMed: PMID 31320177 · NCT04871191 (SATELITE) · Granulomatosis with Polyangiitis
Remdesivir for the Treatment of Covid-19 - Final Report.
Beigel JH, Tomashek KM, Dodd LE, et al. · N Engl J Med · 2020 · Background
PubMed: PMID 32445440 · NCT04492501 · COVID-19
Supportive Treatment with Tocilizumab for COVID-19: A Systematic Review.
Alzghari SK, Acuña VS · J Clin Virol · 2020 · Background
PubMed: PMID 32353761 · NCT04423042 · COVID-19

2019 (31 papers)

No difference in cardiovascular risk of tocilizumab versus abatacept for rheumatoid arthritis: A multi-database cohort study.
Kim SC, Solomon DH, Rogers JR, et al. · Semin Arthritis Rheum · 2019 · Trial result
PubMed: PMID 29673963 · NCT02797769 · Arthritis, Rheumatoid
Tocilizumab, tacrolimus and methotrexate for the prevention of acute graft-versus-host disease: low incidence of lower gastrointestinal tract disease.
Drobyski WR, Szabo A, Zhu F, et al. · Haematologica · 2019 · Trial result
PubMed: PMID 29351985 · NCT03533101 · Cytokine Release Syndrome
Radiotherapy treatment of human inflammatory diseases and conditions: Optimal dose.
Calabrese EJ, Dhawan G, Kapoor R, et al. · Hum Exp Toxicol · 2019 · Trial result
PubMed: PMID 31060383 · NCT04394182 (ULTRA-COVID) · Cytokine Release Syndrome
Baseline metabolic profiles of early rheumatoid arthritis patients achieving sustained drug-free remission after initiating treat-to-target tocilizumab, methotrexate, or the combination: insights from systems biology.
Teitsma XM, Yang W, Jacobs JWG, et al. · Arthritis Res Ther · 2019 · Derived
PubMed: PMID 30322408 · NCT01034137 · Arthritis, Rheumatoid
Inadequate response to treat-to-target methotrexate therapy in patients with new-onset rheumatoid arthritis: development and validation of clinical predictors.
Teitsma XM, Jacobs JWG, Welsing PMJ, et al. · Ann Rheum Dis · 2019 · Derived
PubMed: PMID 29760159 · NCT01034137 · Arthritis, Rheumatoid
Skin Gene Expression Is Prognostic for the Trajectory of Skin Disease in Patients With Diffuse Cutaneous Systemic Sclerosis.
Stifano G, Sornasse T, Rice LM, et al. · Arthritis Rheumatol · 2019 · Derived
PubMed: PMID 29858547 · NCT01532869 · Scleroderma, Systemic
Tocilizumab as an add-on therapy to glucocorticoids during the first 3 months of treatment of Giant cell arteritis: A prospective study.
Samson M, Devilliers H, Ly KH, et al. · Eur J Intern Med · 2019 · Derived
PubMed: PMID 30054122 · NCT01910038 (HORTOCI) · Giant Cell Arteritis
Serum IL-33 level is associated with auto-antibodies but not with clinical response to biologic agents in rheumatoid arthritis.
Rivière E, Sellam J, Pascaud J, et al. · Arthritis Res Ther · 2019 · Derived
PubMed: PMID 29884223 · NCT01000441 (ROC) · Arthritis, Rheumatoid
Sustained Response Following Discontinuation of Methotrexate in Patients With Rheumatoid Arthritis Treated With Subcutaneous Tocilizumab: Results From a Randomized, Controlled Trial.
Kremer JM, Rigby W, Singer NG, et al. · Arthritis Rheumatol · 2019 · Derived
PubMed: PMID 29575803 · NCT01855789 · Arthritis, Rheumatoid
Interleukin-6 receptor inhibition with tocilizumab induces a selective and substantial increase in plasma IP-10 and MIP-1β in non-ST-elevation myocardial infarction.
Kleveland O, Ueland T, Kunszt G, et al. · Int J Cardiol · 2019 · Derived
PubMed: PMID 29961572 · NCT01491074 · Non-ST Elevated Myocardial Infarction
Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate).
Khanna D, Denton CP, Lin CJF, et al. · Ann Rheum Dis · 2019 · Derived
PubMed: PMID 29066464 · NCT01532869 · Scleroderma, Systemic
Tocilizumab discontinuation after attaining remission in patients with rheumatoid arthritis who were treated with tocilizumab alone or in combination with methotrexate: results from a prospective randomised controlled study (the second year of the SURPRISE study).
Kaneko Y, Kato M, Tanaka Y, et al. · Ann Rheum Dis · 2019 · Derived
PubMed: PMID 29853455 · NCT01120366 (SURPRISE) · Arthritis, Rheumatoid
Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis.
Denton CP, Ong VH, Xu S, et al. · Ann Rheum Dis · 2019 · Derived
PubMed: PMID 29853453 · NCT01532869 · Scleroderma, Systemic
The role of exercise combined with tocilizumab in visceral and epicardial adipose tissue and gastric emptying rate in abdominally obese participants: protocol for a randomised controlled trial.
Christensen RH, Wedell-Neergaard AS, Lehrskov LL, et al. · Trials · 2019 · Derived
PubMed: PMID 29720225 · NCT02901496 · Obesity
Interleukin (IL-6) Immunotherapy.
Tanaka T, Narazaki M, Kishimoto T, et al. · Cold Spring Harb Perspect Biol · 2019 · Background
PubMed: PMID 28778870 · NCT03863015 (IMICA) · Inflammation
Add-on tocilizumab versus conventional treatment for systemic sclerosis, and cytokine analysis to identify an endotype to tocilizumab therapy.
Shima Y, Kawaguchi Y, Kuwana M, et al. · Mod Rheumatol · 2019 · Background
PubMed: PMID 29529897 · NCT06297096 (NINTOC-TU) · Scleroderma, Systemic
Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
Rutherford AI, Subesinghe S, Hyrich KL, et al. · Ann Rheum Dis · 2019 · Background
PubMed: PMID 29592917 · NCT04115423 · Arthritis, Rheumatoid
Lymphocytes and monocytes egress peripheral blood within minutes after cessation of steady state exercise: A detailed temporal analysis of leukocyte extravasation.
Rooney BV, Bigley AB, LaVoy EC, et al. · Physiol Behav · 2019 · Background
PubMed: PMID 29885920 · NCT04616235 · Appetitive Behavior
Peripheral Blood Grafts for T Cell-Replete Haploidentical Transplantation Increase the Incidence and Severity of Cytokine Release Syndrome.
Raj RV, Hamadani M, Szabo A, et al. · Biol Blood Marrow Transplant · 2019 · Background
PubMed: PMID 29680516 · NCT03533101 · Cytokine Release Syndrome
Efficacy of Tocilizumab in Patients With Moderate-to-Severe Corticosteroid-Resistant Graves Orbitopathy: A Randomized Clinical Trial.
Perez-Moreiras JV, Gomez-Reino JJ, Maneiro JR, et al. · Am J Ophthalmol · 2019 · Background
PubMed: PMID 30081019 · NCT06367517 · Graves Ophthalmopathy
Improved CNS exposure to tocilizumab after cerebrospinal fluid compared to intravenous administration in rhesus macaques.
Nellan A, McCully CML, Cruz Garcia R, et al. · Blood · 2019 · Background
PubMed: PMID 29954750 · NCT05233397 · Craniopharyngioma
FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome.
Le RQ, Li L, Yuan W, et al. · Oncologist · 2019 · Background
PubMed: PMID 29622697 · NCT04335071 (CORON-ACT) · COVID-19
Interleukin-6 Delays Gastric Emptying in Humans with Direct Effects on Glycemic Control.
Lang Lehrskov L, Lyngbaek MP, Soederlund L, et al. · Cell Metab · 2019 · Background
PubMed: PMID 29731416 · NCT04616235 · Appetitive Behavior
Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial.
l'Ami MJ, Krieckaert CL, Nurmohamed MT, et al. · Ann Rheum Dis · 2019 · Background
PubMed: PMID 28939629 · NCT03895879 (TODORA) · Arthritis, Rheumatoid
Early therapeutic plasma exchange in septic shock: a prospective open-label nonrandomized pilot study focusing on safety, hemodynamics, vascular barrier function, and biologic markers.
Knaup H, Stahl K, Schmidt BMW, et al. · Crit Care · 2019 · Background
PubMed: PMID 30373638 · NCT04492501 · COVID-19
Autologous serum collected 1 h post-exercise enhances natural killer cell cytotoxicity.
Gupta P, Bigley AB, Markofski M, et al. · Brain Behav Immun · 2019 · Background
PubMed: PMID 29656052 · NCT04616235 · Appetitive Behavior
Risk of serious infections in patients with rheumatoid arthritis treated in routine care with abatacept, rituximab and tocilizumab in Denmark and Sweden.
Grøn KL, Arkema EV, Glintborg B, et al. · Ann Rheum Dis · 2019 · Background
PubMed: PMID 30612115 · NCT04115423 · Arthritis, Rheumatoid
Interleukin-6 as a "metabolic hormone".
Ghanemi A, St-Amand J · Cytokine · 2019 · Background
PubMed: PMID 29983356 · NCT04616235 · Appetitive Behavior
Acute and Chronic Effects of Exercise on Appetite, Energy Intake, and Appetite-Related Hormones: The Modulating Effect of Adiposity, Sex, and Habitual Physical Activity.
Dorling J, Broom DR, Burns SF, et al. · Nutrients · 2019 · Background
PubMed: PMID 30131457 · NCT04616235 · Appetitive Behavior
Exercise Training in Cancer Control and Treatment.
Christensen JF, Simonsen C, Hojman P, et al. · Compr Physiol · 2019 · Background
PubMed: PMID 30549018 · NCT04616235 · Appetitive Behavior
Fixed dosing of intravenous tocilizumab in rheumatoid arthritis. Results from a population pharmacokinetic analysis.
Bastida C, Ruiz-Esquide V, Pascal M, et al. · Br J Clin Pharmacol · 2019 · Background
PubMed: PMID 29314183 · NCT03895879 (TODORA) · Arthritis, Rheumatoid

2018 (22 papers)

IL-6 blockade in the management of non-infectious uveitis.
Lopalco G, Fabiani C, Sota J, et al. · Clin Rheumatol · 2018 · Trial result
PubMed: PMID 28528519 · NCT03554161 · Behcet Syndrome
Anti-interleukin 6 receptor tocilizumab in refractory uveitis associated with Behçet's disease: multicentre retrospective study.
Atienza-Mateo B, Calvo-Río V, Beltrán E, et al. · Rheumatology (Oxford) · 2018 · Trial result
PubMed: PMID 29471416 · NCT03554161 · Behcet Syndrome
Severe Cytokine-Release Syndrome after T Cell-Replete Peripheral Blood Haploidentical Donor Transplantation Is Associated with Poor Survival and Anti-IL-6 Therapy Is Safe and Well Tolerated.
Abboud R, Keller J, Slade M, et al. · Biol Blood Marrow Transplant · 2018 · Trial result
PubMed: PMID 27318038 · NCT03533101 · Cytokine Release Syndrome
Radiographic joint damage in early rheumatoid arthritis patients: comparing tocilizumab- and methotrexate-based treat-to-target strategies.
Teitsma XM, Jacobs JWG, Welsing PMJ, et al. · Rheumatology (Oxford) · 2018 · Derived
PubMed: PMID 29095992 · NCT01034137 · Arthritis, Rheumatoid
Identification of differential co-expressed gene networks in early rheumatoid arthritis achieving sustained drug-free remission after treatment with a tocilizumab-based or methotrexate-based strategy.
Teitsma XM, Jacobs JWG, Mokry M, et al. · Arthritis Res Ther · 2018 · Derived
PubMed: PMID 28728565 · NCT01034137 · Arthritis, Rheumatoid
Long-term, interventional, open-label extension study evaluating the safety of tocilizumab treatment in patients with polyarticular-course juvenile idiopathic arthritis from Poland and Russia who completed the global, international CHERISH trial.
Opoka-Winiarska V, Żuber Z, Alexeeva E, et al. · Clin Rheumatol · 2018 · Derived
PubMed: PMID 29654485 · NCT01575769 · Arthritis, Juvenile
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.
Neelapu SS, Locke FL, Bartlett NL, et al. · N Engl J Med · 2018 · Derived
PubMed: PMID 29226797 · NCT02348216 (ZUMA-1) · Lymphoma, Large B-Cell, Diffuse
Immuno-monitoring reveals an extended subclinical disease activity in tocilizumab-treated giant cell arteritis.
Gloor AD, Yerly D, Adler S, et al. · Rheumatology (Oxford) · 2018 · Derived
PubMed: PMID 29961816 · NCT01450137 · Giant Cell Arteritis
Subcutaneous tocilizumab in rheumatoid arthritis: findings from the common-framework phase 4 study programme TOZURA conducted in 22 countries.
Choy E, Caporali R, Xavier R, et al. · Rheumatology (Oxford) · 2018 · Derived
PubMed: PMID 29244149 · NCT01951170 · Arthritis, Rheumatoid
Short-term application of tocilizumab during myocardial infarction (STAT-MI).
Carroll MB, Haller C, Smith C, et al. · Rheumatol Int · 2018 · Derived
PubMed: PMID 29067495 · NCT02419937 (STAT-MI) · Myocardial Infarction
Tocilizumab efficacy and safety in rheumatoid arthritis patients after inadequate response to disease-modifying anti-rheumatic drugs oranti-tumor necrosis factor.
Abdulkader OAF, Qushmaq K, Aljishi F, et al. · Ann Saudi Med · 2018 · Derived
PubMed: PMID 27236390 · NCT01326962 · Arthritis, Rheumatoid
Exercise induced alterations in NK-cell cytotoxicity - methodological issues and future perspectives.
Zimmer P, Schenk A, Kieven M, et al. · Exerc Immunol Rev · 2018 · Background
PubMed: PMID 28230531 · NCT04616235 · Appetitive Behavior
Recreational Physical Activity in Relation to Prostate Cancer-specific Mortality Among Men with Nonmetastatic Prostate Cancer.
Wang Y, Jacobs EJ, Gapstur SM, et al. · Eur Urol · 2018 · Background
PubMed: PMID 28711382 · NCT04616235 · Appetitive Behavior
Cytokine Release Syndrome after Haploidentical Stem Cell Transplantation.
Teachey DT, Grupp SA · Biol Blood Marrow Transplant · 2018 · Background
PubMed: PMID 27543158 · NCT03533101 · Cytokine Release Syndrome
Current clinical evidence of tocilizumab for the treatment of ANCA-associated vasculitis: a prospective case series for microscopic polyangiitis in a combination with corticosteroids and literature review.
Sakai R, Kondo T, Kurasawa T, et al. · Clin Rheumatol · 2018 · Background
PubMed: PMID 28733791 · NCT04871191 (SATELITE) · Granulomatosis with Polyangiitis
Circulating Levels of IL-6 Receptor and gp130 and Long-Term Clinical Outcomes in ST-Elevation Myocardial Infarction.
Ritschel VN, Seljeflot I, Arnesen H, et al. · J Am Heart Assoc · 2018 · Background
PubMed: PMID 27412895 · NCT03004703 (ASSAIL-MI) · Inflammation
Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial.
Kleveland O, Kunszt G, Bratlie M, et al. · Eur Heart J · 2018 · Background
PubMed: PMID 27161611 · NCT03004703 (ASSAIL-MI) · Inflammation
Whole-body hyperthermia and a subthreshold dose of citalopram act synergistically to induce antidepressant-like behavioral responses in adolescent rats.
Hale MW, Lukkes JL, Dady KF, et al. · Prog Neuropsychopharmacol Biol Psychiatry · 2018 · Background
PubMed: PMID 28619470 · NCT03787290 · Inflammation
Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells.
Gust J, Hay KA, Hanafi LA, et al. · Cancer Discov · 2018 · Background
PubMed: PMID 29025771 · NCT05233397 · Craniopharyngioma
Current Use and Trends in Hematopoietic Cell Transplantation in the United States.
D'Souza A, Lee S, Zhu X, et al. · Biol Blood Marrow Transplant · 2018 · Background
PubMed: PMID 28606646 · NCT02206035
Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology.
Channappanavar R, Perlman S · Semin Immunopathol · 2018 · Background
PubMed: PMID 28466096 · NCT04363853
Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association.
Benjamin EJ, Blaha MJ, Chiuve SE, et al. · Circulation · 2018 · Background
PubMed: PMID 28122885 · NCT03863015 (IMICA) · Inflammation

2017 (31 papers)

Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multi-Database Cohort Study.
Kim SC, Solomon DH, Rogers JR, et al. · Arthritis Rheumatol · 2017 · Trial result
PubMed: PMID 28245350 · NCT02797769 · Arthritis, Rheumatoid
Six-year outcomes in broadly HLA-sensitized living donor transplant recipients desensitized with intravenous immunoglobulin and rituximab.
Kahwaji J, Jordan SC, Najjar R, et al. · Transpl Int · 2017 · Trial result
PubMed: PMID 27529314 · NCT03507348 · Kidney Failure, Chronic
Effect of IL-6 receptor blockade on high-sensitivity troponin T and NT-proBNP in rheumatoid arthritis.
Welsh P, Tuckwell K, McInnes IB, et al. · Atherosclerosis · 2017 · Derived
PubMed: PMID 27744141 · NCT00106574 · Arthritis, Rheumatoid
Tofacitinib Versus Biologic Treatments in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors: Results From a Network Meta-analysis.
Vieira MC, Zwillich SH, Jansen JP, et al. · Clin Ther · 2017 · Derived
PubMed: PMID 27889300 · NCT00106522 · Arthritis, Rheumatoid
Patient-reported outcomes in newly diagnosed early rheumatoid arthritis patients treated to target with a tocilizumab- or methotrexate-based strategy.
Teitsma XM, Jacobs JWG, Welsing PMJ, et al. · Rheumatology (Oxford) · 2017 · Derived
PubMed: PMID 29029185 · NCT01034137 · Arthritis, Rheumatoid
Trial of Tocilizumab in Giant-Cell Arteritis.
Stone JH, Tuckwell K, Dimonaco S, et al. · N Engl J Med · 2017 · Derived
PubMed: PMID 28745999 · NCT01791153 · Giant Cell Arteritis
Routine Assessment of Patient Index Data 3 and the American College of Rheumatology/European League Against Rheumatism Provisional Remission Definitions as Predictors of Radiographic Outcome in a Rheumatoid Arthritis Clinical Trial With Tocilizumab.
Khawaja MN, Bergman MJ, Yourish J, et al. · Arthritis Care Res (Hoboken) · 2017 · Derived
PubMed: PMID 27564431 · NCT00106535 · Arthritis, Rheumatoid
Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study).
Kaneko Y, Atsumi T, Tanaka Y, et al. · Ann Rheum Dis · 2017 · Derived
PubMed: PMID 26733110 · NCT01120366 (SURPRISE) · Arthritis, Rheumatoid
Five-year Efficacy and Safety of Tocilizumab Monotherapy in Patients with Rheumatoid Arthritis Who Were Methotrexate- and Biologic-naive or Free of Methotrexate for 6 Months: the AMBITION Study.
Jones G, Wallace T, McIntosh MJ, et al. · J Rheumatol · 2017 · Derived
PubMed: PMID 27909081 · NCT00109408 · Arthritis, Rheumatoid
Enhanced T cell responses to IL-6 in type 1 diabetes are associated with early clinical disease and increased IL-6 receptor expression.
Hundhausen C, Roth A, Whalen E, et al. · Sci Transl Med · 2017 · Derived
PubMed: PMID 27629486 · NCT02293837 (EXTEND) · Diabetes Mellitus, Type 1
Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis.
Gabay C, McInnes IB, Kavanaugh A, et al. · Ann Rheum Dis · 2017 · Derived
PubMed: PMID 26613768 · NCT01119859 · Arthritis, Rheumatoid
Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial.
Burmester GR, Rigby WF, van Vollenhoven RF, et al. · Ann Rheum Dis · 2017 · Derived
PubMed: PMID 26511996 · NCT01007435 · Arthritis, Rheumatoid
Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial.
Burmester GR, Rigby WF, van Vollenhoven RF, et al. · Ann Rheum Dis · 2017 · Derived
PubMed: PMID 28389552 · NCT01007435 · Arthritis, Rheumatoid
EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis.
Yates M, Watts RA, Bajema IM, et al. · Ann Rheum Dis · 2017 · Background
PubMed: PMID 27338776 · NCT04871191 (SATELITE) · Granulomatosis with Polyangiitis
IL-6 Improves Energy and Glucose Homeostasis in Obesity via Enhanced Central IL-6 trans-Signaling.
Timper K, Denson JL, Steculorum SM, et al. · Cell Rep · 2017 · Background
PubMed: PMID 28402851 · NCT04616235 · Appetitive Behavior
Immunotherapeutic implications of IL-6 blockade for cytokine storm.
Tanaka T, Narazaki M, Kishimoto T, et al. · Immunotherapy · 2017 · Background
PubMed: PMID 27381687 · NCT03533101 · Cytokine Release Syndrome
Infections With Biologics in Rheumatoid Arthritis and Related Conditions: a Scoping Review of Serious or Hospitalized Infections in Observational Studies.
Singh JA · Curr Rheumatol Rep · 2017 · Background
PubMed: PMID 27613285 · NCT04115423 · Arthritis, Rheumatoid
Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.
Singh JA, Hossain A, Tanjong Ghogomu E, et al. · Cochrane Database Syst Rev · 2017 · Background
PubMed: PMID 28282491 · NCT04115423 · Arthritis, Rheumatoid
GO-QOL--disease-specific quality of life questionnaire in Graves' orbitopathy.
Sawicka-Gutaj N, Bednarczuk T, Daroszewski J, et al. · Endokrynol Pol · 2017 · Background
PubMed: PMID 26323474 · NCT06367517 · Graves Ophthalmopathy
Impact of treatment with biologic DMARDs on the risk of sepsis or mortality after serious infection in patients with rheumatoid arthritis.
Richter A, Listing J, Schneider M, et al. · Ann Rheum Dis · 2017 · Background
PubMed: PMID 26567181 · NCT04335071 (CORON-ACT) · COVID-19
Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis.
Ramiro S, Sepriano A, Chatzidionysiou K, et al. · Ann Rheum Dis · 2017 · Background
PubMed: PMID 28298374 · NCT04115423 · Arthritis, Rheumatoid
Benefit of Tocilizumab Therapy for Adult-Onset Still Disease Complicated With Acute Respiratory Distress Syndrome.
Morrondo CD, Zarza LP, Gil JG, et al. · J Clin Rheumatol · 2017 · Background
PubMed: PMID 27464783 · NCT04335071 (CORON-ACT) · COVID-19
Tocilizumab in Autoimmune Encephalitis Refractory to Rituximab: An Institutional Cohort Study.
Lee WJ, Lee ST, Moon J, et al. · Neurotherapeutics · 2017 · Background
PubMed: PMID 27215218 · NCT03863015 (IMICA) · Inflammation
Update of EULAR recommendations for the treatment of systemic sclerosis.
Kowal-Bielecka O, Fransen J, Avouac J, et al. · Ann Rheum Dis · 2017 · Background
PubMed: PMID 27941129 · NCT06297096 (NINTOC-TU) · Scleroderma, Systemic
Serum tocilizumab trough concentration can be used to monitor systemic IL-6 receptor blockade in patients with rheumatoid arthritis: a prospective observational cohort study.
Kneepkens EL, van den Oever I, Plasencia CH, et al. · Scand J Rheumatol · 2017 · Background
PubMed: PMID 27440258 · NCT03895879 (TODORA) · Arthritis, Rheumatoid
Whole-Body Hyperthermia for the Treatment of Major Depressive Disorder: A Randomized Clinical Trial.
Janssen CW, Lowry CA, Mehl MR, et al. · JAMA Psychiatry · 2017 · Background
PubMed: PMID 27172277 · NCT03787290 · Inflammation
Tocilizumab's effect on cognitive deficits induced by intracerebroventricular administration of streptozotocin in Alzheimer's model.
Elcioğlu HK, Aslan E, Ahmad S, et al. · Mol Cell Biochem · 2017 · Background
PubMed: PMID 27443846 · NCT03863015 (IMICA) · Inflammation
Molecular Analyses Reveal Inflammatory Mediators in the Solid Component and Cyst Fluid of Human Adamantinomatous Craniopharyngioma.
Donson AM, Apps J, Griesinger AM, et al. · J Neuropathol Exp Neurol · 2017 · Background
PubMed: PMID 28859336 · NCT05233397 · Craniopharyngioma
Efficacy of first-line tocilizumab therapy in early polymyalgia rheumatica: a prospective longitudinal study.
Devauchelle-Pensec V, Berthelot JM, Cornec D, et al. · Ann Rheum Dis · 2017 · Background
PubMed: PMID 26929219 · NCT02888496 (TENOR-IMMUNO) · Polymyalgia Rheumatica
Effects of Tocilizumab on Experimental Severe Acute Pancreatitis and Associated Acute Lung Injury.
Chen KL, Lv ZY, Yang HW, et al. · Crit Care Med · 2017 · Background
PubMed: PMID 26963319 · NCT03863015 (IMICA) · Inflammation
THERAPY OF ENDOCRINE DISEASE: Endocrine dilemma: management of Graves' orbitopathy.
Campi I, Vannucchi G, Salvi M, et al. · Eur J Endocrinol · 2017 · Background
PubMed: PMID 27032693 · NCT04876534 (TOGO) · Graves Ophthalmopathy

2016 (34 papers)

Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial.
Villiger PM, Adler S, Kuchen S, et al. · Lancet · 2016 · Trial result
PubMed: PMID 26952547 · NCT01450137 · Giant Cell Arteritis
Efficacy and safety of tandem hemodialysis and immunoadsorption to desensitize kidney transplant candidates.
Rostaing L, Maggioni S, Hecht C, et al. · Exp Clin Transplant · 2016 · Trial result
PubMed: PMID 25894148 · NCT03507348 · Kidney Failure, Chronic
Kidney Transplants from HLA-Incompatible Live Donors and Survival.
Orandi BJ, Montgomery RA, Segev DL, et al. · N Engl J Med · 2016 · Trial result
PubMed: PMID 27468073 · NCT03507348 · Kidney Failure, Chronic
Tocilizumab in giant cell arteritis: Multicenter open-label study of 22 patients.
Loricera J, Blanco R, Hernández JL, et al. · Semin Arthritis Rheum · 2016 · Trial result
PubMed: PMID 25697557 · NCT03244709 · Giant Cell Arteritis
Outcome after Desensitization in HLA or ABO-Incompatible Kidney Transplant Recipients: A Single Center Experience.
Kauke T, Klimaschewski S, Schoenermarck U, et al. · PLoS One · 2016 · Trial result
PubMed: PMID 26730981 · NCT03507348 · Kidney Failure, Chronic
Clinical efficacy and safety maintained up to 5 years in patients with rheumatoid arthritis treated with tocilizumab in a randomised trial.
Kremer JM, Blanco R, Halland AM, et al. · Clin Exp Rheumatol · 2016 · Derived
PubMed: PMID 27087059 · NCT00106535 · Arthritis, Rheumatoid
Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial.
Khanna D, Denton CP, Jahreis A, et al. · Lancet · 2016 · Derived
PubMed: PMID 27156934 · NCT01532869 · Scleroderma, Systemic
Evaluation of the Disease Activity Score in Twenty-Eight Joints-Based Flare Definitions in Rheumatoid Arthritis: Data From a Three-Year Clinical Trial.
Dougados M, Huizinga TW, Choy EH, et al. · Arthritis Care Res (Hoboken) · 2016 · Derived
PubMed: PMID 26037777 · NCT00810199 · Arthritis, Rheumatoid
A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancer.
Dijkgraaf EM, Santegoets SJ, Reyners AK, et al. · Ann Oncol · 2016 · Derived
PubMed: PMID 26216383 · NCT01637532 (PITCH) · Ovarian Neoplasms
Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA).
Burmester GR, Rubbert-Roth A, Cantagrel A, et al. · Ann Rheum Dis · 2016 · Derived
PubMed: PMID 26056119 · NCT01194414 · Arthritis, Rheumatoid
Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial.
Bijlsma JWJ, Welsing PMJ, Woodworth TG, et al. · Lancet · 2016 · Derived
PubMed: PMID 27287832 · NCT01034137 · Arthritis, Rheumatoid
Early changes in blood-based joint tissue destruction biomarkers are predictive of response to tocilizumab in the LITHE study.
Bay-Jensen AC, Platt A, Siebuhr AS, et al. · Arthritis Res Ther · 2016 · Derived
PubMed: PMID 26787505 · NCT00106535 · Arthritis, Rheumatoid
Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare.
Yun H, Xie F, Delzell E, et al. · Arthritis Rheumatol · 2016 · Background
PubMed: PMID 26315675 · NCT04115423 · Arthritis, Rheumatoid
A Phase I/II Trial of the Interleukin-6 Receptor-Specific Humanized Monoclonal (Tocilizumab) + Intravenous Immunoglobulin in Difficult to Desensitize Patients.
Vo AA, Choi J, Kim I, et al. · Transplantation · 2016 · Background
PubMed: PMID 26018350 · NCT01594424 · Kidney Failure, Chronic
Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial.
Shakoory B, Carcillo JA, Chatham WW, et al. · Crit Care Med · 2016 · Background
PubMed: PMID 26584195 · NCT04335071 (CORON-ACT) · COVID-19
Medical Treatment of Graves' Orbitopathy.
Salvi M, Campi I · Horm Metab Res · 2016 · Background
PubMed: PMID 26361263 · NCT04876534 (TOGO) · Graves Ophthalmopathy
Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry.
Sakai R, Cho SK, Nanki T, et al. · Arthritis Res Ther · 2016 · Background
PubMed: PMID 25880658 · NCT04115423 · Arthritis, Rheumatoid
Voluntary Running Suppresses Tumor Growth through Epinephrine- and IL-6-Dependent NK Cell Mobilization and Redistribution.
Pedersen L, Idorn M, Olofsson GH, et al. · Cell Metab · 2016 · Background
PubMed: PMID 26895752 · NCT04616235 · Appetitive Behavior
European Resuscitation Council and European Society of Intensive Care Medicine Guidelines for Post-resuscitation Care 2015: Section 5 of the European Resuscitation Council Guidelines for Resuscitation 2015.
Nolan JP, Soar J, Cariou A, et al. · Resuscitation · 2016 · Background
PubMed: PMID 26477702 · NCT03863015 (IMICA) · Inflammation
An open-label, pilot trial of adjunctive tocilizumab in schizophrenia.
Miller BJ, Dias JK, Lemos HP, et al. · J Clin Psychiatry · 2016 · Background
PubMed: PMID 26930525 · NCT02874573 · Inflammation
Efficacy of Biological-Targeted Treatments in Takayasu Arteritis: Multicenter, Retrospective Study of 49 Patients.
Mekinian A, Comarmond C, Resche-Rigon M, et al. · Circulation · 2016 · Background
PubMed: PMID 26354797 · NCT03893136 · Takayasu Arteritis
Adipose Tissue Insulin Action and IL-6 Signaling after Exercise in Obese Mice.
Macpherson RE, Huber JS, Frendo-Cumbo S, et al. · Med Sci Sports Exerc · 2016 · Background
PubMed: PMID 25785928 · NCT04616235 · Appetitive Behavior
Identification of targets for rational pharmacological therapy in childhood craniopharyngioma.
Gump JM, Donson AM, Birks DK, et al. · Acta Neuropathol Commun · 2016 · Background
PubMed: PMID 25990246 · NCT05233397 · Craniopharyngioma
Interleukin-6: the missing element of the neurocognitive deterioration in schizophrenia? The focus on genetic underpinnings, cognitive impairment and clinical manifestation.
Frydecka D, Misiak B, Pawlak-Adamska E, et al. · Eur Arch Psychiatry Clin Neurosci · 2016 · Background
PubMed: PMID 25214388 · NCT02874573 · Inflammation
Sample Size in Clinical Cardioprotection Trials Using Myocardial Salvage Index, Infarct Size, or Biochemical Markers as Endpoint.
Engblom H, Heiberg E, Erlinge D, et al. · J Am Heart Assoc · 2016 · Background
PubMed: PMID 26961520 · NCT03004703 (ASSAIL-MI) · Inflammation
Cardioprotection by combined intrahospital remote ischaemic perconditioning and postconditioning in ST-elevation myocardial infarction: the randomized LIPSIA CONDITIONING trial.
Eitel I, Stiermaier T, Rommel KP, et al. · Eur Heart J · 2016 · Background
PubMed: PMID 26385956 · NCT03004703 (ASSAIL-MI) · Inflammation
Anti-Inflammatory Treatment With Colchicine in Acute Myocardial Infarction: A Pilot Study.
Deftereos S, Giannopoulos G, Angelidis C, et al. · Circulation · 2016 · Background
PubMed: PMID 26265659 · NCT03004703 (ASSAIL-MI) · Inflammation
Takayasu Arteritis and Pregnancy.
Comarmond C, Mirault T, Biard L, et al. · Arthritis Rheumatol · 2016 · Background
PubMed: PMID 26315109 · NCT03893136 · Takayasu Arteritis
B Cell Activating Factor (BAFF) and BAFF Receptor Expression in Autoimmune and Nonautoimmune Thyroid Diseases.
Campi I, Tosi D, Rossi S, et al. · Thyroid · 2016 · Background
PubMed: PMID 26214745 · NCT04876534 (TOGO) · Graves Ophthalmopathy
Part 8: Post-Cardiac Arrest Care: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care.
Callaway CW, Donnino MW, Fink EL, et al. · Circulation · 2016 · Background
PubMed: PMID 26472996 · NCT03863015 (IMICA) · Inflammation
Interleukin-6 in ANCA-associated vasculitis: Rationale for successful treatment with tocilizumab.
Berti A, Cavalli G, Campochiaro C, et al. · Semin Arthritis Rheum · 2016 · Background
PubMed: PMID 25841802 · NCT04871191 (SATELITE) · Granulomatosis with Polyangiitis
The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy.
Bartalena L, Baldeschi L, Boboridis K, et al. · Eur Thyroid J · 2016 · Background
PubMed: PMID 27099835 · NCT04876534 (TOGO) · Graves Ophthalmopathy
Effect of intravenous TRO40303 as an adjunct to primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: MITOCARE study results.
Atar D, Arheden H, Berdeaux A, et al. · Eur Heart J · 2016 · Background
PubMed: PMID 25179768 · NCT03004703 (ASSAIL-MI) · Inflammation
Maternal and Neonatal Outcomes in 89 Patients with Takayasu Arteritis (TA): Comparison Before and After the TA Diagnosis.
Assad AP, da Silva TF, Bonfa E, et al. · J Rheumatol · 2016 · Background
PubMed: PMID 26329335 · NCT03893136 · Takayasu Arteritis

2015 (26 papers)

Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1/2 trial.
Kennedy GA, Varelias A, Vuckovic S, et al. · Lancet Oncol · 2015 · Trial result
PubMed: PMID 25456364 · NCT03533101 · Cytokine Release Syndrome
Humoral immune response to vaccines in patients with rheumatoid arthritis treated with tocilizumab: results of a randomised controlled trial (VISARA).
Bingham CO, Rizzo W, Kivitz A, et al. · Ann Rheum Dis · 2015 · Trial result
PubMed: PMID 24448345 · NCT01163747 · Arthritis, Rheumatoid
Serological identification of fast progressors of structural damage with rheumatoid arthritis.
Siebuhr AS, Bay-Jensen AC, Leeming DJ, et al. · Arthritis Res Ther · 2015 · Derived
PubMed: PMID 23945134 · NCT00106535 · Arthritis, Rheumatoid
Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study.
Huizinga TW, Conaghan PG, Martin-Mola E, et al. · Ann Rheum Dis · 2015 · Derived
PubMed: PMID 25169728 · NCT00810199 · Arthritis, Rheumatoid
Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics.
Dennis G, Holweg CT, Kummerfeld SK, et al. · Arthritis Res Ther · 2015 · Derived
PubMed: PMID 25167216 · NCT01119859 · Arthritis, Rheumatoid
Catch-up growth during tocilizumab therapy for systemic juvenile idiopathic arthritis: results from a phase III trial.
De Benedetti F, Brunner H, Ruperto N, et al. · Arthritis Rheumatol · 2015 · Derived
PubMed: PMID 25504861 · NCT00642460 · Arthritis, Juvenile
Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial.
Brunner HI, Ruperto N, Zuber Z, et al. · Ann Rheum Dis · 2015 · Derived
PubMed: PMID 24834925 · NCT00988221 · Arthritis, Juvenile
Discrepancy between clinical and radiological responses to tocilizumab treatment in patients with systemic-onset juvenile idiopathic arthritis.
Aoki C, Inaba Y, Choe H, et al. · J Rheumatol · 2015 · Derived
PubMed: PMID 24786929 · NCT00144612 · Arthritis, Juvenile
Rituximab plus liposomal doxorubicin in HIV-infected patients with KSHV-associated multicentric Castleman disease.
Uldrick TS, Polizzotto MN, Aleman K, et al. · Blood · 2015 · Background
PubMed: PMID 25331113 · NCT01441063 · Castleman Disease
Management of large-vessel vasculitis with FDG-PET: a systematic literature review and meta-analysis.
Soussan M, Nicolas P, Schramm C, et al. · Medicine (Baltimore) · 2015 · Background
PubMed: PMID 25860208 · NCT03244709 · Giant Cell Arteritis
Immunotherapy for Graves' ophthalmopathy.
Salvi M · Curr Opin Endocrinol Diabetes Obes · 2015 · Background
PubMed: PMID 25105999 · NCT04876534 (TOGO) · Graves Ophthalmopathy
Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study.
Salvi M, Vannucchi G, Currò N, et al. · J Clin Endocrinol Metab · 2015 · Background
PubMed: PMID 25494967 · NCT04876534 (TOGO) · Graves Ophthalmopathy
Long-term Therapy With Interleukin 6 Receptor Blockade in Highly Active Neuromyelitis Optica Spectrum Disorder.
Ringelstein M, Ayzenberg I, Harmel J, et al. · JAMA Neurol · 2015 · Background
PubMed: PMID 25985228 · NCT03863015 (IMICA) · Inflammation
Design of the INPULSIS™ trials: two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis.
Richeldi L, Cottin V, Flaherty KR, et al. · Respir Med · 2015 · Background
PubMed: PMID 24834811 · NCT06297096 (NINTOC-TU) · Scleroderma, Systemic
Role of inflammatory markers in Takayasu arteritis disease monitoring.
O'Connor TE, Carpenter HE, Bidari S, et al. · BMC Neurol · 2015 · Background
PubMed: PMID 24678735 · NCT03893136 · Takayasu Arteritis
Long-term effects of tocilizumab therapy for refractory uveitis-related macular edema.
Mesquida M, Molins B, Llorenç V, et al. · Ophthalmology · 2015 · Background
PubMed: PMID 25204610 · NCT02511067 (READ-4)
Interleukin-6 and high-sensitivity C-reactive protein for the prediction of outcomes in non-ST-segment elevation acute coronary syndromes.
López-Cuenca Á, Manzano-Fernández S, Lip GY, et al. · Rev Esp Cardiol (Engl Ed) · 2015 · Background
PubMed: PMID 24775452 · NCT03863015 (IMICA) · Inflammation
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report.
Jagasia MH, Greinix HT, Arora M, et al. · Biol Blood Marrow Transplant · 2015 · Background
PubMed: PMID 25529383 · NCT02206035
Novel investigational drugs targeting IL-6 signaling for the treatment of depression.
Fonseka TM, McIntyre RS, Soczynska JK, et al. · Expert Opin Investig Drugs · 2015 · Background
PubMed: PMID 25585966 · NCT02660528 · Depressive Disorder, Major
Takayasu arteritis presenting as new-onset hypertension.
Fillaus JA, Oliveto J, Cutinha A, et al. · J Clin Rheumatol · 2015 · Background
PubMed: PMID 25275769 · NCT03893136 · Takayasu Arteritis
Therapeutic outcomes of high-dose intravenous steroids in the treatment of dysthyroid optic neuropathy.
Currò N, Covelli D, Vannucchi G, et al. · Thyroid · 2015 · Background
PubMed: PMID 24417307 · NCT04876534 (TOGO) · Graves Ophthalmopathy
The inflammatory response after out-of-hospital cardiac arrest is not modified by targeted temperature management at 33 °C or 36 °C.
Bro-Jeppesen J, Kjaergaard J, Wanscher M, et al. · Resuscitation · 2015 · Background
PubMed: PMID 25150183 · NCT03863015 (IMICA) · Inflammation
Systemic Inflammatory Response and Potential Prognostic Implications After Out-of-Hospital Cardiac Arrest: A Substudy of the Target Temperature Management Trial.
Bro-Jeppesen J, Kjaergaard J, Wanscher M, et al. · Crit Care Med · 2015 · Background
PubMed: PMID 25756419 · NCT03863015 (IMICA) · Inflammation
Causes of vision loss worldwide, 1990-2010: a systematic analysis.
Bourne RR, Stevens GA, White RA, et al. · Lancet Glob Health · 2015 · Background
PubMed: PMID 25104599 · NCT02511067 (READ-4)
Acute exercise preferentially redeploys NK-cells with a highly-differentiated phenotype and augments cytotoxicity against lymphoma and multiple myeloma target cells.
Bigley AB, Rezvani K, Chew C, et al. · Brain Behav Immun · 2015 · Background
PubMed: PMID 24200514 · NCT04616235 · Appetitive Behavior
IL-6, IL-18, sIL-2R, and TNFα proinflammatory markers in depression and schizophrenia patients who are free of overt inflammation.
Al-Hakeim HK, Al-Rammahi DA, Al-Dujaili AH, et al. · J Affect Disord · 2015 · Background
PubMed: PMID 25985379 · NCT02660528 · Depressive Disorder, Major

2014 (33 papers)

Benefits of rituximab combined with intravenous immunoglobulin for desensitization in kidney transplant recipients.
Vo AA, Choi J, Cisneros K, et al. · Transplantation · 2014 · Trial result
PubMed: PMID 24770617 · NCT03507348 · Kidney Failure, Chronic
Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study.
Dougados M, Kissel K, Conaghan PG, et al. · Ann Rheum Dis · 2014 · Trial result
PubMed: PMID 24473673 · NCT00810199 · Arthritis, Rheumatoid
How radiotherapy was historically used to treat pneumonia: could it be useful today?
Calabrese EJ, Dhawan G · Yale J Biol Med · 2014 · Trial result
PubMed: PMID 24348219 · NCT04394182 (ULTRA-COVID) · Cytokine Release Syndrome
Assessment of disease-drug-drug interaction between single-dose tocilizumab and oral contraceptives in women with active rheumatoid arthritis.
Zhang X, Rowell L, Fettner S, et al. · Int J Clin Pharmacol Ther · 2014 · Derived
PubMed: PMID 24161161 · NCT01044498 · Arthritis, Rheumatoid
Longterm safety and effectiveness of the anti-interleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan.
Yokota S, Imagawa T, Mori M, et al. · J Rheumatol · 2014 · Derived
PubMed: PMID 24634205 · NCT00144599 · Arthritis, Juvenile
Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials.
Sieper J, Porter-Brown B, Thompson L, et al. · Ann Rheum Dis · 2014 · Derived
PubMed: PMID 23765873 · NCT01209702 · Spondylitis, Ankylosing
Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
Kivitz A, Olech E, Borofsky M, et al. · Arthritis Care Res (Hoboken) · 2014 · Derived
PubMed: PMID 24942540 · NCT01232569 · Arthritis, Rheumatoid
Continued benefit of tocilizumab plus disease-modifying antirheumatic drug therapy in patients with rheumatoid arthritis and inadequate clinical responses by week 8 of treatment.
Keystone EC, Anisfeld A, Ogale S, et al. · J Rheumatol · 2014 · Derived
PubMed: PMID 24429164 · NCT00106548 · Arthritis, Rheumatoid
Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study.
Genovese MC, Fleischmann R, Furst D, et al. · Ann Rheum Dis · 2014 · Derived
PubMed: PMID 24641941 · NCT01242488 · Arthritis, Rheumatoid
Serial analysis of clinical and imaging indices reveals prolonged efficacy of TNF-α and IL-6 receptor targeted therapies in refractory Takayasu arteritis.
Youngstein T, Peters JE, Hamdulay SS, et al. · Clin Exp Rheumatol · 2014 · Background
PubMed: PMID 24093733 · NCT03893136 · Takayasu Arteritis
Interleukin-6 contributes to early fasting-induced free fatty acid mobilization in mice.
Wueest S, Item F, Boyle CN, et al. · Am J Physiol Regul Integr Comp Physiol · 2014 · Background
PubMed: PMID 24694381 · NCT04687540 · Obesity
The therapeutic outcome to intravenous steroid therapy for active Graves' orbitopathy is influenced by the time of response but not polymorphisms of the glucocorticoid receptor.
Vannucchi G, Covelli D, Campi I, et al. · Eur J Endocrinol · 2014 · Background
PubMed: PMID 24128430 · NCT04876534 (TOGO) · Graves Ophthalmopathy
Retinal morphologic changes and concentrations of cytokines in eyes with diabetic macular edema.
Sonoda S, Sakamoto T, Yamashita T, et al. · Retina · 2014 · Background
PubMed: PMID 23975003 · NCT02511067 (READ-4)
Increased cerebrospinal fluid interleukin-6 levels in patients with schizophrenia and those with major depressive disorder.
Sasayama D, Hattori K, Wakabayashi C, et al. · J Psychiatr Res · 2014 · Background
PubMed: PMID 23290488 · NCT02874573 · Inflammation
Potential utility of rituximab for Graves' orbitopathy.
Salvi M, Vannucchi G, Beck-Peccoz P, et al. · J Clin Endocrinol Metab · 2014 · Background
PubMed: PMID 24009135 · NCT04876534 (TOGO) · Graves Ophthalmopathy
Adult haemophagocytic syndrome.
Ramos-Casals M, Brito-Zerón P, López-Guillermo A, et al. · Lancet · 2014 · Background
PubMed: PMID 24290661 · NCT04560205 (TC19LGH) · COVID-19
Impact of brief exercise on peripheral blood NK cell gene and microRNA expression in young adults.
Radom-Aizik S, Zaldivar F, Haddad F, et al. · J Appl Physiol (1985) · 2014 · Background
PubMed: PMID 23288554 · NCT04616235 · Appetitive Behavior
Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials.
Nitta M, Kishimoto T, Müller N, et al. · Schizophr Bull · 2014 · Background
PubMed: PMID 23720576 · NCT02874573 · Inflammation
Tocilizumab for the treatment of patients with refractory Takayasu arteritis.
Nakaoka Y, Higuchi K, Arita Y, et al. · Int Heart J · 2014 · Background
PubMed: PMID 24309452 · NCT03893136 · Takayasu Arteritis
Managing cytokine release syndrome associated with novel T cell-engaging therapies.
Maude SL, Barrett D, Teachey DT, et al. · Cancer J · 2014 · Background
PubMed: PMID 24667956 · NCT04445272 · COVID-19
NK cells in the tumor microenvironment.
Larsen SK, Gao Y, Basse PH, et al. · Crit Rev Oncog · 2014 · Background
PubMed: PMID 24941376 · NCT04616235 · Appetitive Behavior
An open-label trial of abatacept (CTLA4-IG) in non-severe relapsing granulomatosis with polyangiitis (Wegener's).
Langford CA, Monach PA, Specks U, et al. · Ann Rheum Dis · 2014 · Background
PubMed: PMID 24323392 · NCT04871191 (SATELITE) · Granulomatosis with Polyangiitis
Relationship between Interleukin-6 gene polymorphism and hippocampal volume in antipsychotic-naïve schizophrenia: evidence for differential susceptibility?
Kalmady SV, Venkatasubramanian G, Shivakumar V, et al. · PLoS One · 2014 · Background
PubMed: PMID 24787542 · NCT02874573 · Inflammation
Cost-minimisation analysis of subcutaneous methotrexate versus biologic therapy for the treatment of patients with rheumatoid arthritis who have had an insufficient response or intolerance to oral methotrexate.
Fitzpatrick R, Scott DG, Keary I, et al. · Clin Rheumatol · 2014 · Background
PubMed: PMID 23835658 · NCT02087696 · Arthritis, Rheumatoid
Rapid endovascular catheter core cooling combined with cold saline as an adjunct to percutaneous coronary intervention for the treatment of acute myocardial infarction. The CHILL-MI trial: a randomized controlled study of the use of central venous catheter core cooling combined with cold saline as an adjunct to percutaneous coronary intervention for the treatment of acute myocardial infarction.
Erlinge D, Götberg M, Lang I, et al. · J Am Coll Cardiol · 2014 · Background
PubMed: PMID 24509284 · NCT03004703 (ASSAIL-MI) · Inflammation
Challenges in longitudinal measurements with HR-pQCT: evaluation of a 3D registration method to improve bone microarchitecture and strength measurement reproducibility.
Ellouz R, Chapurlat R, van Rietbergen B, et al. · Bone · 2014 · Background
PubMed: PMID 24614646 · NCT02765074 (REPAIR) · Arthritis, Rheumatoid
Comprehensive prognosis assessment by CMR imaging after ST-segment elevation myocardial infarction.
Eitel I, de Waha S, Wöhrle J, et al. · J Am Coll Cardiol · 2014 · Background
PubMed: PMID 25236513 · NCT03004703 (ASSAIL-MI) · Inflammation
Molecular mechanisms of natural killer cell activation in response to cellular stress.
Chan CJ, Smyth MJ, Martinet L, et al. · Cell Death Differ · 2014 · Background
PubMed: PMID 23579243 · NCT04616235 · Appetitive Behavior
Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema.
Boyer DS, Yoon YH, Belfort R, et al. · Ophthalmology · 2014 · Background
PubMed: PMID 24907062 · NCT02511067 (READ-4)
The endocrinology of food intake.
Begg DP, Woods SC · Nat Rev Endocrinol · 2014 · Background
PubMed: PMID 23877425 · NCT04616235 · Appetitive Behavior
Diabetic macular edema: changing treatment paradigms.
Arevalo JF · Curr Opin Ophthalmol · 2014 · Background
PubMed: PMID 25211039 · NCT02511067 (READ-4)
Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study.
Araki M, Matsuoka T, Miyamoto K, et al. · Neurology · 2014 · Background
PubMed: PMID 24634453 · NCT03863015 (IMICA) · Inflammation
Tocilizumab in refractory Takayasu arteritis: a case series and updated literature review.
Abisror N, Mekinian A, Lavigne C, et al. · Autoimmun Rev · 2014 · Background
PubMed: PMID 23820042 · NCT02101333 (TOCITAKA) · Takayasu Arteritis

2013 (35 papers)

Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica.
Unizony S, Arias-Urdaneta L, Miloslavsky E, et al. · Arthritis Care Res (Hoboken) · 2013 · Trial result
PubMed: PMID 22674883 · NCT03244709 · Giant Cell Arteritis
Living donor kidney transplantation in patients with donor-specific HLA antibodies enabled by anti-CD20 therapy and peritransplant apheresis.
Klein K, Süsal C, Schäfer SM, et al. · Atheroscler Suppl · 2013 · Trial result
PubMed: PMID 23357165 · NCT03507348 · Kidney Failure, Chronic
Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY).
Dougados M, Kissel K, Sheeran T, et al. · Ann Rheum Dis · 2013 · Trial result
PubMed: PMID 22562983 · NCT00810199 · Arthritis, Rheumatoid
Anti-inflammatory effects of low-dose radiotherapy. Indications, dose, and radiobiological mechanisms involved.
Arenas M, Sabater S, Hernández V, et al. · Strahlenther Onkol · 2013 · Trial result
PubMed: PMID 22907572 · NCT04394182 (ULTRA-COVID) · Cytokine Release Syndrome
Early effects of tocilizumab in the treatment of moderate to severe active rheumatoid arthritis: a one-week sub-study of a randomised controlled trial (Rapid Onset and Systemic Efficacy [ROSE] Study).
Yazici Y, Curtis JR, Ince A, et al. · Clin Exp Rheumatol · 2013 · Derived
PubMed: PMID 23305631 · NCT00531817 (ROSE) · Arthritis, Rheumatoid
Tocilizumab as monotherapy or in combination with nonbiologic disease-modifying antirheumatic drugs: twenty-four-week results of an open-label, clinical practice study.
Weinblatt ME, Kremer J, Cush J, et al. · Arthritis Care Res (Hoboken) · 2013 · Derived
PubMed: PMID 22972745 · NCT00891020 · Arthritis, Rheumatoid
Genome-wide association analysis implicates the involvement of eight loci with response to tocilizumab for the treatment of rheumatoid arthritis.
Wang J, Bansal AT, Martin M, et al. · Pharmacogenomics J · 2013 · Derived
PubMed: PMID 22491018 · NCT00106548 · Arthritis, Rheumatoid
Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year.
Kremer JM, Blanco R, Brzosko M, et al. · Arthritis Rheum · 2013 · Derived
PubMed: PMID 21360490 · NCT00106535 · Arthritis, Rheumatoid
IL-6 receptor inhibition positively modulates bone balance in rheumatoid arthritis patients with an inadequate response to anti-tumor necrosis factor therapy: biochemical marker analysis of bone metabolism in the tocilizumab RADIATE study (NCT00106522).
Karsdal MA, Schett G, Emery P, et al. · Semin Arthritis Rheum · 2013 · Derived
PubMed: PMID 22397953 · NCT00106522 · Arthritis, Rheumatoid
Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial.
Gabay C, Emery P, van Vollenhoven R, et al. · Lancet · 2013 · Derived
PubMed: PMID 23515142 · NCT01119859 · Arthritis, Rheumatoid
Tocilizumab inhibits structural joint damage and improves physical function in patients with rheumatoid arthritis and inadequate responses to methotrexate: LITHE study 2-year results.
Fleischmann RM, Halland AM, Brzosko M, et al. · J Rheumatol · 2013 · Derived
PubMed: PMID 23322466 · NCT00106535 · Arthritis, Rheumatoid
Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis.
De Benedetti F, Brunner HI, Ruperto N, et al. · N Engl J Med · 2013 · Derived
PubMed: PMID 23252525 · NCT00642460 · Arthritis, Juvenile
Inflammatory biomarkers, death, and recurrent nonfatal coronary events after an acute coronary syndrome in the MIRACL study.
Zamani P, Schwartz GG, Olsson AG, et al. · J Am Heart Assoc · 2013 · Background
PubMed: PMID 23525424 · NCT03863015 (IMICA) · Inflammation
Association of national initiatives to improve cardiac arrest management with rates of bystander intervention and patient survival after out-of-hospital cardiac arrest.
Wissenberg M, Lippert FK, Folke F, et al. · JAMA · 2013 · Background
PubMed: PMID 24084923 · NCT03863015 (IMICA) · Inflammation
Takayasu arteritis: diagnosis, treatment and prognosis.
Wen D, Du X, Ma CS, et al. · Int Rev Immunol · 2013 · Background
PubMed: PMID 23215768 · NCT03893136 · Takayasu Arteritis
Electronic monitoring of oral therapies in ethnically diverse and economically disadvantaged patients with rheumatoid arthritis: consequences of low adherence.
Waimann CA, Marengo MF, de Achaval S, et al. · Arthritis Rheum · 2013 · Background
PubMed: PMID 23728826 · NCT02087696 · Arthritis, Rheumatoid
Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy.
Teachey DT, Rheingold SR, Maude SL, et al. · Blood · 2013 · Background
PubMed: PMID 23678006 · NCT02007239 · Cytokine Release Syndrome
Evidence for sustained elevation of IL-6 in the CNS as a key contributor of depressive-like phenotypes.
Sukoff Rizzo SJ, Neal SJ, Hughes ZA, et al. · Transl Psychiatry · 2013 · Background
PubMed: PMID 23212583 · NCT02660528 · Depressive Disorder, Major
Tertiary centres have improved survival compared to other hospitals in the Copenhagen area after out-of-hospital cardiac arrest.
Søholm H, Wachtell K, Nielsen SL, et al. · Resuscitation · 2013 · Background
PubMed: PMID 22796541 · NCT03863015 (IMICA) · Inflammation
Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions.
Smolen JS, Schoels MM, Nishimoto N, et al. · Ann Rheum Dis · 2013 · Background
PubMed: PMID 23172750 · NCT02043548 (TIM) · Dermatomyositis
Impact of anti-interleukin-6 receptor blockade on circulating T and B cell subsets in patients with systemic lupus erythematosus.
Shirota Y, Yarboro C, Fischer R, et al. · Ann Rheum Dis · 2013 · Background
PubMed: PMID 22858586 · NCT02043548 (TIM) · Dermatomyositis
Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement.
Schoels MM, van der Heijde D, Breedveld FC, et al. · Ann Rheum Dis · 2013 · Background
PubMed: PMID 23144446 · NCT02043548 (TIM) · Dermatomyositis
Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial.
Oddis CV, Reed AM, Aggarwal R, et al. · Arthritis Rheum · 2013 · Background
PubMed: PMID 23124935 · NCT02043548 (TIM) · Dermatomyositis
High vitreous concentration of IL-6 and IL-8, but not of adhesion molecules in relation to plasma concentrations in proliferative diabetic retinopathy.
Koskela UE, Kuusisto SM, Nissinen AE, et al. · Ophthalmic Res · 2013 · Background
PubMed: PMID 23257933 · NCT02511067 (READ-4)
Tocilizumab - a novel therapy for non-organ-specific autoimmune diseases.
Kaly L, Rosner I · Best Pract Res Clin Rheumatol · 2013 · Background
PubMed: PMID 22424201 · NCT02043548 (TIM) · Dermatomyositis
Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) trial.
Ibanez B, Macaya C, Sánchez-Brunete V, et al. · Circulation · 2013 · Background
PubMed: PMID 24002794 · NCT03004703 (ASSAIL-MI) · Inflammation
Whole-body hyperthermia for the treatment of major depression: associations with thermoregulatory cooling.
Hanusch KU, Janssen CH, Billheimer D, et al. · Am J Psychiatry · 2013 · Background
PubMed: PMID 23820835 · NCT03787290 · Inflammation
Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.
Grupp SA, Kalos M, Barrett D, et al. · N Engl J Med · 2013 · Background
PubMed: PMID 23527958 · NCT02007239 · Cytokine Release Syndrome
Interleukin-6 receptor blockade induces limited repair of bone erosions in rheumatoid arthritis: a micro CT study.
Finzel S, Rech J, Schmidt S, et al. · Ann Rheum Dis · 2013 · Background
PubMed: PMID 22586162 · NCT02765074 (REPAIR) · Arthritis, Rheumatoid
The Berlin definition of ARDS: an expanded rationale, justification, and supplementary material.
Ferguson ND, Fan E, Camporota L, et al. · Intensive Care Med · 2013 · Background
PubMed: PMID 22926653 · NCT04363853
Ranibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatment.
Do DV, Nguyen QD, Khwaja AA, et al. · JAMA Ophthalmol · 2013 · Background
PubMed: PMID 23544200 · NCT02511067 (READ-4)
Disease assessment in Takayasu's arteritis.
Direskeneli H, Aydin SZ, Merkel PA, et al. · Rheumatology (Oxford) · 2013 · Background
PubMed: PMID 23955648 · NCT03893136 · Takayasu Arteritis
A quantitative method for assessing the degree of axial proptosis in relation to orbital tissue involvement in Graves' orbitopathy.
Campi I, Vannucchi GM, Minetti AM, et al. · Ophthalmology · 2013 · Background
PubMed: PMID 23399378 · NCT04876534 (TOGO) · Graves Ophthalmopathy
Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice.
Bykerk VP, Ostör AJ, Alvaro-Gracia J, et al. · Ann Rheum Dis · 2013 · Background
PubMed: PMID 22615456 · NCT02087696 · Arthritis, Rheumatoid
Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy.
Ayzenberg I, Kleiter I, Schröder A, et al. · JAMA Neurol · 2013 · Background
PubMed: PMID 23358868 · NCT03863015 (IMICA) · Inflammation

2012 (23 papers)

Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study.
Yazici Y, Curtis JR, Ince A, et al. · Ann Rheum Dis · 2012 · Derived
PubMed: PMID 21949007 · NCT00531817 (ROSE) · Arthritis, Rheumatoid
Improvements in health-related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumour necrosis factor inhibitors: results from the 24-week randomized controlled RADIATE study.
Strand V, Burmester GR, Ogale S, et al. · Rheumatology (Oxford) · 2012 · Derived
PubMed: PMID 22753773 · NCT00106522 · Arthritis, Rheumatoid
Tocilizumab has no clinically relevant effects on methotrexate pharmacokinetics in patients with rheumatoid arthritis.
Schmitt C, Kuhn B, Zhang X, et al. · Int J Clin Pharmacol Ther · 2012 · Derived
PubMed: PMID 22373834 · NCT00365001 · Arthritis, Rheumatoid
Clinical pharmacology of tocilizumab for the treatment of patients with rheumatoid arthritis.
Zhang X, Peck R · Expert Rev Clin Pharmacol · 2012 · Background
PubMed: PMID 22114882 · NCT04924829 · COVID-19
Serum BAFF concentrations in patients with Graves' disease and orbitopathy before and after immunosuppressive therapy.
Vannucchi G, Covelli D, Currò N, et al. · J Clin Endocrinol Metab · 2012 · Background
PubMed: PMID 22399512 · NCT04876534 (TOGO) · Graves Ophthalmopathy
Medication adherence in patients with rheumatoid arthritis: a critical appraisal of the existing literature.
van den Bemt BJ, Zwikker HE, van den Ende CH, et al. · Expert Rev Clin Immunol · 2012 · Background
PubMed: PMID 22607180 · NCT02087696 · Arthritis, Rheumatoid
Association of plasma IL-6 and soluble IL-6 receptor levels with the Asp358Ala polymorphism of the IL-6 receptor gene in schizophrenic patients.
Sasayama D, Wakabayashi C, Hori H, et al. · J Psychiatr Res · 2012 · Background
PubMed: PMID 21700295 · NCT02874573 · Inflammation
Small dose of rituximab for graves orbitopathy: new insights into the mechanism of action.
Salvi M, Vannucchi G, Currò N, et al. · Arch Ophthalmol · 2012 · Background
PubMed: PMID 22232486 · NCT04876534 (TOGO) · Graves Ophthalmopathy
Rescue treatment with tocilizumab for Takayasu arteritis resistant to TNF-α blockers.
Salvarani C, Magnani L, Catanoso MG, et al. · Clin Exp Rheumatol · 2012 · Background
PubMed: PMID 22410150 · NCT02101333 (TOCITAKA) · Takayasu Arteritis
Immunomodulatory properties and molecular effects in inflammatory diseases of low-dose x-irradiation.
Rödel F, Frey B, Manda K, et al. · Front Oncol · 2012 · Background
PubMed: PMID 23057008 · NCT04380818 · COVID-19
Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE.
Nguyen QD, Brown DM, Marcus DM, et al. · Ophthalmology · 2012 · Background
PubMed: PMID 22330964 · NCT02511067 (READ-4)
Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor.
Navarro-Millán I, Singh JA, Curtis JR, et al. · Clin Ther · 2012 · Background
PubMed: PMID 22444783 · NCT02007239 · Cytokine Release Syndrome
Therapeutic effect of tocilizumab on two patients with polymyositis.
Narazaki M, Hagihara K, Shima Y, et al. · Rheumatology (Oxford) · 2012 · Background
PubMed: PMID 21515628 · NCT02043548 (TIM) · Dermatomyositis
Interleukin 6 in systemic sclerosis and potential implications for targeted therapy.
Muangchan C, Pope JE · J Rheumatol · 2012 · Background
PubMed: PMID 22505699 · NCT02043548 (TIM) · Dermatomyositis
Stress and inflammation reduce brain-derived neurotrophic factor expression in first-episode psychosis: a pathway to smaller hippocampal volume.
Mondelli V, Cattaneo A, Murri MB, et al. · J Clin Psychiatry · 2012 · Background
PubMed: PMID 21672499 · NCT01696929 · Schizophrenia
Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects.
Miller BJ, Buckley P, Seabolt W, et al. · Biol Psychiatry · 2012 · Background
PubMed: PMID 21641581 · NCT02874573 · Inflammation
Efficacy and tolerance of infliximab in refractory Takayasu arteritis: French multicentre study.
Mekinian A, Néel A, Sibilia J, et al. · Rheumatology (Oxford) · 2012 · Background
PubMed: PMID 22223706 · NCT02101333 (TOCITAKA) · Takayasu Arteritis
Low dose ionising radiation leads to a NF-κB dependent decreased secretion of active IL-1β by activated macrophages with a discontinuous dose-dependency.
Lödermann B, Wunderlich R, Frey S, et al. · Int J Radiat Biol · 2012 · Background
PubMed: PMID 22545750 · NCT04380818 · COVID-19
Does glucocorticosteroid-resistant large-vessel vasculitis (giant cell arteritis and Takayasu arteritis) exist and how can remission be achieved? A critical review of the literature.
Kötter I, Henes JC, Wagner AD, et al. · Clin Exp Rheumatol · 2012 · Background
PubMed: PMID 22640655 · NCT03893136 · Takayasu Arteritis
Evaluation of Takayasu arteritis activity by delayed contrast-enhanced magnetic resonance imaging.
Jiang L, Li D, Yan F, et al. · Int J Cardiol · 2012 · Background
PubMed: PMID 21059475 · NCT03893136 · Takayasu Arteritis
Rituximab for refractory granulomatosis with polyangiitis (Wegener's granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations.
Holle JU, Dubrau C, Herlyn K, et al. · Ann Rheum Dis · 2012 · Background
PubMed: PMID 22021864 · NCT04871191 (SATELITE) · Granulomatosis with Polyangiitis
Cyclophosphamide is a highly effective and safe induction therapy in chronic periaortitis: a long-term follow-up of 35 patients with chronic periaortitis.
Binder M, Uhl M, Wiech T, et al. · Ann Rheum Dis · 2012 · Background
PubMed: PMID 21859695 · NCT04762784 · Retroperitoneal Fibrosis
Pathogenesis of Takayasu's arteritis: a 2011 update.
Arnaud L, Haroche J, Mathian A, et al. · Autoimmun Rev · 2012 · Background
PubMed: PMID 21855656 · NCT03893136 · Takayasu Arteritis

2011 (14 papers)

Desensitization in HLA-incompatible kidney recipients and survival.
Montgomery RA, Lonze BE, King KE, et al. · N Engl J Med · 2011 · Trial result
PubMed: PMID 21793744 · NCT03507348 · Kidney Failure, Chronic
Rituximab treatment in patients with active Graves' orbitopathy: effects on proinflammatory and humoral immune reactions.
Vannucchi G, Campi I, Bonomi M, et al. · Clin Exp Immunol · 2011 · Background
PubMed: PMID 20529087 · NCT04876534 (TOGO) · Graves Ophthalmopathy
Prednisone versus tamoxifen in patients with idiopathic retroperitoneal fibrosis: an open-label randomised controlled trial.
Vaglio A, Palmisano A, Alberici F, et al. · Lancet · 2011 · Background
PubMed: PMID 21733570 · NCT04762784 · Retroperitoneal Fibrosis
Retroperitoneal fibrosis: gaining traction on an enigma.
Swartz R, Scheel P · Lancet · 2011 · Background
PubMed: PMID 21733569 · NCT04762784 · Retroperitoneal Fibrosis
Assessment of procalcitonin to predict outcome in hypothermia-treated patients after cardiac arrest.
Stammet P, Devaux Y, Azuaje F, et al. · Crit Care Res Pract · 2011 · Background
PubMed: PMID 22110909 · NCT03863015 (IMICA) · Inflammation
Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Soliman MM, Ashcroft DM, Watson KD, et al. · Ann Rheum Dis · 2011 · Background
PubMed: PMID 21330639 · NCT02087696 · Arthritis, Rheumatoid
Granulocyte-colony-stimulatory factor: a strong inhibitor of natural killer cell function.
Schlahsa L, Jaimes Y, Blasczyk R, et al. · Transfusion · 2011 · Background
PubMed: PMID 20723170 · NCT04616235 · Appetitive Behavior
Combined prednisone and mycophenolate mofetil treatment for retroperitoneal fibrosis: a case series.
Scheel PJ, Feeley N, Sozio SM, et al. · Ann Intern Med · 2011 · Background
PubMed: PMID 21200036 · NCT04762784 · Retroperitoneal Fibrosis
Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries.
Mariette X, Gottenberg JE, Ravaud P, et al. · Rheumatology (Oxford) · 2011 · Background
PubMed: PMID 21148156 · NCT02087696 · Arthritis, Rheumatoid
Physical activity and survival after prostate cancer diagnosis in the health professionals follow-up study.
Kenfield SA, Stampfer MJ, Giovannucci E, et al. · J Clin Oncol · 2011 · Background
PubMed: PMID 21205749 · NCT04616235 · Appetitive Behavior
Roles of IL-6-gp130 Signaling in Vascular Inflammation.
Hou T, Tieu BC, Ray S, et al. · Curr Cardiol Rev · 2011 · Background
PubMed: PMID 19936194 · NCT03004703 (ASSAIL-MI) · Inflammation
Recommendations of the European Association of Echocardiography: how to use echo-Doppler in clinical trials: different modalities for different purposes.
Galderisi M, Henein MY, D'hooge J, et al. · Eur J Echocardiogr · 2011 · Background
PubMed: PMID 21555455 · NCT03004703 (ASSAIL-MI) · Inflammation
Repair of bone erosions in rheumatoid arthritis treated with tumour necrosis factor inhibitors is based on bone apposition at the base of the erosion.
Finzel S, Rech J, Schmidt S, et al. · Ann Rheum Dis · 2011 · Background
PubMed: PMID 21622765 · NCT02765074 (REPAIR) · Arthritis, Rheumatoid
No overall progression and occasional repair of erosions despite persistent inflammation in adalimumab-treated rheumatoid arthritis patients: results from a longitudinal comparative MRI, ultrasonography, CT and radiography study.
Døhn UM, Ejbjerg B, Boonen A, et al. · Ann Rheum Dis · 2011 · Background
PubMed: PMID 20980282 · NCT02765074 (REPAIR) · Arthritis, Rheumatoid

2010 (22 papers)

Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study.
Jones G, Sebba A, Gu J, et al. · Ann Rheum Dis · 2010 · Derived
PubMed: PMID 19297346 · NCT00109408 · Arthritis, Rheumatoid
Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone.
Garnero P, Thompson E, Woodworth T, et al. · Arthritis Rheum · 2010 · Derived
PubMed: PMID 20039425 · NCT00106548 · Arthritis, Rheumatoid
An interleukin-6-related systemic inflammatory syndrome in patients co-infected with Kaposi sarcoma-associated herpesvirus and HIV but without Multicentric Castleman disease.
Uldrick TS, Wang V, O'Mahony D, et al. · Clin Infect Dis · 2010 · Background
PubMed: PMID 20583924 · NCT01441063 · Castleman Disease
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Stone JH, Merkel PA, Spiera R, et al. · N Engl J Med · 2010 · Background
PubMed: PMID 20647199 · NCT04871191 (SATELITE) · Granulomatosis with Polyangiitis
Periarticular bone structure in rheumatoid arthritis patients and healthy individuals assessed by high-resolution computed tomography.
Stach CM, Bäuerle M, Englbrecht M, et al. · Arthritis Rheum · 2010 · Background
PubMed: PMID 20112404 · NCT02765074 (REPAIR) · Arthritis, Rheumatoid
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs.
Smolen JS, Landewé R, Breedveld FC, et al. · Ann Rheum Dis · 2010 · Background
PubMed: PMID 20444750 · NCT02087696 · Arthritis, Rheumatoid
BAFF receptor signaling aids the differentiation of immature B cells into transitional B cells following tonic BCR signaling.
Rowland SL, Leahy KF, Halverson R, et al. · J Immunol · 2010 · Background
PubMed: PMID 20861359 · NCT04876534 (TOGO) · Graves Ophthalmopathy
Ontogeny of sensorimotor gating and immune impairment induced by prenatal immune challenge in rats: implications for the etiopathology of schizophrenia.
Romero E, Guaza C, Castellano B, et al. · Mol Psychiatry · 2010 · Background
PubMed: PMID 18414405 · NCT01696929 · Schizophrenia
Functional polymorphism in the interleukin-6 and interleukin-10 genes in patients with paranoid schizophrenia--a case-control study.
Paul-Samojedny M, Kowalczyk M, Suchanek R, et al. · J Mol Neurosci · 2010 · Background
PubMed: PMID 20393813 · NCT01696929 · Schizophrenia
Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions.
Nishimoto N, Ito K, Takagi N, et al. · Mod Rheumatol · 2010 · Background
PubMed: PMID 20221663 · NCT04115423 · Arthritis, Rheumatoid
Summarizing historical information on controls in clinical trials.
Neuenschwander B, Capkun-Niggli G, Branson M, et al. · Clin Trials · 2010 · Background
PubMed: PMID 20156954 · NCT04335071 (CORON-ACT) · COVID-19
COX-2 inhibitors as antidepressants and antipsychotics: clinical evidence.
Müller N · Curr Opin Investig Drugs · 2010 · Background
PubMed: PMID 20047157 · NCT01696929 · Schizophrenia
Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment.
Müller N, Krause D, Dehning S, et al. · Schizophr Res · 2010 · Background
PubMed: PMID 20570110 · NCT01696929 · Schizophrenia
Physical activity and male colorectal cancer survival.
Meyerhardt JA, Giovannucci EL, Ogino S, et al. · Arch Intern Med · 2010 · Background
PubMed: PMID 20008694 · NCT04616235 · Appetitive Behavior
Leucocytosis after violent Exercise.
Larrabee RC · J Med Res · 2010 · Background
PubMed: PMID 19971455 · NCT04616235 · Appetitive Behavior
Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial.
Laan W, Grobbee DE, Selten JP, et al. · J Clin Psychiatry · 2010 · Background
PubMed: PMID 20492850 · NCT01696929 · Schizophrenia
Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis.
Knevel R, Schoels M, Huizinga TW, et al. · Ann Rheum Dis · 2010 · Background
PubMed: PMID 20448280 · NCT02087696 · Arthritis, Rheumatoid
Population pharmacokinetic analysis of tocilizumab in patients with rheumatoid arthritis.
Frey N, Grange S, Woodworth T, et al. · J Clin Pharmacol · 2010 · Background
PubMed: PMID 20097931 · NCT03895879 (TODORA) · Arthritis, Rheumatoid
Assessment of hand bone loss in rheumatoid arthritis by high-resolution peripheral quantitative CT.
Fouque-Aubert A, Boutroy S, Marotte H, et al. · Ann Rheum Dis · 2010 · Background
PubMed: PMID 20525847 · NCT02765074 (REPAIR) · Arthritis, Rheumatoid
Prenatal infection and schizophrenia: a review of epidemiologic and translational studies.
Brown AS, Derkits EJ · Am J Psychiatry · 2010 · Background
PubMed: PMID 20123911 · NCT01696929 · Schizophrenia
Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis.
Bilgic H, Ytterberg SR, Amin S, et al. · Arthritis Rheum · 2010 · Background
PubMed: PMID 19877033 · NCT02043548 (TIM) · Dermatomyositis
Inflammatory biomarkers and coronary heart disease: from bench to bedside and back.
Biasillo G, Leo M, Della Bona R, et al. · Intern Emerg Med · 2010 · Background
PubMed: PMID 20182820 · NCT03004703 (ASSAIL-MI) · Inflammation

2009 (14 papers)

B-lymphocyte contributions to human autoimmune disease.
Yanaba K, Bouaziz JD, Matsushita T, et al. · Immunol Rev · 2009 · Background
PubMed: PMID 18613843 · NCT04876534 (TOGO) · Graves Ophthalmopathy
Efficacy and safety of anti-TNF agents in the Lombardy rheumatoid arthritis network (LORHEN).
Sarzi-Puttini P, Antivalle M, Marchesoni A, et al. · Reumatismo · 2009 · Background
PubMed: PMID 19132154 · NCT02087696 · Arthritis, Rheumatoid
Rituximab treatment in a patient with severe thyroid-associated ophthalmopathy: effects on orbital lymphocytic infiltrates.
Salvi M, Vannucchi G, Campi I, et al. · Clin Immunol · 2009 · Background
PubMed: PMID 19195932 · NCT04876534 (TOGO) · Graves Ophthalmopathy
Ruptured abdominal aortic aneurysm related to IgG4 periaortitis.
Qian Q, Kashani KB, Miller DV, et al. · N Engl J Med · 2009 · Background
PubMed: PMID 19741239 · NCT04762784 · Retroperitoneal Fibrosis
Tocilizumab: a review of its use in the management of rheumatoid arthritis.
Oldfield V, Dhillon S, Plosker GL, et al. · Drugs · 2009 · Background
PubMed: PMID 19368420 · NCT03004703 (ASSAIL-MI) · Inflammation
Therapeutic effects of interleukin-6 blockade in a murine model of polymyositis that does not require interleukin-17A.
Okiyama N, Sugihara T, Iwakura Y, et al. · Arthritis Rheum · 2009 · Background
PubMed: PMID 19644888 · NCT02043548 (TIM) · Dermatomyositis
Erosive progression is minimal, but erosion healing rare, in patients with rheumatoid arthritis treated with adalimumab. A 1 year investigator-initiated follow-up study using high-resolution computed tomography as the primary outcome measure.
Møller Døhn U, Boonen A, Hetland ML, et al. · Ann Rheum Dis · 2009 · Background
PubMed: PMID 19019887 · NCT02765074 (REPAIR) · Arthritis, Rheumatoid
Interleukin-6 covaries inversely with hippocampal grey matter volume in middle-aged adults.
Marsland AL, Gianaros PJ, Abramowitch SM, et al. · Biol Psychiatry · 2009 · Background
PubMed: PMID 18514163 · NCT01696929 · Schizophrenia
Utilization trends of tumor necrosis factor inhibitors among patients with rheumatoid arthritis in a United States observational cohort study.
Lee SJ, Chang H, Yazici Y, et al. · J Rheumatol · 2009 · Background
PubMed: PMID 19369454 · NCT02087696 · Arthritis, Rheumatoid
Sustained response to tocilizumab, anti-interleukin-6 receptor antibody, in two patients with refractory relapsing polychondritis.
Kawai M, Hagihara K, Hirano T, et al. · Rheumatology (Oxford) · 2009 · Background
PubMed: PMID 19106169 · NCT01041248 · Polychondritis, Relapsing
Abdominal aortic aneurysms: an autoimmune disease?
Jagadesham VP, Scott DJ, Carding SR, et al. · Trends Mol Med · 2009 · Background
PubMed: PMID 18980864 · NCT04762784 · Retroperitoneal Fibrosis
Tendency towards erosive regression on magnetic resonance imaging at 12 months in rheumatoid arthritis patients treated with rituximab.
Døhn UM, Ostergaard M, Bird P, et al. · Ann Rheum Dis · 2009 · Background
PubMed: PMID 19435723 · NCT02765074 (REPAIR) · Arthritis, Rheumatoid
Tocilizumab for multirefractory adult-onset Still's disease.
De Bandt M, Saint-Marcoux B · Ann Rheum Dis · 2009 · Background
PubMed: PMID 19088261 · NCT01002781
Interleukin-6 mediates the increase in NADPH-oxidase in the ketamine model of schizophrenia.
Behrens MM, Ali SS, Dugan LL, et al. · J Neurosci · 2009 · Background
PubMed: PMID 19091984 · NCT01696929 · Schizophrenia

2008 (15 papers)

Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial.
Yokota S, Imagawa T, Mori M, et al. · Lancet · 2008 · Derived
PubMed: PMID 18358927 · NCT00144612 · Arthritis, Juvenile
Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.
Smolen JS, Beaulieu A, Rubbert-Roth A, et al. · Lancet · 2008 · Derived
PubMed: PMID 18358926 · NCT00106548 · Arthritis, Rheumatoid
Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study.
Genovese MC, McKay JD, Nasonov EL, et al. · Arthritis Rheum · 2008 · Derived
PubMed: PMID 18821691 · NCT00106574 · Arthritis, Rheumatoid
IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial.
Emery P, Keystone E, Tony HP, et al. · Ann Rheum Dis · 2008 · Derived
PubMed: PMID 18625622 · NCT00106522 · Arthritis, Rheumatoid
Utilization of biologic agents in rheumatoid arthritis in the United States: analysis of prescribing patterns in 16,752 newly diagnosed patients and patients new to biologic therapy.
Yazici Y, Shi N, John A, et al. · Bull NYU Hosp Jt Dis · 2008 · Background
PubMed: PMID 18537774 · NCT02087696 · Arthritis, Rheumatoid
Functions of natural killer cells.
Vivier E, Tomasello E, Baratin M, et al. · Nat Immunol · 2008 · Background
PubMed: PMID 18425107 · NCT04616235 · Appetitive Behavior
Early diagnostic and prognostic significance of a specific Th1/Th2 cytokine pattern in children with haemophagocytic syndrome.
Tang Y, Xu X, Song H, et al. · Br J Haematol · 2008 · Background
PubMed: PMID 18673367 · NCT02007239 · Cytokine Release Syndrome
Association between interleukin-6 receptor polymorphism and patients with schizophrenia.
Sun S, Wang F, Wei J, et al. · Schizophr Res · 2008 · Background
PubMed: PMID 18508242 · NCT01696929 · Schizophrenia
Polymyalgia rheumatica and giant-cell arteritis.
Salvarani C, Cantini F, Hunder GG, et al. · Lancet · 2008 · Background
PubMed: PMID 18640460 · NCT03244709 · Giant Cell Arteritis
Effect of cyclosporine on reperfusion injury in acute myocardial infarction.
Piot C, Croisille P, Staat P, et al. · N Engl J Med · 2008 · Background
PubMed: PMID 18669426 · NCT03004703 (ASSAIL-MI) · Inflammation
Successful treatment of a patient with Takayasu arteritis using a humanized anti-interleukin-6 receptor antibody.
Nishimoto N, Nakahara H, Yoshio-Hoshino N, et al. · Arthritis Rheum · 2008 · Background
PubMed: PMID 18383395 · NCT02101333 (TOCITAKA) · Takayasu Arteritis
Humanized antihuman IL-6 receptor antibody, tocilizumab.
Nishimoto N, Kishimoto T · Handb Exp Pharmacol · 2008 · Background
PubMed: PMID 18071945 · NCT05233397 · Craniopharyngioma
Post-cardiac arrest syndrome: epidemiology, pathophysiology, treatment, and prognostication. A consensus statement from the International Liaison Committee on Resuscitation (American Heart Association, Australian and New Zealand Council on Resuscitation, European Resuscitation Council, Heart and Stroke Foundation of Canada, InterAmerican Heart Foundation, Resuscitation Council of Asia, and the Resuscitation Council of Southern Africa); the American Heart Association Emergency Cardiovascular Care Committee; the Council on Cardiovascular Surgery and Anesthesia; the Council on Cardiopulmonary, Perioperative, and Critical Care; the Council on Clinical Cardiology; and the Stroke Council.
Neumar RW, Nolan JP, Adrie C, et al. · Circulation · 2008 · Background
PubMed: PMID 18948368 · NCT03863015 (IMICA) · Inflammation
The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study.
Heiberg MS, Koldingsnes W, Mikkelsen K, et al. · Arthritis Rheum · 2008 · Background
PubMed: PMID 18240258 · NCT02087696 · Arthritis, Rheumatoid
Time course of anti-inflammatory effect of low-dose radiotherapy: correlation with TGF-beta(1) expression.
Arenas M, Gil F, Gironella M, et al. · Radiother Oncol · 2008 · Background
PubMed: PMID 18031855 · NCT04380818 · COVID-19

2007 (12 papers)

Radiobiological mechanisms in inflammatory diseases of low-dose radiation therapy.
Rödel F, Keilholz L, Herrmann M, et al. · Int J Radiat Biol · 2007 · Trial result
PubMed: PMID 17487675 · NCT04394182 (ULTRA-COVID) · Cytokine Release Syndrome
Myocardial reperfusion injury.
Yellon DM, Hausenloy DJ · N Engl J Med · 2007 · Background
PubMed: PMID 17855673 · NCT03004703 (ASSAIL-MI) · Inflammation
Gene and protein characteristics reflect functional diversity of CD56dim and CD56bright NK cells.
Wendt K, Wilk E, Buyny S, et al. · J Leukoc Biol · 2007 · Background
PubMed: PMID 16966385 · NCT04616235 · Appetitive Behavior
Development and validation of the Inventory of Depression and Anxiety Symptoms (IDAS).
Watson D, O'Hara MW, Simms LJ, et al. · Psychol Assess · 2007 · Background
PubMed: PMID 17845118 · NCT02206035
A new murine model to define the critical pathologic and therapeutic mediators of polymyositis.
Sugihara T, Sekine C, Nakae T, et al. · Arthritis Rheum · 2007 · Background
PubMed: PMID 17394136 · NCT02043548 (TIM) · Dermatomyositis
Maternal immune activation alters fetal brain development through interleukin-6.
Smith SE, Li J, Garbett K, et al. · J Neurosci · 2007 · Background
PubMed: PMID 17913903 · NCT01696929 · Schizophrenia
Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study.
Salvi M, Vannucchi G, Campi I, et al. · Eur J Endocrinol · 2007 · Background
PubMed: PMID 17218723 · NCT04876534 (TOGO) · Graves Ophthalmopathy
Neurobehavioral and immunological consequences of prenatal immune activation in rats. Influence of antipsychotics.
Romero E, Ali C, Molina-Holgado E, et al. · Neuropsychopharmacology · 2007 · Background
PubMed: PMID 17180123 · NCT01696929 · Schizophrenia
Vascular endothelial growth factor is a critical stimulus for diabetic macular edema.
Nguyen QD, Tatlipinar S, Shah SM, et al. · Am J Ophthalmol · 2007 · Background
PubMed: PMID 17046701 · NCT02511067 (READ-4)
Interleukin-6 covaries inversely with cognitive performance among middle-aged community volunteers.
Marsland AL, Petersen KL, Sathanoori R, et al. · Psychosom Med · 2007 · Background
PubMed: PMID 17132839 · NCT01696929 · Schizophrenia
EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis.
Hellmich B, Flossmann O, Gross WL, et al. · Ann Rheum Dis · 2007 · Background
PubMed: PMID 17170053 · NCT04871191 (SATELITE) · Granulomatosis with Polyangiitis
Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists.
Askling J, Fored CM, Brandt L, et al. · Ann Rheum Dis · 2007 · Background
PubMed: PMID 17261532 · NCT02087696 · Arthritis, Rheumatoid

2006 (13 papers)

Radiation treatment of acute inflammation in mice.
Schaue D, Jahns J, Hildebrandt G, et al. · Int J Radiat Biol · 2006 · Trial result
PubMed: PMID 16368644 · NCT04394182 (ULTRA-COVID) · Cytokine Release Syndrome
Brief communication: tamoxifen therapy for nonmalignant retroperitoneal fibrosis.
van Bommel EF, Hendriksz TR, Huiskes AW, et al. · Ann Intern Med · 2006 · Background
PubMed: PMID 16418409 · NCT04762784 · Retroperitoneal Fibrosis
Retroperitoneal fibrosis.
Vaglio A, Salvarani C, Buzio C, et al. · Lancet · 2006 · Background
PubMed: PMID 16427494 · NCT04762784 · Retroperitoneal Fibrosis
Tamoxifen therapy for retroperitoneal fibrosis.
Vaglio A, Greco P, Buzio C, et al. · Ann Intern Med · 2006 · Background
PubMed: PMID 16618960 · NCT04762784 · Retroperitoneal Fibrosis
Summaries for patients. Tamoxifen for the treatment of retroperitoneal fibrosis.
Ann Intern Med · 2006 · Background
PubMed: PMID 16418405 · NCT04762784 · Retroperitoneal Fibrosis
IL-6-deficient mice show impaired inflammatory response in a model of myosin-induced experimental myositis.
Scuderi F, Mannella F, Marino M, et al. · J Neuroimmunol · 2006 · Background
PubMed: PMID 16725212 · NCT02043548 (TIM) · Dermatomyositis
Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium.
Sampson HA, Muñoz-Furlong A, Campbell RL, et al. · J Allergy Clin Immunol · 2006 · Background
PubMed: PMID 16461139 · NCT02043548 (TIM) · Dermatomyositis
Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction.
Lunde K, Solheim S, Aakhus S, et al. · N Engl J Med · 2006 · Background
PubMed: PMID 16990383 · NCT03004703 (ASSAIL-MI) · Inflammation
Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low--results from RABBIT, the German biologics register.
Listing J, Strangfeld A, Rau R, et al. · Arthritis Res Ther · 2006 · Background
PubMed: PMID 16600016 · NCT02087696 · Arthritis, Rheumatoid
Short term outcome and risk factors for mortality in adults with critical severe acute respiratory syndrome (SARS).
Hu X, Deng Y, Wang J, et al. · J Huazhong Univ Sci Technolog Med Sci · 2006 · Background
PubMed: PMID 15641708 · NCT04363853
Treatment of autoimmune hyperthyroidism in a murine model of Graves' disease with tumor necrosis factor-family ligand inhibitors suggests a key role for B cell activating factor in disease pathology.
Gilbert JA, Kalled SL, Moorhead J, et al. · Endocrinology · 2006 · Background
PubMed: PMID 16794009 · NCT04876534 (TOGO) · Graves Ophthalmopathy
A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema.
Chun DW, Heier JS, Topping TM, et al. · Ophthalmology · 2006 · Background
PubMed: PMID 17011952 · NCT02511067 (READ-4)
In vivo assessment of trabecular bone microarchitecture by high-resolution peripheral quantitative computed tomography.
Boutroy S, Bouxsein ML, Munoz F, et al. · J Clin Endocrinol Metab · 2006 · Background
PubMed: PMID 16189253 · NCT02765074 (REPAIR) · Arthritis, Rheumatoid

2005 (11 papers)

Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis.
Yokota S, Miyamae T, Imagawa T, et al. · Arthritis Rheum · 2005 · Background
PubMed: PMID 15751095 · NCT05233397 · Craniopharyngioma
Acute IL-6 treatment increases fatty acid turnover in elderly humans in vivo and in tissue culture in vitro.
Petersen EW, Carey AL, Sacchetti M, et al. · Am J Physiol Endocrinol Metab · 2005 · Background
PubMed: PMID 15383370 · NCT04687540 · Obesity
A potential role for hydrocortisone in the positive regulation of IL-15-activated NK-cell proliferation and survival.
Perez SA, Mahaira LG, Demirtzoglou FJ, et al. · Blood · 2005 · Background
PubMed: PMID 15755904 · NCT04616235 · Appetitive Behavior
International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies.
Oddis CV, Rider LG, Reed AM, et al. · Arthritis Rheum · 2005 · Background
PubMed: PMID 16142757 · NCT02043548 (TIM) · Dermatomyositis
Clinical effects of COX-2 inhibitors on cognition in schizophrenia.
Müller N, Riedel M, Schwarz MJ, et al. · Eur Arch Psychiatry Clin Neurosci · 2005 · Background
PubMed: PMID 15549344 · NCT01696929 · Schizophrenia
Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family.
Mihara M, Kasutani K, Okazaki M, et al. · Int Immunopharmacol · 2005 · Background
PubMed: PMID 16102523 · NCT05233397 · Craniopharyngioma
Inflammation, atherosclerosis, and coronary artery disease.
Hansson GK · N Engl J Med · 2005 · Background
PubMed: PMID 15843671 · NCT03004703 (ASSAIL-MI) · Inflammation
Novel insights on human NK cells' immunological modalities revealed by gene expression profiling.
Hanna J, Bechtel P, Zhai Y, et al. · J Immunol · 2005 · Background
PubMed: PMID 15557145 · NCT04616235 · Appetitive Behavior
Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial.
Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. · Arthritis Rheum · 2005 · Background
PubMed: PMID 16258899 · NCT02087696 · Arthritis, Rheumatoid
Kidney allograft fibrosis and atrophy early after living donor transplantation.
Cosio FG, Grande JP, Larson TS, et al. · Am J Transplant · 2005 · Background
PubMed: PMID 15816896 · NCT02108600 · Inflammation
Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists.
Carmona L, Gómez-Reino JJ, Rodríguez-Valverde V, et al. · Arthritis Rheum · 2005 · Background
PubMed: PMID 15934089 · NCT02087696 · Arthritis, Rheumatoid

2004 (10 papers)

Natural killer cells and cancer.
Wu J, Lanier LL · Adv Cancer Res · 2004 · Background
PubMed: PMID 14710949 · NCT04616235 · Appetitive Behavior
International consensus on preliminary definitions of improvement in adult and juvenile myositis.
Rider LG, Giannini EH, Brunner HI, et al. · Arthritis Rheum · 2004 · Background
PubMed: PMID 15248228 · NCT02043548 (TIM) · Dermatomyositis
Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial.
Nishimoto N, Yoshizaki K, Miyasaka N, et al. · Arthritis Rheum · 2004 · Background
PubMed: PMID 15188351 · NCT05233397 · Craniopharyngioma
Inhibition of IL-6 for the treatment of inflammatory diseases.
Nishimoto N, Kishimoto T · Curr Opin Pharmacol · 2004 · Background
PubMed: PMID 15251133 · NCT05233397 · Craniopharyngioma
COX-2 inhibition as a treatment approach in schizophrenia: immunological considerations and clinical effects of celecoxib add-on therapy.
Müller N, Ulmschneider M, Scheppach C, et al. · Eur Arch Psychiatry Clin Neurosci · 2004 · Background
PubMed: PMID 14991374 · NCT01696929 · Schizophrenia
Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era.
Meier-Kriesche HU, Schold JD, Srinivas TR, et al. · Am J Transplant · 2004 · Background
PubMed: PMID 14961990 · NCT02108600 · Inflammation
The quantification of infarct size.
Gibbons RJ, Valeti US, Araoz PA, et al. · J Am Coll Cardiol · 2004 · Background
PubMed: PMID 15489082 · NCT03004703 (ASSAIL-MI) · Inflammation
Procalcitonin serum levels after out-of-hospital cardiac arrest.
Fries M, Kunz D, Gressner AM, et al. · Resuscitation · 2004 · Background
PubMed: PMID 14580740 · NCT03863015 (IMICA) · Inflammation
Variations in patients' adherence to medical recommendations: a quantitative review of 50 years of research.
DiMatteo MR · Med Care · 2004 · Background
PubMed: PMID 15076819 · NCT02087696 · Arthritis, Rheumatoid
Postresuscitation disease after cardiac arrest: a sepsis-like syndrome?
Adrie C, Laurent I, Monchi M, et al. · Curr Opin Crit Care · 2004 · Background
PubMed: PMID 15166838 · NCT03863015 (IMICA) · Inflammation

2003 (13 papers)

Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes.
Proven A, Gabriel SE, Orces C, et al. · Arthritis Rheum · 2003 · Trial result
PubMed: PMID 14558057 · NCT03244709 · Giant Cell Arteritis
Interleukin-6 stimulates lipolysis and fat oxidation in humans.
van Hall G, Steensberg A, Sacchetti M, et al. · J Clin Endocrinol Metab · 2003 · Background
PubMed: PMID 12843134 · NCT04687540 · Obesity
Case number 26: systemic idiopathic fibrosis associated with aortitis.
Schultz O, Schuchmann S, Burmester GR, et al. · Ann Rheum Dis · 2003 · Background
PubMed: PMID 12695167 · NCT04762784 · Retroperitoneal Fibrosis
Therapeutic hypothermia after cardiac arrest: an advisory statement by the advanced life support task force of the International Liaison Committee on Resuscitation.
Nolan JP, Morley PT, Vanden Hoek TL, et al. · Circulation · 2003 · Background
PubMed: PMID 12847056 · NCT03863015 (IMICA) · Inflammation
Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study.
Nishimoto N, Yoshizaki K, Maeda K, et al. · J Rheumatol · 2003 · Background
PubMed: PMID 12858437 · NCT05233397 · Craniopharyngioma
The natural history of chronic allograft nephropathy.
Nankivell BJ, Borrows RJ, Fung CL, et al. · N Engl J Med · 2003 · Background
PubMed: PMID 14668458 · NCT02108600 · Inflammation
Costs and predictors of costs in rheumatoid arthritis: a prevalence-based study.
Lajas C, Abasolo L, Bellajdel B, et al. · Arthritis Rheum · 2003 · Background
PubMed: PMID 12579595 · NCT02087696 · Arthritis, Rheumatoid
High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study.
Kinlay S, Schwartz GG, Olsson AG, et al. · Circulation · 2003 · Background
PubMed: PMID 12975259 · NCT03004703 (ASSAIL-MI) · Inflammation
Humanized monoclonal anti-interleukin-6 receptor antibody for treatment of intractable adult-onset Still's disease.
Iwamoto M, Nara H, Hirata D, et al. · Arthritis Rheum · 2003 · Background
PubMed: PMID 12483747 · NCT01002781
Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial.
Granger CB, Mahaffey KW, Weaver WD, et al. · Circulation · 2003 · Background
PubMed: PMID 12925454 · NCT03004703 (ASSAIL-MI) · Inflammation
Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema.
Funatsu H, Yamashita H, Ikeda T, et al. · Ophthalmology · 2003 · Background
PubMed: PMID 13129863 · NCT02511067 (READ-4)
Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial.
Choy EH, Isenberg DA, Garrood T, et al. · Arthritis Rheum · 2003 · Background
PubMed: PMID 12483717 · NCT05233397 · Craniopharyngioma
Survival and effectiveness of leflunomide compared with methotrexate and sulfasalazine in rheumatoid arthritis: a matched observational study.
Aletaha D, Stamm T, Kapral T, et al. · Ann Rheum Dis · 2003 · Background
PubMed: PMID 12972472 · NCT02087696 · Arthritis, Rheumatoid

2002 (7 papers)

Raised plasma G-CSF and IL-6 after exercise may play a role in neutrophil mobilization into the circulation.
Yamada M, Suzuki K, Kudo S, et al. · J Appl Physiol (1985) · 2002 · Background
PubMed: PMID 11960925 · NCT04616235 · Appetitive Behavior
Interleukin-6-deficient mice develop mature-onset obesity.
Wallenius V, Wallenius K, Ahrén B, et al. · Nat Med · 2002 · Background
PubMed: PMID 11786910 · NCT04687540 · Obesity
Plasma level of interleukin-6 is an indicator for predicting diabetic macular edema.
Shimizu E, Funatsu H, Yamashita H, et al. · Jpn J Ophthalmol · 2002 · Background
PubMed: PMID 11853719 · NCT02511067 (READ-4)
Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation.
Henter JI, Samuelsson-Horne A, Aricò M, et al. · Blood · 2002 · Background
PubMed: PMID 12239144 · NCT02007239 · Cytokine Release Syndrome
Cytokine-induced sickness behavior: mechanisms and implications.
Dantzer R · Ann N Y Acad Sci · 2002 · Background
PubMed: PMID 12000023 · NCT04616235 · Appetitive Behavior
The prevalence of rheumatoid arthritis in the general population of Spain.
Carmona L, Villaverde V, Hernández-García C, et al. · Rheumatology (Oxford) · 2002 · Background
PubMed: PMID 11792885 · NCT02087696 · Arthritis, Rheumatoid
Successful cardiopulmonary resuscitation after cardiac arrest as a "sepsis-like" syndrome.
Adrie C, Adib-Conquy M, Laurent I, et al. · Circulation · 2002 · Background
PubMed: PMID 12147537 · NCT03863015 (IMICA) · Inflammation

2001 (5 papers)

Production of interleukin-6 in contracting human skeletal muscles can account for the exercise-induced increase in plasma interleukin-6.
Steensberg A, van Hall G, Osada T, et al. · J Physiol · 2001 · Background
PubMed: PMID 11080265 · NCT04616235 · Appetitive Behavior
Effect of histological damage on long-term kidney transplant outcome.
Nankivell BJ, Fenton-Lee CA, Kuypers DR, et al. · Transplantation · 2001 · Background
PubMed: PMID 11258430 · NCT02108600 · Inflammation
Treatment of idiopathic retroperitoneal fibrosis using cyclosporin.
Marzano A, Trapani A, Leone N, et al. · Ann Rheum Dis · 2001 · Background
PubMed: PMID 11247880 · NCT04762784 · Retroperitoneal Fibrosis
Adverse reactions to disease-modifying anti-rheumatic drugs in clinical practice.
Grove ML, Hassell AB, Hay EM, et al. · QJM · 2001 · Background
PubMed: PMID 11391029 · NCT02087696 · Arthritis, Rheumatoid
The burden of musculoskeletal diseases in the general population of Spain: results from a national survey.
Carmona L, Ballina J, Gabriel R, et al. · Ann Rheum Dis · 2001 · Background
PubMed: PMID 11602475 · NCT02087696 · Arthritis, Rheumatoid

2000 (1 paper)

Exercise and the immune system: regulation, integration, and adaptation.
Pedersen BK, Hoffman-Goetz L · Physiol Rev · 2000 · Background
PubMed: PMID 10893431 · NCT04616235 · Appetitive Behavior

1999 (5 papers)

Pro- and anti-inflammatory cytokine balance in strenuous exercise in humans.
Ostrowski K, Rohde T, Asp S, et al. · J Physiol · 1999 · Background
PubMed: PMID 9925898 · NCT04616235 · Appetitive Behavior
BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator.
Moore PA, Belvedere O, Orr A, et al. · Science · 1999 · Background
PubMed: PMID 10398604 · NCT04876534 (TOGO) · Graves Ophthalmopathy
Delay of gastric emptying by duodenal intubation: sensitive measurement of gastric emptying by the paracetamol absorption test.
Medhus AW, Sandstad O, Bredesen J, et al. · Aliment Pharmacol Ther · 1999 · Background
PubMed: PMID 10233184 · NCT04616235 · Appetitive Behavior
Disappointing longterm results with disease modifying antirheumatic drugs. A practice based study.
Galindo-Rodriguez G, Aviña-Zubieta JA, Russell AS, et al. · J Rheumatol · 1999 · Background
PubMed: PMID 10555887 · NCT02087696 · Arthritis, Rheumatoid
Clinical course and remission rate in patients with early rheumatoid arthritis: relationship to outcome after 5 years.
Eberhardt K, Fex E · Br J Rheumatol · 1999 · Background
PubMed: PMID 9973158 · NCT02087696 · Arthritis, Rheumatoid

1998 (2 papers)

Interleukin-6 derived from hypoxic myocytes promotes neutrophil-mediated reperfusion injury in myocardium.
Sawa Y, Ichikawa H, Kagisaki K, et al. · J Thorac Cardiovasc Surg · 1998 · Background
PubMed: PMID 9731794 · NCT03863015 (IMICA) · Inflammation
Measurement of fatigue in cancer patients: development and validation of the Fatigue Symptom Inventory.
Hann DM, Jacobsen PB, Azzarello LM, et al. · Qual Life Res · 1998 · Background
PubMed: PMID 9610214 · NCT02206035

1997 (1 paper)

Interleukin-3 and interleukin-6 stimulate cortisol secretion from adult human adrenocortical cells.
Weber MM, Michl P, Auernhammer CJ, et al. · Endocrinology · 1997 · Background
PubMed: PMID 9112422 · NCT04616235 · Appetitive Behavior

1996 (2 papers)

Increased serum concentrations of interleukin-6 (IL-6) and soluble IL-6 receptor in patients with Graves' disease.
Salvi M, Girasole G, Pedrazzoni M, et al. · J Clin Endocrinol Metab · 1996 · Background
PubMed: PMID 8768861 · NCT04876534 (TOGO) · Graves Ophthalmopathy
Survival analysis of disease modifying antirheumatic drugs in Spanish rheumatoid arthritis patients.
De La Mata J, Blanco FJ, Gómez-Reino JJ, et al. · Ann Rheum Dis · 1996 · Background
PubMed: PMID 7492236 · NCT02087696 · Arthritis, Rheumatoid

1995 (4 papers)

1994 Consensus Conference on Acute GVHD Grading.
Przepiorka D, Weisdorf D, Martin P, et al. · Bone Marrow Transplant · 1995 · Background
PubMed: PMID 7581076 · NCT02206035
Molecular bases of the acute coronary syndromes.
Libby P · Circulation · 1995 · Background
PubMed: PMID 7758192 · NCT03004703 (ASSAIL-MI) · Inflammation
Hyperglycemia and microvascular and macrovascular disease in diabetes.
Klein R · Diabetes Care · 1995 · Background
PubMed: PMID 7729308 · NCT02511067 (READ-4)
Penetration of interleukin-6 across the murine blood-brain barrier.
Banks WA, Kastin AJ, Gutierrez EG, et al. · Neurosci Lett · 1995 · Background
PubMed: PMID 7845624 · NCT03863015 (IMICA) · Inflammation

1994 (3 papers)

Effects of recombinant human interleukin-6 in cancer patients: a phase I-II study.
van Gameren MM, Willemse PH, Mulder NH, et al. · Blood · 1994 · Background
PubMed: PMID 8068939 · NCT04616235 · Appetitive Behavior
Takayasu arteritis.
Kerr GS, Hallahan CW, Giordano J, et al. · Ann Intern Med · 1994 · Background
PubMed: PMID 7909656 · NCT03893136 · Takayasu Arteritis
Pain assessment: global use of the Brief Pain Inventory.
Cleeland CS, Ryan KM · Ann Acad Med Singap · 1994 · Background
PubMed: PMID 8080219 · NCT02206035

1993 (3 papers)

Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth.
Sato K, Tsuchiya M, Saldanha J, et al. · Cancer Res · 1993 · Background
PubMed: PMID 8428365 · NCT05233397 · Craniopharyngioma
Effects of high- vs moderate-intensity exercise on natural killer cell activity.
Nieman DC, Miller AR, Henson DA, et al. · Med Sci Sports Exerc · 1993 · Background
PubMed: PMID 8231757 · NCT04616235 · Appetitive Behavior
Soft tissue composition and bone mineral status: evaluation by dual-energy X-ray absorptiometry.
Lukaski HC · J Nutr · 1993 · Background
PubMed: PMID 8429400 · NCT04616235 · Appetitive Behavior

1992 (3 papers)

Roentgen therapy for infections: an historical review.
Berk LB, Hodes PJ · Yale J Biol Med · 1992 · Trial result
PubMed: PMID 1750226 · NCT04394182 (ULTRA-COVID) · Cytokine Release Syndrome
Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group.
Rector TS, Cohn JN · Am Heart J · 1992 · Background
PubMed: PMID 1529875 · NCT03004703 (ASSAIL-MI) · Inflammation
Life table analysis of 879 treatment episodes with slow acting antirheumatic drugs in community rheumatology practice.
Morand EF, McCloud PI, Littlejohn GO, et al. · J Rheumatol · 1992 · Background
PubMed: PMID 1613698 · NCT02087696 · Arthritis, Rheumatoid

1990 (2 papers)

Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice.
Brandt SJ, Bodine DM, Dunbar CE, et al. · J Clin Invest · 1990 · Background
PubMed: PMID 2384605 · NCT01441063 · Castleman Disease
The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis.
Arend WP, Michel BA, Bloch DA, et al. · Arthritis Rheum · 1990 · Background
PubMed: PMID 1975175 · NCT03893136 · Takayasu Arteritis

1989 (1 paper)

The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research.
Buysse DJ, Reynolds CF, Monk TH, et al. · Psychiatry Res · 1989 · Background
PubMed: PMID 2748771 · NCT02206035

1987 (2 papers)

Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 2. Early Treatment Diabetic Retinopathy Study Research Group.
Ophthalmology · 1987 · Background
PubMed: PMID 3658348 · NCT02511067 (READ-4)
The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients.
Lingjaerde O, Ahlfors UG, Bech P, et al. · Acta Psychiatr Scand Suppl · 1987 · Background
PubMed: PMID 2887090 · NCT02087696 · Arthritis, Rheumatoid

1986 (1 paper)

Concurrent and predictive validity of a self-reported measure of medication adherence.
Morisky DE, Green LW, Levine DM, et al. · Med Care · 1986 · Background
PubMed: PMID 3945130 · NCT02087696 · Arthritis, Rheumatoid

1985 (1 paper)

Myocardial reperfusion: a double-edged sword?
Braunwald E, Kloner RA · J Clin Invest · 1985 · Background
PubMed: PMID 4056048 · NCT03004703 (ASSAIL-MI) · Inflammation

1976 (1 paper)

Percutaneous needle biopsy of skeletal muscle in physiological and clinical research.
Bergstrom J · Scand J Clin Lab Invest · 1976 · Background
PubMed: PMID 1108172 · NCT04616235 · Appetitive Behavior

Sources and methodology

Publications: ctgov.study_references (PubMed PMIDs auto-attached by ClinicalTrials.gov to each trial), reference types RESULT, DERIVED, and BACKGROUND.
Per-arm outcome values: ctgov.outcome_measurements joined to ctgov.design_outcomes where outcome_type = 'PRIMARY', restricted to phase PHASE3 and PHASE2/PHASE3.
Publication metadata (title, journal, year, authors): PubMed E-utilities efetch.fcgi
Data freshness: Wed, 20 May 2026 23:37:39 GMT.

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).